<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biophys Rev</journal-id><journal-id journal-id-type="iso-abbrev">Biophys Rev</journal-id><journal-title-group><journal-title>Biophysical Reviews</journal-title></journal-title-group><issn pub-type="ppub">1867-2450</issn><issn pub-type="epub">1867-2469</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7817352</article-id><article-id pub-id-type="pmid">33495702</article-id><article-id pub-id-type="publisher-id">784</article-id><article-id pub-id-type="doi">10.1007/s12551-021-00784-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Molecular engineering of antimicrobial peptides: microbial targets, peptide motifs and translation opportunities</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cardoso</surname><given-names>Priscila</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Glossop</surname><given-names>Hugh</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Meikle</surname><given-names>Thomas G.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Aburto-Medina</surname><given-names>Arturo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Conn</surname><given-names>Charlotte E.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sarojini</surname><given-names>Vijayalekshmi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4724-3651</contrib-id><name><surname>Valery</surname><given-names>Celine</given-names></name><address><email>celine.valery@rmit.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.1017.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2163 3550</institution-id><institution>School of Health and Biomedical Sciences, </institution><institution>RMIT University, </institution></institution-wrap>Melbourne, Australia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.1017.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2163 3550</institution-id><institution>School of Science, </institution><institution>RMIT University, </institution></institution-wrap>Melbourne, Australia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.9654.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0372 3343</institution-id><institution>School of Chemical Sciences, </institution><institution>University of Auckland, </institution></institution-wrap>Auckland, New Zealand </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>1</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2021</year></pub-date><volume>13</volume><issue>1</issue><fpage>35</fpage><lpage>69</lpage><history><date date-type="received"><day>23</day><month>12</month><year>2020</year></date><date date-type="accepted"><day>7</day><month>1</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; International Union for Pure and Applied Biophysics (IUPAB) and Springer-Verlag GmbH Germany, part of Springer Nature 2021</copyright-statement></permissions><abstract id="Abs1"><p id="Par1">The global public health threat of antimicrobial resistance has led the scientific community to highly engage into research on alternative strategies to the traditional small molecule therapeutics. Here, we review one of the most popular alternatives amongst basic and applied research scientists, synthetic antimicrobial peptides. The ease of peptide chemical synthesis combined with emerging engineering principles and potent broad-spectrum activity, including against multidrug-resistant strains, has motivated intense scientific focus on these compounds for the past decade. This global effort has resulted in significant advances in our understanding of peptide antimicrobial activity at the molecular scale. Recent evidence of molecular targets other than the microbial lipid membrane, and efforts towards consensus antimicrobial peptide motifs, have supported the rise of molecular engineering approaches and design tools, including machine learning. Beyond molecular concepts, supramolecular chemistry has been lately added to the debate; and helped unravel the impact of peptide self-assembly on activity, including on biofilms and secondary targets, while providing new directions in pharmaceutical formulation through taking advantage of peptide self-assembled nanostructures. We argue that these basic research advances constitute a solid basis for promising industry translation of rationally designed synthetic peptide antimicrobials, not only as novel drugs against multidrug-resistant strains but also as components of emerging antimicrobial biomaterials. This perspective is supported by recent developments of innovative peptide-based and peptide-carrier nanobiomaterials that we also review.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Molecular engineering</kwd><kwd>Antimicrobial peptides</kwd><kwd>Antimicrobial resistance</kwd><kwd>Peptide-target interactions</kwd><kwd>Molecular self-assembly</kwd><kwd>Nanotechnology</kwd><kwd>Biomaterials</kwd></kwd-group><funding-group><award-group><funding-source><institution>Australian Technology Network</institution></funding-source><award-id>LATAM scholarship</award-id><principal-award-recipient><name><surname>Cardoso</surname><given-names>Priscila</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; International Union for Pure and Applied Biophysics (IUPAB) and Springer-Verlag GmbH Germany, part of Springer Nature 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background: the antibiotic resistance global threat and current molecular design approaches</title><sec id="Sec2"><title>Historical perspective</title><p id="Par3">The first documented failure of antimicrobial therapy in humans due to acquired microbial resistance was reported in the 1940s for penicillin, which occurred only a few years after its commercialisation (Wright <xref ref-type="bibr" rid="CR388">2010</xref>). The therapeutic revolution initiated by penicillin motivated the discovery of varied molecular design approaches in the following few decades (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Time sequence of antibiotic discovery and resistance development for the major chemical classes of marketed antibiotics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Chemical class</th><th>Main microbial target</th><th>Antibiotic molecule</th><th>Origin</th><th>Discovery</th><th>1st reported resistance</th><th>Main mechanisms of resistance</th><th>References</th></tr></thead><tbody><tr><td>Beta-lactam</td><td>Peptidoglycan biosynthesis (cell wall)</td><td>Penicillin G</td><td><italic>Penicillium notatum</italic></td><td>1928</td><td>1940</td><td>Hydrolysis, efflux, altered target</td><td>(Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Wright <xref ref-type="bibr" rid="CR388">2010</xref>; Aslam et al. <xref ref-type="bibr" rid="CR9">2018</xref>; Fong et al. <xref ref-type="bibr" rid="CR109">2018</xref>; Malmir et al. <xref ref-type="bibr" rid="CR221">2018</xref>)</td></tr><tr><td>Sulfonamide</td><td>Dihydropteroate synthetase</td><td>Prontosil</td><td>Synthetic</td><td>1932</td><td>1942</td><td>Efflux, altered target</td><td>(Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Duval et al. <xref ref-type="bibr" rid="CR95">2019</xref>)</td></tr><tr><td>Peptide</td><td>Cell membrane</td><td>Gramicidin</td><td><italic>Bacillus brevis</italic></td><td>1939</td><td><p><italic>Gramicidin?</italic>**</p><p>2015: Polymyxin</p></td><td>Altered target, efflux, destruction plasmid-mediated polymyxin resistance gene (<italic>MCR-1</italic>)</td><td>(Farrell et al. <xref ref-type="bibr" rid="CR103">2018</xref>; Magana et al. <xref ref-type="bibr" rid="CR215">2020</xref>)</td></tr><tr><td>Aminoglycoside</td><td>rRNA (translation)</td><td>Streptomycin</td><td><italic>Streptomyces griseus</italic></td><td>1943</td><td>1947</td><td>Phosphorylation, acetylation, nucleotidylation, efflux, altered target</td><td>(Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Duval et al. <xref ref-type="bibr" rid="CR95">2019</xref>)</td></tr><tr><td>Tetracycline</td><td>rRNA (translation)</td><td>Chlortetracycline</td><td><italic>Streptomyces aureofaciens</italic></td><td>1945</td><td>1953</td><td>Monooxygenation, efflux, altered target</td><td>(Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Malmir et al. <xref ref-type="bibr" rid="CR221">2018</xref>; Duval et al. <xref ref-type="bibr" rid="CR95">2019</xref>)</td></tr><tr><td>Nitrofuran</td><td>citric acid cycle, DNA, RNA, and protein synthesis</td><td>Nitrofurantoin</td><td>Synthetic</td><td>1946</td><td>1952</td><td>Decreased activation</td><td>(Sekyere <xref ref-type="bibr" rid="CR318">2018</xref>; Duval et al. <xref ref-type="bibr" rid="CR95">2019</xref>)</td></tr><tr><td>Phenicol</td><td>rRNA (translation)</td><td>Chloramphenicol</td><td><italic>Streptomyces venezuelae</italic></td><td>1947</td><td>1956</td><td>Acetylation, efflux, altered target</td><td>(Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Duval et al. <xref ref-type="bibr" rid="CR95">2019</xref>)</td></tr><tr><td>Macrolide</td><td>rRNA (translation)</td><td>Erythromycin</td><td><italic>Saccharopolyspora erythraea</italic></td><td>1949</td><td>1953</td><td>Hydrolysis, glycosylation, phosphorylation, efflux, altered target</td><td>(Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Duval et al. <xref ref-type="bibr" rid="CR95">2019</xref>)</td></tr><tr><td>Nitroimidazole</td><td>DNA (nucleic acid synthesis)</td><td>Metronidazole</td><td>Synthetic</td><td>1953</td><td>1978</td><td>Decreased drug uptake, efflux, decreased activation, altered target, increased oxygen scavenging capabilities (SOD/catalase/ peroxidase), enhanced activity of DNA repair enzymes</td><td>(Dhand and Snydman <xref ref-type="bibr" rid="CR87">2009</xref>; Duval et al. <xref ref-type="bibr" rid="CR95">2019</xref>)</td></tr><tr><td>Glycopeptide</td><td>Peptidoglycan biosynthesis (cell wall)</td><td>Vancomycin</td><td><italic>Amycolatopsis orientalis</italic></td><td>1953</td><td>1986</td><td>Reprogramming peptidoglycan biosynthesis</td><td>(Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Malmir et al. <xref ref-type="bibr" rid="CR221">2018</xref>; Duval et al. <xref ref-type="bibr" rid="CR95">2019</xref>)</td></tr><tr><td>Streptogramin</td><td>rRNA (translation)</td><td>Virginiamycin</td><td><italic>Streptomyces virginiae</italic></td><td>1955</td><td>1964</td><td>C-O lyase (type B streptogramins), acetylation (type A streptogramins), efflux, altered target</td><td>(Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Schwarz et al. <xref ref-type="bibr" rid="CR316">2016</xref>)</td></tr><tr><td>Ansamycin</td><td>Transcription</td><td>Rifamycin</td><td><italic>Streptomyces</italic></td><td>1957</td><td>1963</td><td>ADP-ribosylation, efflux, altered target</td><td>(Malmir et al. <xref ref-type="bibr" rid="CR221">2018</xref>)</td></tr><tr><td>Pyrimidine -antimetabolite antibiotics</td><td>Dihydrofolate reductase</td><td>trimethoprim</td><td>Synthetic</td><td>1961</td><td>1972</td><td>Efflux, altered target</td><td>(Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Duval et al. <xref ref-type="bibr" rid="CR95">2019</xref>)</td></tr><tr><td>Lincosamide</td><td>rRNA (translation)</td><td>Lincomycin</td><td><italic>Streptomyces lincolnensis</italic></td><td>1962</td><td>1979</td><td>Nucleotidylation, efflux, altered target</td><td>(Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Duval et al. <xref ref-type="bibr" rid="CR95">2019</xref>)</td></tr><tr><td>Quinolone</td><td>DNA replication, Topoisomerase inhibitors</td><td>Nalidixic acid</td><td>Synthetic</td><td>1962</td><td>1966</td><td>Acetylation, efflux, altered target</td><td>(Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Duval et al. <xref ref-type="bibr" rid="CR95">2019</xref>)</td></tr><tr><td>Oxazolidinone</td><td>rRNA (translation)</td><td>Linezolid</td><td>Synthetic</td><td>1978</td><td>1999</td><td>Efflux, altered target</td><td>(Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Malmir et al. <xref ref-type="bibr" rid="CR221">2018</xref>; Duval et al. <xref ref-type="bibr" rid="CR95">2019</xref>)</td></tr><tr><td>Lipopeptide</td><td>Cell membrane</td><td>Daptomycin</td><td><italic>Streptomyces roseosporus</italic></td><td>1987</td><td>2005</td><td>Altered target</td><td>(Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Duval et al. <xref ref-type="bibr" rid="CR95">2019</xref>)</td></tr></tbody></table><table-wrap-foot><p>**No report found for a precise year</p></table-wrap-foot></table-wrap></p><p id="Par4">Gramicidin was the first reported antimicrobial peptide (AMP), isolated from the soil bacteria <italic>Bacillus brevis</italic> in 1939, while defensin was the first evidenced animal AMP, isolated from rabbit leukocytes. Despite these early discoveries, it was only after the 1960s that global interest and research efforts were devoted to antimicrobial peptides, due to the rise of multidrug-resistant microbial pathogens. Presently, over 5000 AMPs have been reported (Zhang and Gallo <xref ref-type="bibr" rid="CR400">2016</xref>; Travkova et al. <xref ref-type="bibr" rid="CR354">2017</xref>).</p><p id="Par5">Microbial evolution towards acquiring resistance to marketed drugs kept increasing over the twentieth century and early twenty-first century (Ventola <xref ref-type="bibr" rid="CR358">2015a</xref>; Aslam et al. <xref ref-type="bibr" rid="CR9">2018</xref>; Kennedy and Read <xref ref-type="bibr" rid="CR173">2018</xref>; Peterson and Kaur <xref ref-type="bibr" rid="CR281">2018</xref>). Decades of fundamental research unravelled four main types of molecular resistance mechanisms: secretion of inactivating enzymes, secretion of efflux pumps, immunity and bypass, and target modification. A number of excellent reviews have compiled these mechanisms for the antimicrobial agents currently on the market (Table <xref rid="Tab1" ref-type="table">1</xref>, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) (Davies and Davies <xref ref-type="bibr" rid="CR76">2010</xref>; Malmir et al. <xref ref-type="bibr" rid="CR221">2018</xref>; Ribeiro da Cunha et al. <xref ref-type="bibr" rid="CR300">2019</xref>; Magana et al. <xref ref-type="bibr" rid="CR215">2020</xref>). Two main factors are identified as favouring the increase of antimicrobial resistance: the generalized use and misuse of antimicrobial therapies and the insufficient discovery of new antimicrobial therapies (Table <xref rid="Tab1" ref-type="table">1</xref>) (Ventola <xref ref-type="bibr" rid="CR358">2015a</xref>; Aslam et al. <xref ref-type="bibr" rid="CR9">2018</xref>; Kennedy and Read <xref ref-type="bibr" rid="CR173">2018</xref>; Peterson and Kaur <xref ref-type="bibr" rid="CR281">2018</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Main molecular mechanisms of action and resistance for marketed antibiotics. Modified from Wright <xref ref-type="bibr" rid="CR388">2010</xref></p></caption><graphic xlink:href="12551_2021_784_Fig1_HTML" id="MO1"/></fig></p><p id="Par6">Worldwide, numerous organizations, like the Centre for Disease Control and Prevention (CDC), the Infectious Diseases Society of America, the World Economic Forum, and the World Health Organization (WHO) have recognized antibiotic resistance as a &#x0201c;global public health concern&#x0201d;. Numerous attempts have been made to delineate the diverse aspects of antibiotic resistance (Li et al. <xref ref-type="bibr" rid="CR205">2012</xref>; Crofts et al. <xref ref-type="bibr" rid="CR68">2017</xref>; Sierra et al. <xref ref-type="bibr" rid="CR325">2017</xref>). WHO published several documents to guide the development of new antimicrobials, such as the list of global priority pathogens and corresponding target diseases (WHO <xref ref-type="bibr" rid="CR380">2017</xref>). In 2015, WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) as the first global system to collect official national antimicrobial resistance data in selected bacterial pathogens (WHO <xref ref-type="bibr" rid="CR379">2015</xref>). In a span of 4&#x000a0;years, 91 countries and territories had already enrolled in the system. Based on worldwide data, the GLASS report of May 2020 revealed a worrying number of common bacterial infections increasingly resistant to available antibiotics (WHO <xref ref-type="bibr" rid="CR384">2020b</xref>).</p><p id="Par7">Recently, concerns have been raised regarding an aggravation of the inappropriate use of antibiotics during the COVID-19 pandemic. Consequently, the WHO issued guidance to &#x0201c;NOT recommend antibiotic therapy or prophylaxis for patients with mild or moderate COVID-19 unless signs and symptoms of a bacterial infection exist&#x0201d; (Getahun et al. <xref ref-type="bibr" rid="CR123">2020</xref>).</p></sec><sec id="Sec3"><title>Global priority pathogens and infectious diseases</title><p id="Par8">The WHO priority list contains 12 bacterial families, including the ESKAPE pathogens (<italic>Enterococcus faecium</italic>, <italic>Staphylococcus aureus</italic>, <italic>Klebsiella pneumoniae</italic>, <italic>Acinetobacter baumannii</italic>, <italic>Pseudomonas aeruginosa</italic>, and <italic>Enterobacter species</italic>), which are known to represent a global threat to human health (WHO <xref ref-type="bibr" rid="CR380">2017</xref>). Mycobacteria was not included in the catalogue, because it is already considered a global priority for which innovative new treatments are urgently needed. The main objective of the list was to identify the most important resistant bacteria at a global level for which there is an urgent need for new treatments, in order to encourage the prioritisation of funding and incentives, to align research and development priorities of public health and to garner global coordination in the fight against those pathogens. The WHO priority pathogens were selected through a multi-criteria decision analysis technique contemplating both expert opinion and evidence-based data, following ten criteria: all-cause mortality, healthcare and community burden, prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in hospital and community settings, treatability and current pipeline (Santajit and Indrawattana <xref ref-type="bibr" rid="CR307">2016</xref>; WHO <xref ref-type="bibr" rid="CR380">2017</xref>; Parish <xref ref-type="bibr" rid="CR274">2019</xref>; De Oliveira et al. <xref ref-type="bibr" rid="CR80">2020</xref>).</p><p id="Par9">In May 2020, WHO released a report comprising the target product profiles (TTP) for needed antimicrobial agents for priority diseases, namely enteric fever, gonorrhoea, neonatal sepsis, and urinary tract infections. Table <xref rid="Tab2" ref-type="table">2</xref> compiles the diseases considered as priority targets, together with their available treatments and reported antimicrobial resistance (WHO <xref ref-type="bibr" rid="CR385">2020c</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Available treatment and reported antimicrobial resistance for enteric fever, gonorrhoea, neonatal sepsis, and urinary tract infections. Adapted from&#x000a0;WHO (WHO <xref ref-type="bibr" rid="CR385">2020c</xref>)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Disease</th><th>Pathogen</th><th>Antibiotic resistance</th><th>Available treatment</th></tr></thead><tbody><tr><td>Enteric fever</td><td><italic>Salmonella typhi</italic> or <italic>Salmonella paratyphi</italic></td><td><p>Resistant to all major antibiotic categories (varies upon the region)</p><p>Asia: ciprofloxacin resistance in <italic>S. typhi</italic> or <italic>S. paratyphi</italic> is close to 100%</p></td><td><p>1) Ampicillin, chloramphenicol, co-trimoxazole and fluoroquinolones (not effective in many regions)</p><p>2) Cefixime, azithromycin and ceftriaxone</p><p>3) Extra resistant strains: azithromycin and carbapenems</p></td></tr><tr><td>Gonorrhoea</td><td><italic>Neisseria gonorrhoeae</italic></td><td>Resistance to all oral antimicrobials used for treatment: sulphonamides, penicillins, tetracyclines, macrolides and fluoroquinolones</td><td>1) Ceftriaxone and azithromycin (resistance has been reported)</td></tr><tr><td>Neonatal sepsis</td><td><p>Most common:</p><p><italic>E coli, Klebsiella</italic> sp<italic>., Acinetobacter</italic> sp.<italic>, P aeruginosa, S aureus</italic></p></td><td>Varies</td><td>1) Ampicillin or penicillin in combination with gentamicin (resistance has been reported)</td></tr><tr><td>Urinary tract infections</td><td>Most common: <italic>E coli</italic>, <italic>K pneumoniae</italic>, <italic>Enterobacteriaceae</italic></td><td>Fluoroquinolones. Resistance data to ampicillin, amoxicillin/clavulanic acid, oral cephalosporins, co-trimoxazole and ciprofloxacin.</td><td><p>1) Acute pyelonephritis: fluoroquinolones in countries with low resistance rates</p><p>2) Cystitis: nitrofurantoin, fosfomycin trometamol and pivmecillinam</p></td></tr></tbody></table></table-wrap></p><p id="Par10">The increasing occurrence of fungal infections that are resistant to the limited number of commonly used antifungal classes, such as triazoles, echinocandins, and polyenes, has lead the WHO to develop a priority list of fungal pathogens. This list is programmed to be launched at the end of 2021 with the main purpose of defining R&#x00026;D priorities with identified public health needs. In April 2020, a first meeting of the WHO antifungal expert group took place to establish the parameters for pathogen selection. The priority fungal pathogens initially set out include: <italic>Candida auris; azole-resistant Candida</italic> spp.<italic>;</italic> azole-resistant <italic>Aspergillus fumigatus; Cryptococcus neoformans</italic>, <italic>Cryptococcus gattii</italic>; <italic>Pneumocystis jirovecii</italic> and <italic>Mucorales</italic>. Further evaluation will be made based on limitations of treatment options due to resistance and/or existing treatability issues for those pathogens (WHO <xref ref-type="bibr" rid="CR383">2020a</xref>).</p></sec><sec id="Sec4"><title>Molecular design approaches in the pre-clinical and clinical pipelines</title><p id="Par11">Since the publication of the first priority list by WHO in 2017 and until September 2019, eight new antibiotics were approved by the US and European authorities (FDA/EMA) with activity against the priority pathogens. However, most of these products are not very innovative, being derivatives of known classes, such as the tetracycline derivatives eravacycline, omadacycline, or sarecyclin, the cephalosporin derivative cefiderocol and the combination therapy imipenem-cilastatin-relebactam. Sarecycline is indicated for moderate to severe acne caused by Cutibacterium acnes while the combination therapy imipenem-cilastatin-relebactam and cefiderocol were approved for complicated urinary tract infections (Andrei et al. <xref ref-type="bibr" rid="CR8">2019</xref>; EMA <xref ref-type="bibr" rid="CR98">2020</xref>; FDA <xref ref-type="bibr" rid="CR104">2020</xref>).</p><p id="Par12">As of September 2019, the WHO listed 49 small molecules and 10 biological molecules in clinical development that target priority pathogens, <italic>Mycobacterium tuberculosis</italic> and <italic>Clostridium difficile</italic>. Besides this high number, only six of these therapies did not display cross-resistance to existing antibiotics and between those six only two were active against multidrug-resistant Gram negative bacteria. This can be explained by the general lack of chemical diversity. Indeed, most of the new antimicrobial small molecules in clinical trials are combinatory therapies of beta lactams with beta-lactamase inhibitors or tetracycline derivatives. The six innovative small molecule antibiotics include two boronate beta-lactam inhibitors (taniborbactam-cefepime and VNRX-7145&#x02014;ceftibuten), two new topoisomerase inhibitors (zoliflodacin and gepotidacin), a new FabI inhibitor (afabicin), and a FtsZ inhibitor (TXA709) (WHO <xref ref-type="bibr" rid="CR381">2019a</xref>). Antimicrobial biological medicines in clinical development include mono/polyclonal antibodies and endolysins, which all can be considered innovative, as they target new structures through new modes of action (classes: anti-<italic>Staphylococcus aureus</italic> immunoglobulin M (IgM) monoclonal antibody; anti-<italic>Staphylococcus aureus</italic> IgG monoclonal antibody; phage endolysin; anti-<italic>Pseudomonas aeruginosa</italic> IgG monoclonal antibody; anti-<italic>Pseudomonas aeruginosa</italic> serotype O11 IgG monoclonal antibody; anti-<italic>Staphylococcus aureus</italic> IgG monoclonal antibody; anti-<italic>Staphylococcus aureus</italic> IgG monoclonal antibody; anti-<italic>Clostridium difficile</italic> polyclonal antibody). However, the high cost of biologicals compared to small molecules limits their potential use as alternative treatments to current therapies (Peterson and Kaur <xref ref-type="bibr" rid="CR281">2018</xref>; WHO <xref ref-type="bibr" rid="CR381">2019a</xref>).</p><p id="Par13">The first comprehensive global overview of the antibacterial pre-clinical pipeline was published by the WHO in 2019, compiling 252 antibacterial products being developed in 145 institutions around the world. The review identified relatively innovative products, with many projects including direct-acting small molecules (<italic>n</italic>&#x000a0;=&#x02009;108, 42.9%), antimicrobial peptides (<italic>n</italic>&#x000a0;=&#x02009;27, 10.7%), and phage/phage-derived peptides (<italic>n</italic>&#x000a0;=&#x02009;28, 11.1%) (WHO <xref ref-type="bibr" rid="CR382">2019b</xref>). Considering the WHO priority pathogens list, examination of the pre-clinical pipeline projects indicates that a significant number of products were focused on single pathogenic species, representing a consistent shift rather than broader spectrum agents. Almost one-third of these products target bacterial cell wall synthesis or directly act on the bacterial membrane because of the less likely occurrence of resistance to these mechanisms of action (Kennedy and Read <xref ref-type="bibr" rid="CR173">2018</xref>). However, for these new non-traditional approaches, the failure rate in clinical trials is considerably higher than that of proven pathways for new agents of existing antibiotic classes. Finding innovative antimicrobial entities is scientifically complex and less successful than drug discovery in other fields. The challenges include (i) in order to avoid single-step resistance, find compounds that have more than one binding site; (ii) discover molecules that penetrate the outer layers of Gram negative cell walls without being pumped out immediately by efflux pumps; and (iii) overcome toxicity problems due to the usual high concentrations of the antimicrobials required to kill bacteria (Ventola <xref ref-type="bibr" rid="CR359">2015b</xref>; Kennedy and Read <xref ref-type="bibr" rid="CR173">2018</xref>; Peterson and Kaur <xref ref-type="bibr" rid="CR281">2018</xref>).</p></sec><sec id="Sec5"><title>Antimicrobial drug discovery: latest approaches</title><p id="Par14">Historically, the most successful means of antibacterial discovery have been the screening of natural products obtained from microbial sources. To date, most of the antibiotics available on the market are natural or semi-synthetic/synthetic compounds derived from natural molecules (Simmons et al. <xref ref-type="bibr" rid="CR328">2010</xref>; Renwick et al. <xref ref-type="bibr" rid="CR299">2016</xref>; Parish <xref ref-type="bibr" rid="CR274">2019</xref>). Several approaches can be employed in the discovery of natural antimicrobials, such as diversity-based approaches (culturing the &#x0201c;uncultured&#x0201d; bacteria; co-culture; examine rare bacterial taxa and unusual habitats), ribosome engineering, genetic engineering, and genome mining, as developed below (Goodfellow and Fiedler <xref ref-type="bibr" rid="CR131">2010</xref>; Renwick et al. <xref ref-type="bibr" rid="CR299">2016</xref>; Wohlleben et al. <xref ref-type="bibr" rid="CR387">2016</xref>). These approaches are supported by recent advances in computational models and combinatorial chemistry to rationally discover new drugs and improve current antimicrobials (Pucci <xref ref-type="bibr" rid="CR290">2006</xref>; Simmons et al. <xref ref-type="bibr" rid="CR328">2010</xref>; Renwick et al. <xref ref-type="bibr" rid="CR299">2016</xref>; Blaskovich et al. <xref ref-type="bibr" rid="CR31">2017</xref>).</p><sec id="Sec6"><title>Natural antibiotics discovery: diversity-based approaches</title><p id="Par15">Less than 1% of the microbes present in the environment can be cultivated in the laboratory. In support of the global effort to cultivate new microbial taxa, nutrient media and diffusion chambers have been successfully used in high-throughput cultivation for several microbes such as marine isolates (Amann et al. <xref ref-type="bibr" rid="CR5">1995</xref>; Nichols et al. <xref ref-type="bibr" rid="CR255">2010</xref>; Wohlleben et al. <xref ref-type="bibr" rid="CR387">2016</xref>). Soil <italic>Actinomycetes</italic>, particularly <italic>Streptomyces</italic> species, have been the source of most natural antibiotics in use nowadays. In recent years, after decades of exploiting terrestrial <italic>Streptomycetes</italic>, the search has shifted to rare <italic>Actinomycetes</italic> and other taxa of bacteria such as <italic>Cyanobacteria</italic> and <italic>Proteobacteria</italic>. Novel <italic>Actinomycetes</italic> species and their novel natural products have been discovered in deep ocean sediments, hyper-arid desert soils, and hot springs to name a few unusual habitats. Endophytic bacteria present in plant tissues and plant rhizospheres, and symbiotic bacteria such as the actinobacteria living in mutualistic association with fungal growing attine ants, bacterial-nematode associations, or even human commensals are being sourced for novel antibiotics. Goodfellow and Fiedler have outlined a bioprospecting strategy where species from extreme or unusual habitats are cultivated with selective isolation methods, novel taxa are recognized by dereplication, and then screened for natural products (Hosaka et al. <xref ref-type="bibr" rid="CR152">2009</xref>; Goodfellow and Fiedler <xref ref-type="bibr" rid="CR131">2010</xref>; Wohlleben et al. <xref ref-type="bibr" rid="CR387">2016</xref>). In the environment, microorganisms are rarely found in isolation. Several reports have shown that microorganisms that grow in co-culture with another species result in induction of antibiotic production, often related to previously silent gene clusters. Co-cultures can induce silent antibiotic genes because of competition (Hosaka et al. <xref ref-type="bibr" rid="CR152">2009</xref>; Wohlleben et al. <xref ref-type="bibr" rid="CR387">2016</xref>).</p></sec><sec id="Sec7"><title>Ribosome engineering, genetic engineering and genome mining</title><p id="Par16">Ribosome engineering is an approach to discover microbes with spontaneous mutations in their ribosome or RNA polymerase, through screening antibiotic-resistant mutants. Some selected mutants may have elevated secondary metabolite production or produce new series of natural products with interesting biological activities. A simple way to introduce ribosomal mutations is by exposing strains to aminoglycoside antibiotics. Strains that become resistant to these antibiotics harbour mutations in the ribosome. Resistance to other ribosome targeting antibiotics such as gentamicin or erythromycin could also stimulate antibiotic production (Hosaka et al. <xref ref-type="bibr" rid="CR152">2009</xref>; Zhu et al. <xref ref-type="bibr" rid="CR405">2019</xref>).</p><p id="Par17">Eliminating genes for one secondary metabolite can stimulate the production of silent pathways. This was verified when ten new amexanthomycins were produced after the deletion of rifamycin synthesis genes in the <italic>Amycolatopsis mediterranei</italic>. Furthermore, by introducing or altering the expression of a heterologous global regulator, the secondary metabolome can change unpredictably. Many biosynthetic gene clusters include pathway-specific regulators that when overexpressed can increase the yield of the natural product or stimulate a previously silent cluster (e.g., production of stambomycin by <italic>Streptomyces ambofaciens</italic>) (Laureti et al. <xref ref-type="bibr" rid="CR187">2011</xref>; Li et al. <xref ref-type="bibr" rid="CR206">2018</xref>; Rajeev <xref ref-type="bibr" rid="CR297">2018</xref>).</p><p id="Par18">Genome mining can be applied to predict the synthesis of new compounds. Genes synthesizing natural products are contained in biosynthetic gene clusters. Those clusters are modular, following an assembly line method with the number of modules correlating to the number of molecular building blocks incorporated in the product. Normally, there is a core cluster that models the product and adjacent genes that change the product such as acyltransferases and genes that confer self-resistance (Blin et al. <xref ref-type="bibr" rid="CR32">2017</xref>; Rajeev <xref ref-type="bibr" rid="CR297">2018</xref>). Genome mining tools can connect biosynthetic gene clusters to their corresponding natural products, being empowered to find the accessory tailoring domains and use the information to predict structural features and physicochemical properties of the final product. The most important of these are PRISM (PRediction Informatics for Secondary Metabolomes) (Skinnider et al. <xref ref-type="bibr" rid="CR330">2017</xref>) and antiSMASH (antibiotics and Secondary Metabolite Analysis SHell) (Blin et al. <xref ref-type="bibr" rid="CR32">2017</xref>; Rajeev <xref ref-type="bibr" rid="CR297">2018</xref>). Those computational tools can foresee the number of biosynthetic gene clusters in a selected genome and the structures of the natural products. Other important tools which are restricted to peptide natural products are Pep2Path (Medema et al. <xref ref-type="bibr" rid="CR231">2014</xref>), NRPQuest (for non-ribosomal peptides) (Mohimani et al. <xref ref-type="bibr" rid="CR241">2014a</xref>) and RiPPQuest (for ribosomal peptides) (Mohimani et al. <xref ref-type="bibr" rid="CR242">2014b</xref>).</p></sec><sec id="Sec8"><title>Bioactive-guided screening and target-based drug discovery</title><p id="Par19">Two main principles have been applied as the basis for effective drug discovery programmes: (i) target-oriented screening: aiming to identify compounds that are compatible with a known and validated molecular target; (ii) bioactive-guided screening: after the identification of the active substance, efforts are made to analyse the target and the mode of action of the compound (Goodfellow and Fiedler <xref ref-type="bibr" rid="CR131">2010</xref>; Jackson et al. <xref ref-type="bibr" rid="CR156">2018</xref>; Parish <xref ref-type="bibr" rid="CR274">2019</xref>).</p><p id="Par20">Target-based drug discovery has a great potential. This approach starts with identifying compounds or pathways that are essential to the pathogen. Genome sequencing can help to identify unique targets specific to bacteria, providing high specificity over human cells, and targets can be selected that are either common to all bacteria or specific to certain species. After selection of the target, they are characterized, validated and screened against a panel of small molecules or chemical libraries to identify those that affect them. Then, the selected molecules are evaluated for their suitability as drugs (low toxicity, good bacterial penetration and bioavailability) and later attempts are made to improve their potency and pharmacokinetic properties (Simmons et al. <xref ref-type="bibr" rid="CR328">2010</xref>; Parish <xref ref-type="bibr" rid="CR274">2019</xref>). Structure-based drug discovery (SBDD) is an example for target-based drug discovery. An antimicrobial drug target should be essential have a unique function in the pathogen and exhibit an activity that can be altered by a small molecule. After, protocols for high-throughput screening and de novo design are used to establish new drugs and their antimicrobial structure&#x02013;activity relationship (Simmons et al. <xref ref-type="bibr" rid="CR328">2010</xref>).</p></sec></sec><sec id="Sec9"><title>Antimicrobial peptides as promising new drugs</title><p id="Par21">Antimicrobial peptides (AMPs) are small proteins usually composed of up to 50 amino acid residues, which, depending on their composition, size and conformation, can be arranged in different groups such as cationic peptides (largest), non-cationic peptides, aromatic peptides or those derived from oxygen-binding proteins (Vizioli and Salzet <xref ref-type="bibr" rid="CR363">2002</xref>). Apart from the peptide charge, the features mentioned above may be essential for their antimicrobial activity (Friedrich et al. <xref ref-type="bibr" rid="CR115">2000</xref>). AMPs have exhibited broad-spectrum activity against many Gram negative and Gram positive strains as well as fungi (Chung and Khanum <xref ref-type="bibr" rid="CR63">2017</xref>) and are produced by both animals and plants (Zasloff <xref ref-type="bibr" rid="CR396">2002</xref>). They have been used for the treatment of Candidiasis (Danesi et al. <xref ref-type="bibr" rid="CR73">2002</xref>) and have also been useful against replication of HIV1 by eliminating viral gene expression (Wachinger et al. <xref ref-type="bibr" rid="CR367">1998</xref>). Antimicrobial peptides are part of the innate immune defence of organisms (Peschel and Sahl <xref ref-type="bibr" rid="CR278">2006</xref>); they may present antibacterial, antifungal, antiparasitic and antiviral activity (Hancock and Diamond <xref ref-type="bibr" rid="CR142">2000</xref>). They are one of the strategies used by leukocytes to kill microorganisms after being ingested (Otto <xref ref-type="bibr" rid="CR269">2010</xref>). AMPs also have a signalling function and can activate immune cells (Yang et al. <xref ref-type="bibr" rid="CR389">1999</xref>). AMPs bind to the anionic bacterial surface and can integrate into the cytoplasmic membrane, making pores to kill the microorganism, since most of them are cationic (CAMPs) and show amphipathic properties (Brown and Hancock <xref ref-type="bibr" rid="CR43">2006</xref>). In humans, most AMPs belong to the beta defensin family (Ganz <xref ref-type="bibr" rid="CR119">2003</xref>) while the LL-37 peptide belongs to the cathelicidin family (D&#x000fc;rr et al. <xref ref-type="bibr" rid="CR94">2006</xref>).</p><p id="Par22">Most of the naturally occurring antimicrobial peptides have rather long sequences, which can compromise their application as commercial drugs due to the high cost of protein production at industrial scale. Hence, research is focussing on identifying short active fragments as a base to develop new AMPs, using a range of molecular engineering strategies, which are the topic of this review. Short AMPs represent a chemical class of promising new drugs due to their robust biomimetic mechanisms of action, their relative ease of synthesis, and low production cost when compared to biologicals. With a clearer understanding of AMP pharmacokinetics and structural biology, these peptides are increasingly gaining attention as therapeutic agents (da Costa et al. <xref ref-type="bibr" rid="CR70">2015</xref>; Magana et al. <xref ref-type="bibr" rid="CR215">2020</xref>; Mookherjee et al. <xref ref-type="bibr" rid="CR245">2020</xref>).</p></sec></sec><sec id="Sec10"><title>Molecular targets and mechanisms of action involved in peptide antimicrobial activity</title><p id="Par23">The bactericidal and/or bacteriostatic activity of AMPs primarily depends upon their ability to interact with bacterial membranes or cell walls, as a direct cell death mechanism or means to reach intracellular targets (Kang et al. <xref ref-type="bibr" rid="CR169">2014</xref>; da Costa et al. <xref ref-type="bibr" rid="CR70">2015</xref>; Zhang and Gallo <xref ref-type="bibr" rid="CR400">2016</xref>; Le et al. <xref ref-type="bibr" rid="CR189">2017</xref>; Mookherjee et al. <xref ref-type="bibr" rid="CR245">2020</xref>). Mechanisms of action that target the microbial membrane are amongst the preferred ones to develop new agents, as less likely to engender&#x000a0;resistance (Kennedy and Read <xref ref-type="bibr" rid="CR173">2018</xref>). For these reasons, the interactions of antimicrobial peptides with the microbial lipid membrane have been the focus of intense research, with molecular mechanisms being unravelled. Lipopolysaccharides (LPS) are other essential components of the Gram negative bacterial cell membrane. Given the negative charge of LPS, cationic AMPs strongly interact with these compounds, which constitute another antimicrobial target of choice. Interestingly, immunomodulatory activity has been reported through the interaction of AMPs with LPS, and also with microbial nucleic acids or other immune ligands. Various microbial intracellular targets are emerging from fundamental research, with growing evidence that potent AMPs target multiple functions. Bacterial biofilms recently gained attention as extracellular AMP targets to prevent infection spread.</p><sec id="Sec11"><title>Lipid membrane</title><sec id="Sec12"><title>Lipid membrane disruption</title><p id="Par24">Several modes of action have been suggested for bacterial membrane disruption by peptides, including carpet, barrel-stave, toroidal pore formations and aggregate mechanism (Chan et al. <xref ref-type="bibr" rid="CR56">2006</xref>; Kang et al. <xref ref-type="bibr" rid="CR169">2014</xref>; Bechinger and Gorr <xref ref-type="bibr" rid="CR17">2017</xref>; Nagarajan et al. <xref ref-type="bibr" rid="CR251">2018</xref>; Mookherjee et al. <xref ref-type="bibr" rid="CR245">2020</xref>) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). In the carpet model, the peptides align and accumulate parallel to the surface of the membrane until they reach a critical concentration, leading to changes in the membrane fluidity and/or reduction in membrane barrier properties resulting in membrane permeabilization. The membrane is disrupted in a detergent-like way, with no need of peptide insertion into the hydrophobic core of the bilayer. For the barrel-stave model, peptides interact laterally, resulting in the formation of a structure that behaves like a protein ion channel. In the toroidal pore model, the peptides interact only with the head groups of the lipids, affecting the local curvature of the membrane and resulting in the formation of high curvature peptide-lipid toroids. Another model is the aggregate mechanism, when peptides cross the membrane without causing significant membrane disruption. Once inside the cell, AMPs aim at intracellular targets (da Costa et al. <xref ref-type="bibr" rid="CR70">2015</xref>; Le et al. <xref ref-type="bibr" rid="CR189">2017</xref>; Mookherjee et al. <xref ref-type="bibr" rid="CR245">2020</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Membrane disruption molecular models and some intracellular targets of AMPs. Reproduced from Mookherjee et al. <xref ref-type="bibr" rid="CR245">2020</xref>. <italic>Copyright &#x000a9; 2020, Springer Nature Limited</italic></p></caption><graphic xlink:href="12551_2021_784_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec13"><title>Negative Gaussian curvature model</title><p id="Par25">A body of research has focussed on the link between the mechanism of action of AMPs and the ability of these peptides to generate negative Gaussian curvature (or saddle-splay curvature) in the bacterial membrane, which is known to destabilize the membrane (Schmidt et al. <xref ref-type="bibr" rid="CR309">2011</xref>; Schmidt and Wong <xref ref-type="bibr" rid="CR308">2013</xref>; Lee et al. <xref ref-type="bibr" rid="CR192">2016</xref>). This effect is strongly linked to the membrane lipid composition&#x02014;the presence of anionic lipids, and lipids of intrinsic negative curvature including phosphatidylethanolamine (PE)-based lipids and cardiolipin increase the susceptibility to AMPs (Som et al. <xref ref-type="bibr" rid="CR333">2009</xref>; Schmidt et al. <xref ref-type="bibr" rid="CR309">2011</xref>). PE is the main phospholipid found in the plasma membrane of Gram negative bacteria. It has been shown that the presence of these negative curvature lipids may reduce the energy required to form membrane pores associated with disruption of the bilayer by AMPs (Zimmerberg and Kozlov <xref ref-type="bibr" rid="CR406">2006</xref>). In contrast, cholesterol, which is more typical of eukaryotic membranes and acts to rigidify the lipid bilayer, appears to inhibit the effect of AMPs (Verly et al. <xref ref-type="bibr" rid="CR361">2008</xref>).</p><p id="Par26">The role of negative Gaussian curvature in the AMP mechanism of action has also been demonstrated using peptide-mimicking phenylene ethynylenes (Yang et al. <xref ref-type="bibr" rid="CR391">2008</xref>). The ability of these compounds to induce permeation in bacterial membranes was again shown to require the presence of phosphatidylethanolamine (PE)-based lipids, which promote negative Gaussian curvature in membranes. A mutant PE-knockout strain of <italic>E. coli</italic> was shown to out-survive the wild type strain following addition of phenylene ethynylenes (Yang et al. <xref ref-type="bibr" rid="CR391">2008</xref>).</p><p id="Par27">Lee et al. used a machine learning approach to predict whether a series of membrane-permeating &#x003b1;-helical peptides of various sequence homologies were likely to be antimicrobial (Lee et al. <xref ref-type="bibr" rid="CR192">2016</xref>). Sequence homologies were restricted to peptides 20&#x02013;25 residues in length, with homology to known AMPs, and high &#x003b1;-helical content. A support vector machine (SVM)-based classifier was used to generate a metric &#x003c3; based on the distance from the SVM hyperplane&#x02014;this metric was not correlated with the peptide&#x02019;s minimum inhibitory concentration, but instead with the ability of the peptide to generate negative Gaussian curvature in a lipid membrane. Small-angle x-ray scattering (SAXS) experiments on unilamellar vesicles following the addition of selected peptides showed the formation of coexisting bicontinuous cubic lipid phases of Pn3m and Im3m symmetry. These phases are based around a fundamental lipid bilayer structure with a non-positive Gaussian curvature (although they maintain zero mean curvature) (Lee et al. <xref ref-type="bibr" rid="CR192">2016</xref>).</p></sec><sec id="Sec14"><title>Peptide secondary structure and membrane activity</title><p id="Par28">Membrane active AMPs comprise peptides of varied secondary structures commonly classified into &#x003b1;-helical, &#x003b2;-sheet, or unstructured (random coil) conformations<italic>.</italic> Examples of &#x003b1;-helical antimicrobial peptides include magainin, temporins and melittin, which undergo a conformational change from unstructured in solution to an amphipathic helix when in interaction with the lipid membrane. All these peptides are cationic and disrupt the membrane of Gram positive and Gram negative bacteria. They also exhibit activity against fungal species (Lombardi et al. <xref ref-type="bibr" rid="CR212">2019</xref>). Membrane active &#x003b2;-sheet antimicrobial peptides can already be structured in solution, due to rigid conformations eventually stabilised by disulphide bridges, as for instance the natural host defense peptides defensins and their designed synthetic cyclic derivatives (Scudiero et al. <xref ref-type="bibr" rid="CR317">2015</xref>). Pioneering work by Ghadiri&#x02019;s group showed that de novo designed cyclic D,L-peptides can form pores within membranes and exert antimicrobial activity (Fernandez-Lopez et al. <xref ref-type="bibr" rid="CR105">2001</xref>). Membrane active unstructured/extended antimicrobial peptides can adopt an amphipathic fold within membranes to induce disruption or simply be translocated to the intracellular space. The activity of such AMPs generally involves intracellular targets via specific amino acid motifs, including proline-rich AMPs originated from insects, or tryptophan and arginine rich peptides such as indolicidin (Le et al. <xref ref-type="bibr" rid="CR189">2017</xref>).</p></sec><sec id="Sec15"><title>Toxicity: membrane composition selectivity</title><p id="Par29">Due to differences in the membrane composition of different microbes/organism and cell types (Table <xref rid="Tab3" ref-type="table">3</xref>), most AMPs can be cell-selective, by discriminating between the target membranes.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Major membrane lipids for bacterial, fungal and mammalian cell types</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Cell type</th><th>Major membrane lipids</th><th>References</th></tr></thead><tbody><tr><td>Bacterial</td><td>Phosphatidylcholine (PC), phosphatidylglycerol (PG), and phosphatidylethanolamines (PE)</td><td>(Shrestha et al. <xref ref-type="bibr" rid="CR324">2013</xref>; John et al. <xref ref-type="bibr" rid="CR160">2017</xref>; Travkova et al. <xref ref-type="bibr" rid="CR354">2017</xref>; Nielsen et al. <xref ref-type="bibr" rid="CR258">2018</xref>)</td></tr><tr><td>Fungal</td><td>Phosphatidylcholine (PC), phosphatidylethanolamines (PE), phosphatidylinositol (PI) and ergosterol.</td><td>(Cho et al. <xref ref-type="bibr" rid="CR59">2013</xref>; Shrestha et al. <xref ref-type="bibr" rid="CR324">2013</xref>)</td></tr><tr><td>Mammalian</td><td>Phosphatidylcholine (PC) and cholesterol</td><td>(Shrestha et al. <xref ref-type="bibr" rid="CR324">2013</xref>; John et al. <xref ref-type="bibr" rid="CR160">2017</xref>; Travkova et al. <xref ref-type="bibr" rid="CR354">2017</xref>)</td></tr></tbody></table></table-wrap></p><p id="Par30">Membrane selectivity is governed by phospholipid composition and the resulting net charge of the membrane (Yeaman and Yount <xref ref-type="bibr" rid="CR392">2003</xref>), parameters which can differ significantly between prokaryotic and eukaryotic cells. Though not always the case, significant levels of antibacterial activity are achievable with minimal haemolysis and cytotoxicity, resulting in a high therapeutic index, which can be gauged by the ratio of minimum haemolytic concentration (MHC) to minimum inhibitory concentration (MIC).</p><p id="Par31">Numerous studies have found that antimicrobial peptide charge (which is typically cationic) plays a considerable role in the mechanism through which AMPs achieve cell selectivity. In mammalian cells, the outer lipid leaflet is typically comprised of zwitterionic phosphatidylcholine and sphingomyelin species, with anionic lipids distributed asymmetrically within the inner leaflet (Verkleij et al. <xref ref-type="bibr" rid="CR360">1973</xref>). In contrast, bacterial cell membranes contain an abundance of anionic phospholipids such as phosphatidylglycerol and cardiolipin. Other structural molecules, such as the negatively charged lipopolysaccharides in Gram negative bacteria, and teichoic acids in Gram positive bacteria, further contribute to the net negative charge of bacterial cell membranes. As a result, electrostatic interactions lead to preferential binding between AMPs and bacterial membranes (Christensen et al. <xref ref-type="bibr" rid="CR62">1988</xref>; Matsuzaki et al. <xref ref-type="bibr" rid="CR226">1997</xref>; Silvestro et al. <xref ref-type="bibr" rid="CR327">1997</xref>).</p><p id="Par32">However, significant differences in a given peptide&#x02019;s antimicrobial activity are observed when assayed against different bacterial species, pointing to separate mechanisms beyond simple membrane charge. Aside from fundamental structural differences between species, several studies have indicated that amongst anionic phospholipids, head group structure and hydrocarbon chain length further regulate peptide-membrane interactions. As assessed via DSC, the AMP protegrin-1 was found to influence the thermotropic phase behaviour of exposed DPPG vesicles significantly more than those comprised of DPPA, despite net negative charge of both lipid species being equal (Jing et al. <xref ref-type="bibr" rid="CR159">2005</xref>). It was additionally found that while the peptide bound to both DMPG and DSPG liposomes, penetration of protegrin-1 into the hydrophobic region of the bilayer only occurred for DMPG. This second observation was explained by the lipid tail packing, which is tighter in DSPG due to increased van der Waals forces between the longer hydrocarbon chains, resulting in an increased energy barrier for peptide insertion.</p><p id="Par33">Further contributing to cell selectivity are the hydrophobic interactions occurring between the hydrophobic portions of amphipathic peptides and the cell membrane. It has been demonstrated that peptides with high MHC values exhibit strong interactions with membranes comprised of the zwitterionic phosphatidylcholine, while non-haemolytic peptides do not. With increasing insight into the parameters responsible for activity and selectivity, attempts have been made to modify or engineer existing antimicrobial peptides, with an aim to increase efficacy. It has been noted that increases in cationic charge up to approximately +&#x02009;10 increase antimicrobial activity with minimal impact on haemolytic activity (Zelezetsky and Tossi <xref ref-type="bibr" rid="CR398">2006</xref>).</p><p id="Par34">The effect on antimicrobial and haemolytic activity of peptide hydrophobicity, hydrophobic moment and angle subtended by the positively charged helix face were examined by Dathe et al. using a series of magainin and model peptides (Dathe et al. <xref ref-type="bibr" rid="CR74">1997</xref>). It was found that increases in each of these three parameters increased both activity against Gram positive bacteria and haemolytic activity to a similar extent. It was suggested that such increases in activity were driven by hydrophobic peptide&#x02013;membrane interactions, particularly given that the erythrocyte membrane is largely comprised of zwitterionic PC and PE phospholipids. MIC values for the Gram positive <italic>S. aureus</italic> remained below the EC50 for haemolysis, and the model KLA peptides (+&#x02009;6 net charge) displayed lower MICs than magainins (+&#x02009;4 net charge), indicating that Gram positive activity remains dependent on peptide charge as well (Dathe et al. <xref ref-type="bibr" rid="CR74">1997</xref>). Activity against Gram negative bacteria showed little change as these parameters were altered, and it was reasoned that Gram negative activity was governed predominantly by electrostatic interactions. This observation would appear to explain the prokaryotic specificity of magainin, while more hydrophobic AMPs such as melittin exhibit activity against both bacterial and mammalian cell membranes (Dathe et al. <xref ref-type="bibr" rid="CR74">1997</xref>).</p><p id="Par35">If one considers the action of AMPs as a combination of electrostatic and hydrophobic interactions with a membrane, then for more neutral membranes, where electrostatic peptide-lipid interactions are minimized, the hydrophobic effect plays a more predominant role regarding host cell toxicity. Hydrophobicity is an essential feature for AMP-membrane interactions. However, the increase of the hydrophobic interaction is strongly correlated with mammalian cell toxicity and loss of antimicrobial specificity. Therefore, many AMPs are moderately hydrophobic, to optimise selective toxicity towards microbial cell membranes. Selective antimicrobial activity results from a delicate balance of hydrophobic and electrostatic interactions between an antimicrobial peptide and the targeted membrane (Giuliani and Rinaldi <xref ref-type="bibr" rid="CR125">2011</xref>; Kang et al. <xref ref-type="bibr" rid="CR169">2014</xref>; Ong et al. <xref ref-type="bibr" rid="CR267">2014</xref>; Sierra et al. <xref ref-type="bibr" rid="CR325">2017</xref>).</p></sec></sec><sec id="Sec16"><title>Other cellular targets: lipopolysaccharides and intracellular targets</title><p id="Par36">Lipopolysaccharides (LPS) are hallmark components of Gram negative bacteria outer membranes. LPS can be described as containing a lipid domain (lipid A or endotoxin) covalently bound to a &#x0201c;core&#x0201d; oligosaccharide and an antigen polysaccharide (O-antigen). Endotoxins exhibit pro-inflammatory activity via binding to innate immunity receptors, the Toll-like receptors present in animal immune cells. Hence, targeting LPS can result in Gram negative bactericidal activity via outer membrane destabilisation and in reducing endotoxin activity (Raetz and Whitfield <xref ref-type="bibr" rid="CR295">2002</xref>). Given the LPS amphipathic nature and negative charge, cationic amphipathic peptides are expected to significantly interact with LPS. This is the case for natural AMPs such as melittin, magainin and protegrin (Ding et al. <xref ref-type="bibr" rid="CR89">2003</xref>), but also synthetic peptides, which have been shown to destabilise the Gram negative bacterial outer membrane and to exhibit anti-toxin activity (Lakshminarayanan et al. <xref ref-type="bibr" rid="CR183">2016</xref>; Heinbockel et al. <xref ref-type="bibr" rid="CR145">2018</xref>).</p><p id="Par37">However, endogenous antimicrobial peptides have also been shown to exhibit pro-inflammatory activity by complexation of immune ligands, including LPS and nucleic acids. Indeed, complexes of microbial ligands by endogenous AMPs are currently thought to be potentially immune-stimulant to signal microbial invasion to the immune system (Lee et al. <xref ref-type="bibr" rid="CR197">2019a</xref>). The interplay between the immune system and antimicrobial peptides is complex and is currently being investigated on a case by case basis, with excellent reviews available on the topic (Hilchie et al. <xref ref-type="bibr" rid="CR150">2013</xref>; Mookherjee et al. <xref ref-type="bibr" rid="CR245">2020</xref>).</p><p id="Par38">Intracellular microbial targets identified for natural AMPs span from binding nucleic acids, the ribosome or protein chaperones, to inhibiting protein metabolism, cell division or cell wall synthesis. Over the past decade, an increasing number of natural AMPs have been shown to inhibit multiple microbial functions (Le et al. <xref ref-type="bibr" rid="CR189">2017</xref>; Mookherjee et al. <xref ref-type="bibr" rid="CR245">2020</xref>). For instance, it was evidenced that the short cationic peptide indolicidin, a cathelicidin with high tryptophan and arginine content, induces non-bactericidal membrane permeabilisation and binds intracellular duplex DNA via the peptide motif PWWP to inhibit microbial DNA replication and transcription (Ghosh et al. <xref ref-type="bibr" rid="CR124">2014</xref>). Although intracellular targets may provide an interesting addition or alternative for the molecular engineering of AMPs, few synthetic peptides have been specifically designed to target such microbial components to date and few of these&#x000a0;peptide motifs have been identified (Le et al. <xref ref-type="bibr" rid="CR189">2017</xref>).</p></sec><sec id="Sec17"><title>Targeting microbial colonies: biofilm components and bacterial adhesion</title><p id="Par39">Bacterial biofilms are resilient drug-resistant communities of surface-adhered bacteria encapsulated within a sturdy extracellular matrix that acts as a physical barrier (Dunne Jr. <xref ref-type="bibr" rid="CR93">2002</xref>). Medical implants such as catheters are often compromised due to the formation of bacterial biofilms on the surface of the device; the rate of biofilm formation being affected by the material of the device (Quirynen and Bollen <xref ref-type="bibr" rid="CR292">1995</xref>; Garrett et al. <xref ref-type="bibr" rid="CR121">2008</xref>; Song et al. <xref ref-type="bibr" rid="CR334">2015</xref>). While this is typically remedied by simply replacing the medical device, an infection forming a resilient biofilm on a more permanent implant such as a prosthetic joint is disastrous. Biofilms may also form on living tissue such as <italic>P. aeruginosa</italic> colonisation of the lungs in immunocompromised cystic fibrosis patients (Lam et al. <xref ref-type="bibr" rid="CR184">1980</xref>). This is mainly due to the innate resistance of bacterial biofilms to antibiotics and disinfectants (Oie et al. <xref ref-type="bibr" rid="CR265">1996</xref>). Biofilm formation is also associated with several diseases and medical complications such as diabetic foot ulcer infections (Neut et al. <xref ref-type="bibr" rid="CR254">2011</xref>), ear infections, and urinary tract infections (Vestby et al. <xref ref-type="bibr" rid="CR362">2020</xref>).</p><p id="Par40">Aside from the cells themselves, microbial biofilms are primarily composed of exopolysaccharides such as the teichoic acids of Gram positive <italic>Staphylococci</italic> and several from Gram negative species such as <italic>P. aeruginosa</italic> (Byrd et al. <xref ref-type="bibr" rid="CR47">2009</xref>; Colvin et al. <xref ref-type="bibr" rid="CR67">2012</xref>). These polysaccharides are involved in surface adhesion during the initial stage of biofilm formation (Flemming <xref ref-type="bibr" rid="CR107">1993</xref>). Proteins and extracellular microbial DNA are also major components of biofilm systems (Whitchurch et al. <xref ref-type="bibr" rid="CR378">2002</xref>; Flemming and Wingender <xref ref-type="bibr" rid="CR108">2010</xref>). Exopolysaccharides effect a local environment like that of an extracellular matrix, allowing for microbial cells to remain attached to the surface and resist shear forces (Donlan and Costerton <xref ref-type="bibr" rid="CR91">2002</xref>). Biofilm-residing microbial cells are less metabolically active than planktonic phase cells, allowing for perseverance in nutrient-deficient environments, and may contribute to higher resistance to antibiotics targeting metabolic pathways (Walters 3rd et al. <xref ref-type="bibr" rid="CR369">2003</xref>). In bacterial biofilms, the cells participate in communication via quorum sensing (QS) (Li and Tian <xref ref-type="bibr" rid="CR201">2012</xref>). QS arises from the bacterial generation and detection of signalling molecules called autoinducers (AIs), which are typically acyl homoserine lactones and other compounds biosynthesised from S-adenosylmethionine (Parveen and Cornell <xref ref-type="bibr" rid="CR276">2011</xref>; Papenfort and Bassler <xref ref-type="bibr" rid="CR273">2016</xref>). While Gram negative species utilise small molecule AIs, Gram positive bacteria such as <italic>S. aureus</italic> employ cyclic oligopeptides as autoinducer peptides (AIPs), which may be mimicked by synthetic peptides in order to block the quorum sensing pathway and the generation of virulence factors (Mayville et al. <xref ref-type="bibr" rid="CR228">1999</xref>; Thoendel et al. <xref ref-type="bibr" rid="CR352">2011</xref>; Zhu and Lau <xref ref-type="bibr" rid="CR403">2011</xref>).</p><p id="Par41">The design of anti-biofilm peptides is a more nuanced approach compared to that of AMP inhibitors of planktonic cells as membrane disruption is not the sole mechanism sought after for anti-biofilm peptides (Sakala and Reches <xref ref-type="bibr" rid="CR305">2018</xref>; Dostert et al. <xref ref-type="bibr" rid="CR92">2019</xref>). However, it has been suggested that AMPs are more suitable as anti-biofilm agents compared to traditional antibiotics since the membrane remains a target irrespective of the metabolic state of the cell (Hurdle et al. <xref ref-type="bibr" rid="CR154">2011</xref>). The downside of this is of course that higher than usual concentrations of AMPs may be required, which may also induce haemolytic or cytotoxic effects. The distinct growth stages of biofilms may be targeted such as by inhibiting bacterial adhesion in the first place or interfering with growth and quorum sensing (Table <xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Examples of short synthetic anti-biofilm peptides and their biofilm targets</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Peptide</th><th>Target</th><th>Description</th><th>Microbes</th><th>Reference</th></tr></thead><tbody><tr><td>DOPA-pfp-pfp-OMe*</td><td>Cell adhesion</td><td>Forms self-assembled nanostructures on inorganic surfaces that impede bacterial adhesion</td><td><italic>P. aeruginosa</italic>, <italic>E. coli</italic></td><td>(Maity et al. <xref ref-type="bibr" rid="CR218">2014</xref>)</td></tr><tr><td>PEG-GZ3.163 (4-methylhexanoyl-(PEG)-C-d-Dab-Dab-Leu-d-Phe-Dab-Dab-Leu-NH<sub>2</sub>)</td><td>Cell adhesion</td><td>Polymer attached linear lipopeptide coating that prevents biofilm formation on inorganic surfaces</td><td><italic>P. aeruginosa</italic>, <italic>E. coli</italic></td><td>(De Zoysa and Sarojini <xref ref-type="bibr" rid="CR81">2017</xref>)</td></tr><tr><td>Co-polymer-Tet-26 (WIVVIWRRKRRRC)</td><td>Cell adhesion</td><td>Tet-26 attached to polymer brush surface inhibits biofilm formation</td><td><italic>P. aeruginosa</italic>, <italic>S. aureus</italic></td><td>(Gao et al. <xref ref-type="bibr" rid="CR120">2011</xref>)</td></tr><tr><td>1018 (VRLIVAVRIWRR-NH<sub>2</sub>)</td><td>(p)ppGpp signalling</td><td>Inhibits (p)ppGpp, interfering with bacterial stringent response</td><td><italic>P. aeruginosa</italic>, <italic>E. coli</italic>, <italic>A. baumanii</italic>, <italic>B. cenocepacia</italic>, <italic>S. enterica</italic>, <italic>K. pneumoniae</italic>, <italic>S. aureus</italic> (MRSA)</td><td>(de la Fuente-Nunez et al. <xref ref-type="bibr" rid="CR77">2014</xref>)</td></tr><tr><td><p>DJK-5</p><p>[d-(VQLRRIRVWVIR)]</p><p>DJK-6</p><p>[d-(VQWRRIRVWVIR)]</p></td><td>(p)ppGpp signalling</td><td>Inhibits (p)ppGpp, interfering with bacterial stringent response</td><td><italic>P. aeruginosa</italic>, <italic>E. coli</italic>, <italic>A. baumanii</italic>, <italic>K. pneumoniae</italic>, <italic>S. enterica</italic></td><td>(de la Fuente-Nunez et al. <xref ref-type="bibr" rid="CR78">2015</xref>)</td></tr><tr><td><p>LIVRHK</p><p>LIVRRK</p></td><td>Quorum sensing (competency stimulation)</td><td>Short AIP mimicking peptides that inhibit quorum sensing</td><td><italic>S. aureus</italic></td><td>(Taha et al. <xref ref-type="bibr" rid="CR345">2019</xref>)</td></tr></tbody></table><table-wrap-foot><p>*<italic>pfp</italic>, pentafluorophenylalanine</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec18"><title>Antimicrobial peptide self-assembly and activity</title><p id="Par42">A correlation between peptide self-assembly and antimicrobial activity was suggested by the discovery that (i) amyloidogenic sequences can exhibit antimicrobial properties and (ii) endogenous antimicrobial proteins can form amyloid-like nanofibrillar aggregates (Sood et al. <xref ref-type="bibr" rid="CR335">2008</xref>; Jang et al. <xref ref-type="bibr" rid="CR157">2011</xref>; Kagan et al. <xref ref-type="bibr" rid="CR166">2012</xref>). Similarly, two molecular design approaches supported the interplay between peptide self-assembly and antimicrobial activity: (i) peptide sequences firstly designed to self-assemble into nanostructures, then discovered to exhibit antimicrobial activity; (ii) or the opposite, peptide sequences designed towards antimicrobial activity&#x02014;essentially by membrane disruption&#x02014;then discovered to self-assemble into hydrogels and/or supramolecular nanostructures (Tian et al. <xref ref-type="bibr" rid="CR353">2015</xref>; Shi et al. <xref ref-type="bibr" rid="CR323">2021</xref>). Although the requirement of amphipathic sequences is an obvious common physicochemical property shared by both molecular designs, the mechanisms of action by which peptide oligomers or nanostructures can damage microbial cells emerged relatively recently. Interestingly, the microbial membrane is not the only target that can be affected by peptide self-assembled species, as reviewed below.</p><sec id="Sec19"><title>Peptide amyloidogenic properties and antimicrobial activity</title><p id="Par43">The amyloid beta (A&#x003b2;) peptide, which self-assembles into the so-called amyloid nanofibrillar aggregates in the brain of Alzheimer&#x02019;s disease patients, was shown to exhibit broad-spectrum antimicrobial activity against bacteria and fungi (Soscia et al. <xref ref-type="bibr" rid="CR336">2010</xref>; Bourgade et al. <xref ref-type="bibr" rid="CR39">2016</xref>). Unexpectedly, the amyloid beta (A&#x003b2;) peptide was found to be of equivalent or greater antimicrobial potency as the human host defence peptide LL-37, suggesting unrecognised normal functions of the A&#x003b2; peptide in the innate immune response to microbial infections (Soscia et al. <xref ref-type="bibr" rid="CR336">2010</xref>). Mechanistic studies support that A&#x003b2; peptide antimicrobial activity is caused by the formation of ion channels within the microbial membranes, e.g. similar mechanism of action as its toxicity to brain cells (Kagan et al. <xref ref-type="bibr" rid="CR166">2012</xref>). A number of mechanisms of membrane disruption were unravelled to explain amyloid toxicity towards brain cells, including the insertion of toxic oligomers and membrane interactions with mature nanofibrils (Dharmadana et al. <xref ref-type="bibr" rid="CR88">2017</xref>). These molecular interactions can be hypothesised to apply to microbial membranes too (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Main models of membrane disruption by amyloid oligomers. Reproduced from Dharmadana et al. <xref ref-type="bibr" rid="CR88">2017</xref>. <italic>Copyright &#x000a9; 2017, The Royal Society Publishing</italic></p></caption><graphic xlink:href="12551_2021_784_Fig3_HTML" id="MO3"/></fig></p><p id="Par44">Further supporting a correlation between self-assembly and antimicrobial activity, endogenous antimicrobial proteins and peptides were shown in vitro to undergo self-assembly into amyloid-like nanofibrillar aggregates, e.g. the human peptide LL-37 (Sood et al. <xref ref-type="bibr" rid="CR335">2008</xref>), protegrin-1 (Jang et al. <xref ref-type="bibr" rid="CR157">2011</xref>), or human &#x003b1;-defensin peptides (Chairatana et al. <xref ref-type="bibr" rid="CR53">2016</xref>). Two main mechanisms of action related to self-assembly were identified for these natural AMPs: either microbial membrane permeabilization by cytotoxic oligomers (Sood et al. <xref ref-type="bibr" rid="CR335">2008</xref>) and/or the entanglement of bacteria within &#x0201c;nanonets&#x0201d; formed by antimicrobial peptide nanostructures (Chairatana et al. <xref ref-type="bibr" rid="CR53">2016</xref>; Chairatana and Nolan <xref ref-type="bibr" rid="CR52">2017</xref>), which relates to biofilm targeting.</p></sec><sec id="Sec20"><title>Membrane disruption upon peptide self-assembly</title><p id="Par45">A few excellent reviews compile examples of self-assembling synthetic peptides that exhibit antimicrobial activity (Tian et al. <xref ref-type="bibr" rid="CR353">2015</xref>; Malekkhaiat H&#x000e4;ffner and Malmsten <xref ref-type="bibr" rid="CR219">2018</xref>; Lombardi et al. <xref ref-type="bibr" rid="CR212">2019</xref>; Shi et al. <xref ref-type="bibr" rid="CR323">2021</xref>). The large majority of systems are amphipathic cationic peptides that affect the microbial membrane, either by lipid phase destabilisation or pore formation, eventually leading to cell lysis and death. In most cases, the peptide amphipathic design is responsible for intrinsic self-assembly, while hydrophobic and cationic charges ensure interactions with phospholipids and membrane insertion leading to antimicrobial activity. Hence, the amphipathic cationic design is sufficient to drive self-assembly while ensuring activity. By introducing rational variations in the amphipathic design in a single peptide system, various research groups succeeded in fine-tuning self-assembly into supramolecular structures of different morphologies and/or hydrogels while conserving antimicrobial activity (Shi et al. <xref ref-type="bibr" rid="CR323">2021</xref>). Recently, Gazit et al. exploited the self-assembly of the Phe-Phe dipeptide into precipitated nanotubes to create solid nanotube arrays on surfaces. Such nanostructured surfaces exhibit antibacterial activity by mechanical disruption of the bacterial membrane (Schnaider et al. <xref ref-type="bibr" rid="CR313">2017</xref>). This mechanism is directly inspired from the natural antibacterial properties of micro-spikes on dragonfly wings, which paved the way to diverse research on antimicrobial nanostructured surfaces of various chemical compositions (Elbourne et al. <xref ref-type="bibr" rid="CR97">2017</xref>).</p><p id="Par46">Few studies report on the direct characterisation of bacterial membrane disruption of monomeric versus self-assembled peptides for comparable sequences. Although one would expect synergy between self-assembly and membrane disruption, current reports support subtlety and system specificity of this structure-function relationship. For instance, rationally designed cationic amphipathic &#x0201c;multidomain peptides&#x0201d; (MDPs) self-assemble into nanofibers, which have been shown to directly interact with lipid membranes as assembled peptides. However, when the nanofibers form hydrogels, antimicrobial activity is affected by rheological properties (Jiang et al. <xref ref-type="bibr" rid="CR158">2015</xref>). Interestingly, the same group reported an increase in melittin selective toxicity towards model bacterial membranes over mammalian membranes when assembled on MDP nanofibers. This result was assigned to the different conformations adopted by melittin in its monomeric and assembled forms when presented to the lipid membrane (Chen et al. <xref ref-type="bibr" rid="CR58">2019</xref>). Another example is the rationally designed family of ultrashort battacin-inspired peptides, with some peptides shown to self-assemble into nanostructures and hydrogels while other sequences remain as small oligomeric species in solution. These peptides act by targeting the microbial membrane. Although there is a clear difference in self-assembling properties for these related sequences, it appeared difficult to draw a direct correlation with the antimicrobial activity measured on various strains (Glossop et al. <xref ref-type="bibr" rid="CR127">2019</xref>). The understanding of the direct interplay between self-assembly and antimicrobial activity requires more research to enunciate generic rules.</p></sec><sec id="Sec21"><title>Other targets than membranes affected by peptide self-assembly</title><p id="Par47">Rational design of peptide sequences to self-assemble into toxic aggregates within bacterial cells was reported for a few examples, although this approach remains marginal and mechanistic details still need to be unravelled. A smart design involving dephosphorylation induced self-assembly of a tripeptide derivative into toxic intracellular nanofibers was for instance reported (Yang et al. <xref ref-type="bibr" rid="CR390">2007</xref>). Such a peptide antibiotic was shown to be bacteriostatic. Another approach to induce intracellular peptide aggregation focused on bacterial genome screening to identify aggregation-prone sequences (Bednarska et al. <xref ref-type="bibr" rid="CR19">2016</xref>). Interestingly, antibacterial peptide sequences were obtained, including against resistant strains and with good indications of specific toxicity. Intracellular aggregation resulted in bacterial cell death.</p><p id="Par48">Extracellular peptide self-assembly, especially when resulting into hydrogels, can lead to bacteria entrapment and prevent cell mobility. This effect was reported for both natural antimicrobial sequences (Chairatana et al. <xref ref-type="bibr" rid="CR53">2016</xref>; Chairatana and Nolan <xref ref-type="bibr" rid="CR52">2017</xref>) and synthetic self-assembling peptides (Jiang et al. <xref ref-type="bibr" rid="CR158">2015</xref>). It is noteworthy that the matrix structure of bacterial biofilms relies on amyloid-like protein self-assembly into nanofibers. Hence, the current research effort on amyloid nanofibril self-assembly inhibition may lead to the discovery of compounds that chemically hinder biofilm formation (Andreasen et al. <xref ref-type="bibr" rid="CR7">2019</xref>).</p><p id="Par49">The self-assembly of endogenous antimicrobial peptides in complex with nucleic acids (DNA or RNA) has been shown to control Toll-like receptors activation and subsequent pro-inflammatory responses. Interestingly, it was recently supported that structural specificity of these complexes might be essential for triggering an immune response: the peptides self-assemble into nanoscaffolds that present ordered nucleic acids to immune receptors (Schmidt et al. <xref ref-type="bibr" rid="CR310">2015</xref>; Lee et al. <xref ref-type="bibr" rid="CR194">2017b</xref>; Lee et al. <xref ref-type="bibr" rid="CR198">2019b</xref>). Although this recently emerged area of research is directly relevant to auto-immune diseases, it may hold promise for unravelling novel mechanisms that promote antimicrobial activity and/or modulate immunogenicity to support novel peptide designs.</p></sec></sec><sec id="Sec22"><title>Mechanisms of resistance to antimicrobial peptides</title><p id="Par50">Microbial pathogens have developed distinct systems to resist the effect of antimicrobial peptides. These systems involve the destruction of antimicrobial peptides, change of their target and removal of peptides from their site of action (Gunn <xref ref-type="bibr" rid="CR138">2001</xref>; Joo and Otto <xref ref-type="bibr" rid="CR164">2015</xref>). Some of the defence mechanisms of bacteria versus AMPs include sequestration or degradation by secreted proteases (Mattiuzzo et al. <xref ref-type="bibr" rid="CR227">2014</xref>), impedance by biofilm formation and exopolymers (Bechinger and Gorr <xref ref-type="bibr" rid="CR17">2017</xref>), surface modification (Gunn <xref ref-type="bibr" rid="CR138">2001</xref>), cytoplasmic membrane alteration and export by multidrug efflux pumps (Nizet <xref ref-type="bibr" rid="CR260">2006</xref>). Excellent reviews have provided details on these mechanisms and are presented in Table <xref rid="Tab5" ref-type="table">5</xref> and Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref> (Guilhelmelli et al. <xref ref-type="bibr" rid="CR136">2013</xref>; Joo et al. <xref ref-type="bibr" rid="CR165">2016</xref>) (Table <xref rid="Tab5" ref-type="table">5</xref>, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<table-wrap id="Tab5"><label>Table 5</label><caption><p>Mechanisms of resistance to AMPs by bacteria, adapted from (Guilhelmelli et al. <xref ref-type="bibr" rid="CR136">2013</xref>; Joo et al. <xref ref-type="bibr" rid="CR165">2016</xref>)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Resistance mechanisms</th><th>Gram positive bacteria</th><th>Gram negative bacteria</th></tr></thead><tbody><tr><td>Extracellular proteins</td><td>Proteolytic degradation, sequestration</td><td>Proteolytic degradation</td></tr><tr><td>Exopolymers</td><td>PIA*, PGA**</td><td>Polysialic acid, alginate</td></tr><tr><td>Surface modification</td><td>Repulsion by D-alanylation of TA steric hindrance by L-rhamnosylation of WTA lipid II modification</td><td>Repulsion by lipid A phosphate modification increased OM rigidity by lipid A acylation O-antigen of LPS</td></tr><tr><td>Cytoplasmic membrane alteration</td><td>Charge repulsion by PG amino acylation</td><td>Increased IM rigidity by PG acylation</td></tr><tr><td>Efflux pumps</td><td>Export by ABC transporters</td><td>Export by RND family efflux pumps</td></tr></tbody></table><table-wrap-foot><p>*Polysaccharide intercellular adhesin or poly/N/acetyl glucosamine (PIA)</p><p>**Poly-gamma-glutamic acid (PGA)</p></table-wrap-foot></table-wrap><fig id="Fig4"><label>Fig. 4</label><caption><p>Mechanisms of bacterial resistance to AMPs. (1) Extracellular proteases perform proteolytic degradation; (2) sequestration can occur by extracellular matrix or extracellular proteins; (3) alanylated teichoic acids create electrostatic repulsion; (4) aminoacylated peptidoglycan also create electrostatic repulsion; (5) lack of lipid II-binding AMPs by pentapeptide alteration; (6) AMPs rejection by efflux pumps; (7) proteolytic cleavage by cytosolic protease after uptake by transporters; (8) sequestration or steric hindrance by O-antigen of LPS; (9) amine compound-added lipid A creates electrostatic repulsion; (10) lipid A acylation creates increased rigidity. Figure modified from Joo et al. <xref ref-type="bibr" rid="CR165">2016</xref></p></caption><graphic xlink:href="12551_2021_784_Fig4_HTML" id="MO4"/></fig></p><sec id="Sec23"><title>Extracellular proteolytic degradation</title><p id="Par51">Extracellular proteins are the first mechanism of defence and include proteases that degrade AMPs. Some of these proteases are SepA, aureolysin (metalloproteases), V8 protease and SepB that can protect against the human cathelicidin LL-37 (Schmidtchen et al. <xref ref-type="bibr" rid="CR312">2002</xref>; Bara&#x00144;ska-Rybak et al. <xref ref-type="bibr" rid="CR15">2005</xref>; Frick et al. <xref ref-type="bibr" rid="CR114">2011</xref>). It has been observed that the interaction of SpeB and a host protein: alpha2M-binding (GRAB) creates a complex with a proteinase inhibitor bound on the surface that increases the resistance to LL-37 (Nyberg et al. <xref ref-type="bibr" rid="CR261">2004</xref>). Also, SpeB-degraded host proteoglycans release dermatan sulphate that neutralizes human alpha defensin HNP-1 (Schmidtchen et al. <xref ref-type="bibr" rid="CR311">2001</xref>) amongst others (Schmidtchen et al. <xref ref-type="bibr" rid="CR312">2002</xref>).</p><p id="Par52">Within Gram negative bacteria, the omptin family are aspartate proteases located in the enterobacterial outer membrane (OM) that cleave LL-37 and cathelicidin-related antimicrobial peptide (CRAMP) (Stumpe et al. <xref ref-type="bibr" rid="CR341">1998</xref>; Guina et al. <xref ref-type="bibr" rid="CR137">2000</xref>; Galv&#x000e1;n et al. <xref ref-type="bibr" rid="CR118">2008</xref>). Metalloproteases are also important for Gram negative bacteria since several AMPs such as LL-37, human beta defensin HBD-1 and the porcine AMP protegrin-1 are neutralized by the metalloprotease ZapA (Belas et al. <xref ref-type="bibr" rid="CR20">2004</xref>). This metalloprotease is produced by <italic>P. mirabilis</italic> and is not specific to AMPs as it also degrades components of the cell matrix (actin, collagen) and antibodies (Belas et al. <xref ref-type="bibr" rid="CR20">2004</xref>). The degradation of alpha and beta defensins has also been observed in <italic>Porphyromonas gingivalis</italic> (Carlisle et al. <xref ref-type="bibr" rid="CR50">2009</xref>).</p><p id="Par53">Similarly, various cationic AMPs (CAMPs) can be degraded by ZmpA and ZmpB produced by <italic>B. cenocepacia</italic> (Kooi and Sokol <xref ref-type="bibr" rid="CR179">2009</xref>). The degradation can also occur intracellularly with the help of transport proteins such as the ABC transporter that is encoded by the <italic>sapABCDFZ</italic> (Groisman et al. <xref ref-type="bibr" rid="CR135">1992</xref>; Mason et al. <xref ref-type="bibr" rid="CR222">2005</xref>). Moreover, an increased expression of genes in the sap operon is caused by the binding of the CAMPs by the SapA that leads to their proteolytic degradation (Mason et al. <xref ref-type="bibr" rid="CR222">2005</xref>; Mason et al. <xref ref-type="bibr" rid="CR223">2006</xref>; Shelton et al. <xref ref-type="bibr" rid="CR322">2011</xref>) as observed with <italic>H. influenzae</italic> with several AMPs such as LL-37, HBD-2, HBD-3 and HNP-1 and melittin (Mason et al. <xref ref-type="bibr" rid="CR224">2011</xref>). It is also important to note that inactivating AMPs highly depends on the structure of the target peptide. Linear structures are easier to degrade because the proteolytic areas are more exposed to cleavage than those with disulfide bonds. Bacteriocins such as lantibiotics contain sophisticated post-translational modification, presenting a resistance mechanism towards proteolytic degradation by the host or competing microorganisms (Bierbaum and Sahl <xref ref-type="bibr" rid="CR28">2009</xref>).</p><p id="Par54">Another resistance mechanism is the sequestration of AMPs. Staphylokinase is an important extracellular AMP-sequestering molecule that targets alpha defensins (HNP1 and 2) (Bokarewa and Tarkowski <xref ref-type="bibr" rid="CR37">2004</xref>). Another streptococcal sequester is streptococcal inhibitor of complement (SIC). It protects <italic>S. pyogenes</italic> from defensins, LL-37 and the membrane attack complex (&#x000c5;kesson et al. <xref ref-type="bibr" rid="CR2">1996</xref>; Frick et al. <xref ref-type="bibr" rid="CR113">2003</xref>).</p><p id="Par55">Also, some streptococcal cell surface-attached proteins such as M1 and PilB from <italic>S. pyogenes</italic> and <italic>S. agalactiae</italic> respectively bind cathelicidins (LL-37 and CRAMP) providing resistance to AMPs (Maisey et al. <xref ref-type="bibr" rid="CR217">2008</xref>; Lauth et al. <xref ref-type="bibr" rid="CR188">2009</xref>).</p></sec><sec id="Sec24"><title>Exopolymers and biofilms</title><p id="Par56">A bacterial biofilm exhibits higher resistance to AMPs and antibiotics compared to planktonic bacteria (Nickel et al. <xref ref-type="bibr" rid="CR256">1985</xref>; Mah and O&#x02019;Toole <xref ref-type="bibr" rid="CR216">2001</xref>). This is partially due to AMPs not being able to penetrate the biofilm matrix since EPS and capsular polysaccharides (CPS) can adsorb incoming antimicrobials, hinder their traversal into the biofilm, and limit their local concentration at the cells (Sugano et al. <xref ref-type="bibr" rid="CR342">2016</xref>; Singh et al. <xref ref-type="bibr" rid="CR329">2017</xref>). This property also applies especially to cationic AMPS (CAMPs), which have been found to bind to the anionic exopolysaccharide alginate from <italic>P. aeruginosa</italic> biofilms. This sequestering of CAMPs arises from the same mechanism by which they target anionic components of bacterial membranes. Negatively charged extracellular DNA (eDNA) is another major component of biofilms that may bind CAMPs (Mulcahy et al. <xref ref-type="bibr" rid="CR247">2008</xref>; Montanaro et al. <xref ref-type="bibr" rid="CR244">2011</xref>).</p><p id="Par57">eDNA is important for biofilm regulation and is secreted or released by lysed cells during biofilm growth, allowing for horizontal gene transfer within the bacterial population and also acting as a potential source of nutrients (Spoering and Gilmore <xref ref-type="bibr" rid="CR337">2006</xref>; Flemming and Wingender <xref ref-type="bibr" rid="CR108">2010</xref>; Mulcahy et al. <xref ref-type="bibr" rid="CR248">2010</xref>; Okshevsky and Meyer <xref ref-type="bibr" rid="CR266">2015</xref>) It has been proposed that this sharing of genetic material may enhance antimicrobial resistance, adaptability, and pathogenicity in the biofilm (Sykes <xref ref-type="bibr" rid="CR344">2010</xref>; Vorkapic et al. <xref ref-type="bibr" rid="CR364">2016</xref>) Furthermore, the chelation of cations such as magnesium (Mg<sup>2+</sup>) by eDNA may trigger virulence responses in <italic>P. aeruginosa</italic> leading to AMP resistance (Mulcahy et al. <xref ref-type="bibr" rid="CR247">2008</xref>; Lewenza <xref ref-type="bibr" rid="CR199">2013</xref>; Wilton et al. <xref ref-type="bibr" rid="CR386">2016</xref>; Ibanez de Aldecoa et al. <xref ref-type="bibr" rid="CR155">2017</xref>).</p><p id="Par58">Polysaccharide intercellular adhesin (PIA) provides AMP resistance in different forms: it is efficient against LL-37, cationic HDB-3 and anionic dermicidin (Vuong et al. <xref ref-type="bibr" rid="CR366">2004b</xref>; Wang et al. <xref ref-type="bibr" rid="CR372">2004b</xref>), its deacetylation increases its positive net charge and repels CAMPs (Vuong et al. <xref ref-type="bibr" rid="CR365">2004a</xref>), but is also crucial for biofilm formation and enhanced resistance (Heilmann et al. <xref ref-type="bibr" rid="CR144">1996</xref>; Rupp et al. <xref ref-type="bibr" rid="CR303">1999</xref>; Vuong et al. <xref ref-type="bibr" rid="CR366">2004b</xref>). The CPS of <italic>Klebsiella pneumoniae</italic> or <italic>P. aeruginosa</italic> impedes CAMPs by electrostatic trapping (Campos et al. <xref ref-type="bibr" rid="CR48">2004</xref>; Llobet et al. <xref ref-type="bibr" rid="CR211">2008</xref>). Other capsules such as M protein and the hyaluronic acid capsule of group <italic>A streptococci</italic> also sequester AMPs (Cole et al. <xref ref-type="bibr" rid="CR65">2010</xref>).</p><p id="Par59">Bacteria (<italic>P. aeruginosa</italic> and <italic>S. pyogenes</italic>) can also exploit the host polysaccharide to sequester AMPs after degrading their host proteoglycan matrix with bacterial proteases (Schmidtchen et al. <xref ref-type="bibr" rid="CR311">2001</xref>). Exopolysaccharides play a major role in the resistance to LL-37 in <italic>P. aeruginosa</italic> and other lung pathogens (Herasimenka et al. <xref ref-type="bibr" rid="CR148">2005</xref>; Foschiatti et al. <xref ref-type="bibr" rid="CR110">2009</xref>). Also, in <italic>Pseudomonas</italic> species, alginate plays an important role in AMP resistance in biofilms (Hentzer et al. <xref ref-type="bibr" rid="CR147">2001</xref>). Alginate acts by mimicking the microbial membrane inducing changes in AMPs and prevents their diffusion since it binds and induces peptide aggregation (Chan et al. <xref ref-type="bibr" rid="CR54">2004</xref>; Chan et al. <xref ref-type="bibr" rid="CR55">2005</xref>). Poly-gamma-glutamic acid (PGA) exists only in Gram positive bacteria and coagulase-negative <italic>staphylococci</italic> and forms an extracellular capsule that protects from phagocytosis by leukocytes (Ogunleye et al. <xref ref-type="bibr" rid="CR263">2015</xref>). Although it protects from dermcidin, LL-37 and HBD-3 like PIA, it does not facilitate biofilm formation (Kocianova et al. <xref ref-type="bibr" rid="CR177">2005</xref>; Otto <xref ref-type="bibr" rid="CR268">2008</xref>).</p><p id="Par60">For these reasons, eradication of matured biofilms by AMPs is a complicated task, especially in vivo, where there may be limitations to the concentration of AMP allowed in treatments within a therapeutic window. Recent efforts to overcome the antibiotic resistance of biofilms involve the use of DNase to counter the effects of eDNA. DNase has been reported to disperse or destabilise bacterial biofilms of several medically relevant pathogens including <italic>S. aureus</italic>, <italic>P. aeruginosa</italic>, <italic>E. coli</italic> and <italic>C. jejuni</italic> (Tetz and Tetz <xref ref-type="bibr" rid="CR350">2010</xref>; Kaplan et al. <xref ref-type="bibr" rid="CR171">2012</xref>; Baelo et al. <xref ref-type="bibr" rid="CR12">2015</xref>; Brown et al. <xref ref-type="bibr" rid="CR44">2015</xref>) This gives credence to the further development of potential co-administration treatments of DNases and AMPs as a means of overcoming the resistance granted to bacteria by the biofilm matrix and its components (Jones et al. <xref ref-type="bibr" rid="CR163">2013</xref>; Fleming and Rumbaugh <xref ref-type="bibr" rid="CR106">2017</xref>).</p></sec><sec id="Sec25"><title>Surface modification</title><p id="Par61">The critical molecules on the cell surface involved in the resistance to AMPs are the anionic polymers attached to the outermost cell surface, teichoic acids (TA) in Gram positive cell wall and lipopolysaccharides (LPS) in the Gram negative outer membrane. TA represent 60% of the cell wall in Gram positive bacteria and provide a negative cell charge (Kojima et al. <xref ref-type="bibr" rid="CR178">1985</xref>; Bera et al. <xref ref-type="bibr" rid="CR24">2007</xref>) but alanylation on free hydroxyls of the repeating sugars confers a positive charge to TA and this in turn decreases the attraction of CAMPs as observed with <italic>S. aureus</italic> (Peschel et al. <xref ref-type="bibr" rid="CR279">1999</xref>). D-alanylation also increases cell density suggesting a reduction of the permeability and electrostatic repulsion (Saar-Dover et al. <xref ref-type="bibr" rid="CR304">2012</xref>). Gram negative <italic>Bordetella pertussis</italic> uses D-alanylation via Dra (a Dlt homologue) to decrease the negative charge on the OM and increases resistance to LL-37, HNP-1, HNP-2 and polymyxin B (Taneja et al. <xref ref-type="bibr" rid="CR348">2013</xref>). Another mechanism involves the L-rhamnosylation of WTA in <italic>L. monocytogenes</italic> that increases the steric impediment in the cell wall (Carvalho et al. <xref ref-type="bibr" rid="CR51">2015</xref>).</p><p id="Par62">Modification of lipid II (which is an important cell wall building block and peptidoglycan precursor) is also performed by many bacteria to evade AMPs. The modification consists in the replacement of the terminal D-alanine with D-lactate or D-serine to prevent vancomycin binding to the D-Ala-D-Ala dipeptide and blocking the transpeptidation required for cell wall synthesis (Kahne et al. <xref ref-type="bibr" rid="CR167">2005</xref>). Lipid II with D-lactate or D-serine is found on resistant strains conferring them a 1000-fold increased resistance to vancomycin (Bugg et al. <xref ref-type="bibr" rid="CR45">1991</xref>). Bacteriocins and human AMPs HNP-1 and HBD-3 also use lipid II for pore formation (Br&#x000f6;tz et al. <xref ref-type="bibr" rid="CR42">1998</xref>) and block cell wall biosynthesis respectively (de Leeuw et al. <xref ref-type="bibr" rid="CR79">2010</xref>).</p><p id="Par63">In Gram negative bacteria, LPS provides a negative charge (as TA in Gram positive bacteria) and its alteration is required for resistance to AMPs. Thus, amine containing molecules such as glycine, phosphoethanolamine (PEA) and 4-amino-4-deoxy-T-arabinose (Ara4N) increase the positive charge of LPS by modifying lipid A. <italic>Acinetobacter baumannii</italic> and <italic>Bordetella</italic> species perform the modification of lipid A with galactosamine or glucosamine (Llewellyn et al. <xref ref-type="bibr" rid="CR210">2012</xref>; Pelletier et al. <xref ref-type="bibr" rid="CR277">2013</xref>; Shah et al. <xref ref-type="bibr" rid="CR321">2014</xref>). The attachment of PEA onto phosphates in lipid A by <italic>S. typhimurium</italic>, <italic>Neisseria gonorrhoea</italic> and <italic>A. baumanii</italic> also decreases the anionic properties of LPS (Lee et al. <xref ref-type="bibr" rid="CR190">2004a</xref>; Lewis et al. <xref ref-type="bibr" rid="CR200">2013</xref>; Pelletier et al. <xref ref-type="bibr" rid="CR277">2013</xref>). <italic>Burkholderia</italic> and <italic>N. meningitidis</italic> constitutively express PEA-attached lipid A conferring them a higher resistance to AMPs (Tzeng et al. <xref ref-type="bibr" rid="CR355">2005</xref>; Loutet and Valvano <xref ref-type="bibr" rid="CR213">2011</xref>). The removal of anionic phosphate groups from lipid A provides the same effect of adding positive molecules to LPS; this is done by phosphatases in <italic>F. novicida</italic> (Wang et al. <xref ref-type="bibr" rid="CR371">2004a</xref>; Wang et al. <xref ref-type="bibr" rid="CR373">2006</xref>). In addition to the mentioned mechanisms, the O-antigen (outermost long polysaccharide chain in LPS) provides an extra barrier to Gram negative bacteria. A couple of studies have confirmed it is essential for AMP resistance in <italic>Brucella abortus</italic> and <italic>B. cenocepacia</italic> (Allen et al. <xref ref-type="bibr" rid="CR4">1998</xref>; Loutet et al. <xref ref-type="bibr" rid="CR214">2006</xref>).</p></sec><sec id="Sec26"><title>Alteration of the cytoplasmic membrane structure</title><p id="Par64">Since the cytoplasmic membrane is the major target of AMPs, bacteria modify it with different strategies. One of them is the amino acylation of the phosphatidyl glycerol (PG) head group, which masks anionic phosphates with cationic primary amines. This prevents CAMPs attraction to anionic head groups and results in electrostatic repulsion (Peschel et al. <xref ref-type="bibr" rid="CR280">2001</xref>). The protein responsible for this amino acylation is the multipeptide resistance factor (MprF) and was first described in <italic>S. aureus</italic> (Peschel et al. <xref ref-type="bibr" rid="CR280">2001</xref>). The C-terminal synthase domain of MprF uses PG and aminoacyl-tRNA as substrates, the resulting aminoacyl-PG is sent to the outer leaflet of the cytoplasmic membrane by MprF (Ernst et al. <xref ref-type="bibr" rid="CR99">2009</xref>). A different combination of substrates has been used by other bacteria such as Ala-PG in <italic>P. aeruginosa</italic> (Klein et al. <xref ref-type="bibr" rid="CR175">2009</xref>), Lys-PG and Lys-CL in <italic>Listeria monocytogenes</italic> (Thedieck et al. <xref ref-type="bibr" rid="CR351">2006</xref>) and Lys-PG and Ala-PG in <italic>Clostridium perfringes</italic> (Johnston et al. <xref ref-type="bibr" rid="CR161">2004</xref>). Lys-PG has also been reported in Gram negative bacteria such as <italic>Caulobacter crescentus</italic> (Jones and Smith <xref ref-type="bibr" rid="CR162">1979</xref>) or <italic>Rhizobium tropici</italic> (Sohlenkamp et al. <xref ref-type="bibr" rid="CR332">2007</xref>). Finally, the increase of saturated acyl chains can provide a higher membrane rigidity and higher resistance to nisin and pediocin in <italic>L. monocytogenes</italic> and <italic>E. faecalis</italic> respectively (Mazzotta and Montville <xref ref-type="bibr" rid="CR229">1997</xref>; Kumariya et al. <xref ref-type="bibr" rid="CR181">2015</xref>). Similarly, the addition of carotenoid phyloxanthin has been reported to stabilize the acyl chains in the membrane and increase its rigidity in <italic>S. aureus</italic> (Mishra et al. <xref ref-type="bibr" rid="CR238">2011</xref>).</p></sec><sec id="Sec27"><title>Efflux pumps</title><p id="Par65">Efflux pumps can remove the AMPs even when they have attached to the cytoplasmic membrane. They are energy-dependent transporters that expel not only AMPs but also other antibiotics (Poole <xref ref-type="bibr" rid="CR286">2007</xref>). Gram negative bacteria contain a resistance-nodulation-cell division (RND) family of transporters (Piddock <xref ref-type="bibr" rid="CR283">2006</xref>; Delmar et al. <xref ref-type="bibr" rid="CR85">2014</xref>). A typical AMP efflux pump of this family has three components: (1) inner membrane proton/ AMP antiporter, (2) an outer membrane (OM) transporter and (3) a periplasmic accessory protein that provides stability to the whole complex. Some of examples of efflux pumps in Gram negative bacteria include AcrAB-TolC in <italic>K. pneumoniae,</italic> which is efficient against polymyxin B and HNP-1, HBD-1 (human defensins), and VexAB-TolC of <italic>V. cholerae</italic> that also protects from polymyxin B (Bina et al. <xref ref-type="bibr" rid="CR29">2008</xref>). RosA, RosB in <italic>Y. enterocolotica</italic> and <italic>K. pneumoniae</italic> is a major facilitator superfamily (MFS) efflux pump that also confers resistance to polymyxin B (Bengoechea and Skurnik <xref ref-type="bibr" rid="CR23">2000</xref>; Padilla et al. <xref ref-type="bibr" rid="CR272">2010</xref>).</p><p id="Par66">Within Gram positive bacteria, AMP-exporting efflux pumps are ATP-binding cassette (ABC) transporters that can secrete or produce immunity against newly synthesized AMPs (Gebhard <xref ref-type="bibr" rid="CR122">2012</xref>). NisT of <italic>Lactococcus lactis</italic> exports nisin (Qiao and Saris <xref ref-type="bibr" rid="CR291">1996</xref>) and Epi FEG of <italic>S. epidermidis</italic> exports epidermin and gallidermin (Otto et al. <xref ref-type="bibr" rid="CR270">1998</xref>). The BceAb type are another group of two-component ABC transporters that are active on lantibiotics, cyclic AMPs and defensins, glycopeptides and cathelicidin and have a wider range of action vs. AMPs (Gebhard <xref ref-type="bibr" rid="CR122">2012</xref>). The transporter VraFG in <italic>S. aureus</italic> provides resistance to several AMPs (nisin, bacitracin, vancomycin, indolicidin, LL-37 and HBD-3 (Li et al. <xref ref-type="bibr" rid="CR202">2007a</xref>; Falord et al. <xref ref-type="bibr" rid="CR102">2012</xref>; Gebhard <xref ref-type="bibr" rid="CR122">2012</xref>). The BceAb-type transporters have also been detected in <italic>B. subtilis</italic>, <italic>S. pneumoniae</italic> and other Gram positive bacteria (Becker et al. <xref ref-type="bibr" rid="CR18">2000</xref>; Ohki et al. <xref ref-type="bibr" rid="CR264">2003</xref>; Collins et al. <xref ref-type="bibr" rid="CR66">2010</xref>; Gebhard <xref ref-type="bibr" rid="CR122">2012</xref>). The MefE/Mel is a unique efflux pump in <italic>S. pneumoniae</italic> of the MFS and ABC families that confers resistance to LL-37 (Ambrose et al. <xref ref-type="bibr" rid="CR6">2005</xref>; Z&#x000e4;hner et al. <xref ref-type="bibr" rid="CR395">2010</xref>).</p></sec><sec id="Sec28"><title>Sensing systems</title><p id="Par67">The AMP resistance mechanisms are regulated by sensors and regulators in order to save energy. The antimicrobial peptide sensor (Aps) was first observed in <italic>S. epidermidis</italic> and is also known as GraRs or GraRSX (Li et al. <xref ref-type="bibr" rid="CR203">2007b</xref>). It has three components: a membrane-bound AMP sensing histidine kinase (ApsS), DNA-binding response regulator (ApsR) and another component (ApsS). The expression of genes involved in AMP resistance mechanisms is regulated by the Aps and one of them is the <italic>dlt</italic> operon for TA alanylation, the <italic>mprF</italic> gene for PG lysinylation and the <italic>vraFG</italic> ABC transporter.</p><p id="Par68">Systems homologous to Aps are also found in Gram positive pathogens such as <italic>Bacillus anthracis</italic>, <italic>Clostridium difficile</italic>, <italic>L. monocytogenes</italic>, <italic>S. pneumoniae</italic> and <italic>Sthaphylococcus haemolyticus</italic> (Li et al. <xref ref-type="bibr" rid="CR203">2007b</xref>). Other systems that sense and regulate resistance mechanisms are BceSR of <italic>B. subtilis</italic>, BraSRVraSR in <italic>S. aureus</italic> and LiaFSR in <italic>Streptococci</italic> (Suntharalingam et al. <xref ref-type="bibr" rid="CR343">2009</xref>).</p><p id="Par69">Within Gram negative bacteria, the PhoPQ acts as a central regulator (Groisman et al. <xref ref-type="bibr" rid="CR134">1989</xref>; Miller et al. <xref ref-type="bibr" rid="CR237">1989</xref>). PhoPQ is located in the cytoplasmic membrane and is a histidine kinase sensor while PhoP is the corresponding DNA-binding response regulator. PhoPQ and PmrAB (another two-component system) regulate lipid A modifications involved with AMP resistance (Gunn et al. <xref ref-type="bibr" rid="CR139">1998</xref>; Herrera et al. <xref ref-type="bibr" rid="CR149">2010</xref>). Some PhoPQ homologous are found in several strains such as <italic>S. typhimurium</italic>, <italic>Y. pestis</italic> and <italic>Shigella flexneri</italic> (Moss et al. <xref ref-type="bibr" rid="CR246">2000</xref>; Oyston et al. <xref ref-type="bibr" rid="CR271">2000</xref>; Rebeil et al. <xref ref-type="bibr" rid="CR298">2004</xref>; Bader et al. <xref ref-type="bibr" rid="CR11">2005</xref>).</p></sec></sec><sec id="Sec29"><title>Molecular engineering approaches for antimicrobial peptide motif design</title><p id="Par70">AMPs isolated from natural sources typically exhibit common sequence motifs: the peptides are 12&#x02013;50 amino acid long, are highly cationic (net charge between +&#x02009;2 and +&#x02009;9) and amphipathic, with around 50% of hydrophobic residues in their sequence (Hancock and Sahl <xref ref-type="bibr" rid="CR143">2006</xref>). Starting from these general design rules, recent strategies for AMP molecular engineering include the use of high-throughput screening, machine learning, modelling tools and combinatorial libraries to aid in the identification and initial characterization of lead sequences (Kang et al. <xref ref-type="bibr" rid="CR169">2014</xref>; Zhang and Gallo <xref ref-type="bibr" rid="CR400">2016</xref>; Bechinger and Gorr <xref ref-type="bibr" rid="CR17">2017</xref>).</p><sec id="Sec30"><title>Bioinformatic tools</title><p id="Par71">Considering the structural diversity of AMPs, bioinformatics has significant advantages in the computational enumeration of all possible peptide sequences (Travkova et al. <xref ref-type="bibr" rid="CR354">2017</xref>; Nagarajan et al. <xref ref-type="bibr" rid="CR251">2018</xref>). Online databases that contain large AMP libraries and several bioinformatic functions based on classification algorithms and machine learning have been built in the past decade to assist on the rational design of antimicrobial peptides, allowing the identification and optimization of new lead sequences in a time and cost-effective manner. A classic application of those tools is the use of artificial neural network (ANN), quantitative matrices (QM) and support vector machine (SVM) to predict antibacterial peptides (Wang and Wang <xref ref-type="bibr" rid="CR370">2004</xref>; Kang et al. <xref ref-type="bibr" rid="CR169">2014</xref>; Wang et al. <xref ref-type="bibr" rid="CR374">2016a</xref>; Zhang and Gallo <xref ref-type="bibr" rid="CR400">2016</xref>). Computer-assisted AMP design is useful for estimating the desired biological activity from the primary peptide structure. There are five types of prediction methods for AMPs; (1) prediction based on mature peptide sequences only (2) prediction based on precursor sequences only, (3) prediction based on both mature and precursor sequences, (4) prediction based on sequence similarity of the modifying enzymes and (5) prediction based on genomic information. The databases can also indicate related information such as specific target, antimicrobial activity and cytotoxicity (Hammam and Fliss <xref ref-type="bibr" rid="CR140">2010</xref>). Commonly used online databases are compiled in Table <xref rid="Tab6" ref-type="table">6</xref>. Online peptide modelling tools are also available to assess physicochemical parameters, such as aggregation in aqueous media and pharmacokinetic profiles. Examples of modelling tools include (i)TANGO to predict amyloid cross-beta aggregation (Rousseau et al. <xref ref-type="bibr" rid="CR302">2006</xref>; Goldschmidt et al. <xref ref-type="bibr" rid="CR128">2010</xref>); (ii) ZipperDB to evaluate the peptide fibrillogenic propensity profile (Rousseau et al. <xref ref-type="bibr" rid="CR302">2006</xref>; Goldschmidt et al. <xref ref-type="bibr" rid="CR128">2010</xref>); (iii) GROMACS to perform molecular dynamics simulations (Pronk et al. <xref ref-type="bibr" rid="CR289">2013</xref>); and (iv) SWISSADME to predict pharmacokinetic properties, drug-like nature and medicinal chemistry friendliness (Daina et al. <xref ref-type="bibr" rid="CR72">2017</xref>).<table-wrap id="Tab6"><label>Table 6</label><caption><p>Commonly used online databases for antimicrobial peptide prediction</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Online databases</th><th>Content</th><th>References</th></tr></thead><tbody><tr><td><p>Collection of antimicrobial peptides (CAMPR3)</p><p><ext-link ext-link-type="uri" xlink:href="http://www.camp.bicnirrh.res.in/">http://www.camp.bicnirrh.res.in/</ext-link></p></td><td>Natural and synthetic AMPs</td><td>(Waghu et al. <xref ref-type="bibr" rid="CR368">2016</xref>)</td></tr><tr><td><p><ext-link ext-link-type="uri" xlink:href="http://www.cabi.org/bookshop/book/9781786390394">Antimicrobial peptide</ext-link> database (APD)</p><p><ext-link ext-link-type="uri" xlink:href="http://aps.unmc.edu/AP/">http://aps.unmc.edu/AP/</ext-link></p></td><td>Natural and synthetic AMPs</td><td>(Wang and Wang <xref ref-type="bibr" rid="CR370">2004</xref>; Wang et al. <xref ref-type="bibr" rid="CR374">2016a</xref>)</td></tr><tr><td><p>Linking AMPs database (LAMP2)</p><p><ext-link ext-link-type="uri" xlink:href="http://biotechlab.fudan.edu.cn/database/lamp/index.php">http://biotechlab.fudan.edu.cn/database/lamp/index.php</ext-link></p></td><td>Natural and synthetic AMPs</td><td>(Zhao et al. <xref ref-type="bibr" rid="CR402">2013</xref>)</td></tr><tr><td><p>Database of antimicrobial activity and structure of peptides (DBAASP)</p><p><ext-link ext-link-type="uri" xlink:href="https://dbaasp.org/">https://dbaasp.org/</ext-link></p></td><td>Ribosomal, non-ribosomal and synthetic AMP</td><td>(Pirtskhalava et al. <xref ref-type="bibr" rid="CR285">2016</xref>)</td></tr><tr><td><p>Data repository of antimicrobial peptides (DRAMP)</p><p><ext-link ext-link-type="uri" xlink:href="http://dramp.cpu-bioinfor.org/">http://dramp.cpu-bioinfor.org/</ext-link></p></td><td>Natural and synthetic AMPs (patent and AMPs in drug development)</td><td>(Kang et al. <xref ref-type="bibr" rid="CR170">2019</xref>).</td></tr><tr><td><p>Yet Another database of antimicrobial peptides (YADMP)</p><p><ext-link ext-link-type="uri" xlink:href="http://yadamp.unisa.it/default.aspx">http://yadamp.unisa.it/default.aspx</ext-link></p></td><td>Natural and synthetic AMPs</td><td/></tr><tr><td><p>Plant antimicrobial peptides (PhytAMP)</p><p><ext-link ext-link-type="uri" xlink:href="http://phytamp.pfba-lab-tun.org/main.php">http://phytamp.pfba-lab-tun.org/main.php</ext-link></p></td><td>Plant AMPs</td><td>(Hammami et al. <xref ref-type="bibr" rid="CR141">2008</xref>)</td></tr><tr><td><p>Bactibase</p><p><ext-link ext-link-type="uri" xlink:href="http://bactibase.hammamilab.org/main.php">http://bactibase.hammamilab.org/main.php</ext-link></p></td><td>Bacteriocins</td><td>(Hammam and Fliss <xref ref-type="bibr" rid="CR140">2010</xref>).</td></tr><tr><td><p>Antiviral peptides database (AVPdb)</p><p><ext-link ext-link-type="uri" xlink:href="http://crdd.osdd.net/servers/avpdb/index.php">http://crdd.osdd.net/servers/avpdb/index.php</ext-link></p></td><td>Antiviral peptides</td><td>(Qureshi et al. <xref ref-type="bibr" rid="CR293">2014</xref>).</td></tr></tbody></table></table-wrap></p><p id="Par72">Machine learning has recently been applied as a high-throughput molecular design approach for AMPs, fed by the increased depth of molecular understanding of AMP activity, especially membrane activity, and by the immense molecular dataset compiled by researchers over the past decades (Lee et al. <xref ref-type="bibr" rid="CR193">2017a</xref>; Lee et al. <xref ref-type="bibr" rid="CR195">2018a</xref>; Lee et al. <xref ref-type="bibr" rid="CR196">2018b</xref>). Although in its early ages, such high-throughput methods hold promises for a boost to the development of lead candidates for clinical translation of rationally designed minimal antimicrobial peptides.</p></sec><sec id="Sec31"><title>Top-down molecular design</title><p id="Par73">In top-down molecular design, an AMP sequence, generally from a natural source, is used as a starting template for systematic sequence truncation, amino acid substitution, hybridization and cyclization in order to obtain important information on the structural activity correlation and further design shorter AMPs with improved antimicrobial activity and selectivity (Ong et al. <xref ref-type="bibr" rid="CR267">2014</xref>; da Costa et al. <xref ref-type="bibr" rid="CR70">2015</xref>). Evolutionary conserved AMPs typically have long sequences of amino acids with redundancy in the sequence required for potent antimicrobial activities, thus trimming the natural AMP sequence allows a shorter active motif to be acquired, which can have reduced cost involved in the industrial scale production of the synthetic AMP for therapeutic use. Furthermore, the removal of naturally occurring peptide regions with undesired properties could also yield synthetic derivatives with reduced toxicity or immunogenicity (Ong et al. <xref ref-type="bibr" rid="CR267">2014</xref>; da Costa et al. <xref ref-type="bibr" rid="CR70">2015</xref>). Applying the principle of template modification, it is also possible to construct hybrid peptides composed by truncated fragments from multiple types of naturally occurring AMPs, so-called multidomain peptides. The resulting sequences could offer an effective strategy to capitalize on the desirable properties of the individual parent peptides. Such an approach typically involves the amalgamation of a sequence from a potent, but comparatively toxic AMP with a less active AMP having lower toxicity (Bianco et al. <xref ref-type="bibr" rid="CR27">2013</xref>; Ong et al. <xref ref-type="bibr" rid="CR267">2014</xref>; Zhu et al. <xref ref-type="bibr" rid="CR404">2017</xref>). Alanine scanning is another typical top-down approach to studying the structure-activity relationship (SAR) of an AMP to in turn optimize the peptide. Exemplary AMP alanine scanning studies include that of polymyxin B, which elucidated the SAR but also gave credence to optimized structures. More recently, alanine scanning on tridecaptin A1 (Kanazawa et al. <xref ref-type="bibr" rid="CR168">2009</xref>; Cochrane et al. <xref ref-type="bibr" rid="CR64">2014</xref>; Ballantine et al. <xref ref-type="bibr" rid="CR13">2019</xref>) revealed favourable modifications to retain activity but at a reduced synthetic cost, whereas alanine scanning of the linear battacin octapeptide revealed a truncated pentapeptide sequence that retained most of its antimicrobial activity (De Zoysa et al. <xref ref-type="bibr" rid="CR82">2015</xref>). Additional top-down designs include NSAID drug-peptide conjugates exhibiting antimicrobial, anti-inflammatory and self-assembling hydrogelator properties all in one due to the modification of a self-assembling peptide (McCloskey et al. <xref ref-type="bibr" rid="CR230">2016</xref>). Further techniques include the reorientation of a peptide structure without changing the amino acid composition, such as in the case of retro, inverso and retro-inverso peptide modifications (Chorev and Goodman <xref ref-type="bibr" rid="CR61">1995</xref>; Li et al. <xref ref-type="bibr" rid="CR204">2010</xref>; Parthsarathy et al. <xref ref-type="bibr" rid="CR275">2013</xref>).</p></sec><sec id="Sec32"><title>Bottom-up molecular design</title><p id="Par74">Bottom-up molecular design relies on the fundamental understanding of the impact of key chemical peptide features for antimicrobial activity (Frecer et al. <xref ref-type="bibr" rid="CR112">2004</xref>; Zelezetsky and Tossi <xref ref-type="bibr" rid="CR398">2006</xref>). A simplified approach is typically applied such as combining (i) cationic amino acids for electrostatic interactions with the microbial membranes and (ii) non-polar amino acids for insertion or permeation of the microbial membrane (Sfor&#x000e7;a et al. <xref ref-type="bibr" rid="CR320">2004</xref>; Matsuzaki <xref ref-type="bibr" rid="CR225">2009</xref>; Oddo and Hansen <xref ref-type="bibr" rid="CR262">2017</xref>). This approach is highly attractive for drug development as it can lead to the identification of the smallest motif or pharmacophore essential for antimicrobial effects, which could in turn increase the ease of optimization through systematic modifications to the short peptide sequence (Gordon et al. <xref ref-type="bibr" rid="CR132">2005</xref>; Ong et al. <xref ref-type="bibr" rid="CR267">2014</xref>) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>Three-stage de novo peptide design workflow diagram. (1) design inputs and sequence selection; (2) fold specificity; (3) approximate binding affinity. Modified from Smadbeck et al. <xref ref-type="bibr" rid="CR331">2014</xref></p></caption><graphic xlink:href="12551_2021_784_Fig5_HTML" id="MO5"/></fig></p><p id="Par75">Combined with bioinformatics, a complete de novo peptide design framework usually consists in three stages: an optimization-based sequence selection, fold specificity calculation and approximate binding affinity calculation (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>) (Klepeis et al. <xref ref-type="bibr" rid="CR176">2004</xref>; Smadbeck et al. <xref ref-type="bibr" rid="CR331">2014</xref>). The first stage of the method is a sequence selection stage which uses a set of design inputs such as biologically relevant constraints in an integer linear optimization model to produce a rank ordered list of sequences with the lowest potential energy in a given template structure. The comparative model in peptides is based on the fact that sequence similarity implies structural similarity, thus the structure of an active peptide can be predicted by comparing the amino acid sequence to that of known native 3D structures. However, similar structures can be found for peptides with different sequences. The second stage collects the top sequences from the sequence selection stage and determines the specificity of candidates for the target. It determines how well-designed sequences fold into the desired template structure compared to the native sequence. The sequences with the top fold specificity values are then run through a computationally rigorous third stage to calculate the approximate binding affinity of the sequences to the target. Those peptides with the highest predicted binding affinity are then validated experimentally (Klepeis et al. <xref ref-type="bibr" rid="CR176">2004</xref>; Smadbeck et al. <xref ref-type="bibr" rid="CR331">2014</xref>).</p><p id="Par76">Multivalent ligand design is another technique for AMP motif design, wherein multiple copies of an AMP are appended to a branched core. Branched multivalent peptide systems have also been investigated extensively in antimicrobial peptide design. Early study on multiple antigen peptide (MAP) systems was eventually translated into the field of antimicrobial peptide chemistry due to the inherent proteolytic stability of MAP ligands (Tam <xref ref-type="bibr" rid="CR346">1988</xref>; Bracci et al. <xref ref-type="bibr" rid="CR40">2003</xref>). This technique typically involves appending identical AMPs to a branched multi-lysine core to yield a multivalent peptide array and was utilised by Pini et al. to form a tetrabranched M33 antimicrobial peptide system with high proteolytic stability (Pini et al. <xref ref-type="bibr" rid="CR284">2010</xref>).</p></sec><sec id="Sec33"><title>Antimicrobial peptide motifs and their rationale</title><p id="Par77">A number of peptide motifs have been identified to promote antimicrobial activity and pharmacokinetic properties that aid molecular engineering translatable AMPs, as developed below.</p><sec id="Sec34"><title>Necessary peptide features for antimicrobial activity</title><p id="Par78">Several studies have established that strong antimicrobial potencies can be obtained with engineered synthetic AMPs consisting of a cationic amino acid combined with a non-polar amino acid. Thus, AMPs generally contain positively charged amino acid residues (Dab, Orn, Lys and Arg) and hydrophobic residues (Phe, Trp, Tyr, Met) in a ratio varying from 1:1 to 1:2. Their primary structure is often characterized by a net positive charge of +&#x02009;2 to +&#x02009;9. Hydrophobic and non-charged peptides such as the aromatic peptide diphenylalanine have also shown antimicrobial activity due mainly to hydrophobic interactions (Strom et al. <xref ref-type="bibr" rid="CR339">2002</xref>; Klepeis et al. <xref ref-type="bibr" rid="CR176">2004</xref>; Ong et al. <xref ref-type="bibr" rid="CR267">2014</xref>).</p><p id="Par79">It has been reported that increasing the positive charge of the peptide results in increasing antibacterial activity. However, there is a limit since a very high net charge can lead to an enhanced haemolytic propensity and a loss of antimicrobial activity. Additionally, the most common motif found in AMPs is the secondary structures; however, many of them also exist as unstructured conformers (Galdiero et al. <xref ref-type="bibr" rid="CR117">2013</xref>; Falanga et al. <xref ref-type="bibr" rid="CR101">2017</xref>).</p><p id="Par80">Studies have suggested that a free N-terminal amino group and an amidated C-terminal on a peptide are correlated to a high antimicrobial activity. Thus, the balance between cationic residues, aromatic residues, an amidated C-terminal end and a free N-terminal amino group constitutes a highly efficient motif in antimicrobial peptides (Strom et al. <xref ref-type="bibr" rid="CR339">2002</xref>; Chen et al. <xref ref-type="bibr" rid="CR57">2010</xref>; Deslouches et al. <xref ref-type="bibr" rid="CR86">2013</xref>; Ong et al. <xref ref-type="bibr" rid="CR267">2014</xref>).</p></sec><sec id="Sec35"><title>Choice of specific amino acids</title><p id="Par81">Arginine and lysine are the most common cationic residues in AMP sequences as they are protonated under physiological conditions and have been found to be related strong antimicrobial activities. While the incorporation of arginine residues in AMPs confers greater antimicrobial activity, their presence is frequently associated with relatively higher haemolytic activities as compared to the use of lysine residues.</p><p id="Par82">Due to their common occurrence in many naturally occurring AMPs such as cathelicidins, the combination of cationic arginine with hydrophobic tryptophan residues represents one of the most extensively investigated designs for synthetic AMPs. This combination is believed to be extremely efficient as the guanidinium side chain of arginine undergoes hydrogen bonding with negatively charged microbial membranes while participating in cationic&#x02013;&#x003c0; interactions with the aromatic indole side chain of tryptophan, making AMP penetration into the hydrophobic lipid bilayer more energetically favoured. The bulky amphipathic character of the indole side chain in Trp is also believed to aid in the interfacial association of AMP with lipid bilayers and to mediate cohesive hydrophobic interactions with the lipid acyl chains during membrane penetration (Strom et al. <xref ref-type="bibr" rid="CR339">2002</xref>; Klepeis et al. <xref ref-type="bibr" rid="CR176">2004</xref>; Ong et al. <xref ref-type="bibr" rid="CR267">2014</xref>).</p></sec><sec id="Sec36"><title>Secondary and supramolecular structures</title><p id="Par83">In addition to the amphipathic content of the peptide primary sequence, their folding into distinct secondary structures either in the presence of bacterial membranes (e.g. cathelicidins and magainins) or constitutively (e.g. the defensins) is also a well-studied motif for antimicrobial activity. Generally, a basic repeating sequence pattern of amino acids that can be arranged into stabilized &#x003b1;-helical, &#x003b2;-sheet and/or hairpin structures are selected (Chen et al. <xref ref-type="bibr" rid="CR57">2010</xref>; Deslouches et al. <xref ref-type="bibr" rid="CR86">2013</xref>; Ong et al. <xref ref-type="bibr" rid="CR267">2014</xref>). Due to charge repulsion between cationic entities, linear AMPs often remain as free unstructured molecules in aqueous solutions, which facilitate their diffusion across the bacterial capsule and/or cell wall to the membrane lipid bilayers. Various peptide motifs were reported to enhance the stability of specific secondary structures, including for AMPs. For instance, the high proline content of insect AMPs has been correlated to a high helical propensity favouring membrane insertion (Chen et al. <xref ref-type="bibr" rid="CR57">2010</xref>; Ong et al. <xref ref-type="bibr" rid="CR267">2014</xref>).</p><p id="Par84">Although self-assembly may inherently arise from amphipathic primary and/or secondary structures, simple aromatic motifs recently emerged as chemical tricks to induce the intrinsic formation of peptide supramolecular structures in solution via mainly pi-stacking interactions. Notable examples include (i) fluorenylmethoxycarbonyl (Fmoc) driving self-assembly when conjugated to peptides, generally resulting in the formation of hydrogels, and (ii) the amyloid-derived diphenylalanine motif inducing self-assembly into nanofibers or nanotubes when present in a sequence. These motifs were incorporated into numerous de novo designed peptides, including self-assembling AMPs (Schnaider et al. <xref ref-type="bibr" rid="CR313">2017</xref>; Glossop et al. <xref ref-type="bibr" rid="CR127">2019</xref>).</p></sec><sec id="Sec37"><title>Non-proteinogenic amino acids and peptide termini</title><p id="Par85">Unnatural residues, such as D-amino acids, improve proteolytic stability because proteases have poor affinity for unnatural side chains (Weinstock et al. <xref ref-type="bibr" rid="CR377">2012</xref>). Another common modification is N-alkylation of amino acids, typically N-methylation, which can improve pharmacokinetic properties. Studies on the cyclic peptide somatostatin yielded analogues with up to 10% improved oral bioavailability when N-methylated at certain points (Biron et al. <xref ref-type="bibr" rid="CR30">2008</xref>). While N-terminal acylation reduces the overall charge of the peptide, it improves proteolytic stability depending on the sequence and may also drastically improve antimicrobial activity of AMPs or grant activity to inactive sequences (Malina and Shai <xref ref-type="bibr" rid="CR220">2005</xref>; Radzishevsky et al. <xref ref-type="bibr" rid="CR294">2005</xref>; Glossop et al. <xref ref-type="bibr" rid="CR126">2018</xref>). Amidation is a common C-terminal modification employed to improve the antimicrobial potency of peptides in two ways, by increasing the net charge of the peptide and by enhancing proteolytic stability, thus improving half-life times in vivo (Stromstedt et al. <xref ref-type="bibr" rid="CR340">2009</xref>; Kumar et al. <xref ref-type="bibr" rid="CR180">2014</xref>; Mura et al. <xref ref-type="bibr" rid="CR250">2016</xref>). N-terminal acetylation and amidation may also enhance helicity by stabilising hydrogen bonding (Fairman et al. <xref ref-type="bibr" rid="CR100">1989</xref>; Stromstedt et al. <xref ref-type="bibr" rid="CR340">2009</xref>).</p></sec><sec id="Sec38"><title>Fluorination</title><p id="Par86">Fluorination is a frequent modification in medicinal chemistry and as such has been translated to peptide and protein engineering (Yoder and Kumar <xref ref-type="bibr" rid="CR393">2002</xref>). A small subset of AMPs feature naturally halogenated residues such as bromotryptophan in hagfish cathelicidins and hedistin (Uzzell et al. <xref ref-type="bibr" rid="CR356">2003</xref>; Tasiemski et al. <xref ref-type="bibr" rid="CR349">2007</xref>). Fluorination has been employed to enhance AMP activity through stabilised conformation and increased proteolytic resistance. Most notably, analogues of melittin substituting every leucine residue for 5,5,5-trifluoroleucine exhibited enhanced binding to DOPC vesicle membranes due to improved self-association in solution from hydrophobic interactions from trifluoroleucine (Niemz and Tirrell <xref ref-type="bibr" rid="CR259">2001</xref>). Furthermore, fluorinated buforin and magainin analogues were found to exhibit modest resistance to trypsin proteolytic degradation while retaining or improving in antimicrobial efficacy (Meng and Kumar <xref ref-type="bibr" rid="CR236">2007</xref>). However, this came at the cost of greater hemolysis in some fluorinated analogues. Studies on longer helical sequences by Lee et al. have also reported on the benefits of fluorination, in this case by hexafluoroleucine, in enhancing helical protein stability (Lee et al. <xref ref-type="bibr" rid="CR191">2004b</xref>). Further study of substitutions with hexafluoroleucine generated the magainin analogue fluorogainin-1, which resisted proteolytic degradation under the same conditions that degraded the unfluorinated parent peptide, while exhibiting improved antimicrobial activity towards <italic>K. pneumoniae and S. aureus</italic> (Gottler et al. <xref ref-type="bibr" rid="CR133">2008</xref>). Overall, fluorination has generally positive outcomes when designing synthetic AMPs.</p></sec></sec><sec id="Sec39"><title>Antimicrobial peptide lipidation</title><sec id="Sec40"><title>Lipopeptide motifs and antimicrobial activity</title><p id="Par87">There are several examples of inactive peptides that gained antimicrobial activity upon conjugation of a hydrophobic acyl group (Malina and Shai <xref ref-type="bibr" rid="CR220">2005</xref>). Structure-activity studies were conducted by generating lipopeptides of varying fatty acid lengths (Nasompag et al. <xref ref-type="bibr" rid="CR253">2015</xref>; Glossop et al. <xref ref-type="bibr" rid="CR126">2018</xref>). Over improving lipid membrane insertion, fatty acid conjugation may enhance secondary structure characteristics: magainin-2 analogues showed tuneable helical, &#x003b2;-sheet, and oligomeric conformations depending on the size of attached fatty acid, from heptanoyl to palmitoyl in length (Avrahami and Shai <xref ref-type="bibr" rid="CR10">2002</xref>). Typically, longer fatty acids improve lipopeptide antimicrobial activity, but at a certain threshold also contribute to cytotoxicity. The acyl group may vary widely in structure from saturated fatty acyl moieties to unsaturated, branched or aromatic groups (Chooi and Tang <xref ref-type="bibr" rid="CR60">2010</xref>).</p><p id="Par88">Prime examples of lipopeptide antibiotics that have undergone extensive structure-activity studies are the polymyxins and daptomycin. These lipopeptides are cyclic in structure and contain a majority of cationic and anionic charged side chains, respectively, and a fatty acyl chain in addition to hydrophobic residues. Both of these drugs have potent antimicrobial activity, even against multidrug-resistant strains (Dixon and Chopra <xref ref-type="bibr" rid="CR90">1986</xref>; Steenbergen et al. <xref ref-type="bibr" rid="CR338">2005</xref>; Zavascki et al. <xref ref-type="bibr" rid="CR397">2007</xref>). Structure-activity studies on polymyxins revealed that acyl chain length is also important for the spectrum of activity against pathogens. Polymyxin B analogues were found to have ideal acyl chains of 7&#x02013;9 carbon length (Naoki et al. <xref ref-type="bibr" rid="CR252">2004</xref>). Studies on magainin analogues indicate that the fatty acyl moiety can modulate solution conformation and cell selectivity as well (Avrahami and Shai <xref ref-type="bibr" rid="CR10">2002</xref>). The primary sequence of the peptide component has the greatest influence over peptide hydrophobicity, stability, net charge and secondary structure. Lipopeptides may be cyclic or linear and may or may not have an exocyclic peptide region to which the fatty acyl chain is conjugated. An example of important primary peptide sequence is the hydrophobic dipeptide motif observed in polymyxin B (D-Phe-6, L-Leu-7) and E (D-Leu-6, L-Leu-7). The hydrophobic region provided by this dipeptide in the macrocycle is considered to contribute significantly to the amphipathicity of the lipopeptide as well as its biological interaction with Gram negative bacterial outer membranes (Pristovsek and Kidric <xref ref-type="bibr" rid="CR287">1999</xref>). The same phenylalanine and leucine combinations are seen in octapeptins (Velkov et al. <xref ref-type="bibr" rid="CR357">2017</xref>).</p><p id="Par89">Charged amino acids are important determinants of lipopeptide surfactant and antimicrobial activity as they contribute to the hydrophilicity and electrostatic interactions of the peptide at physiological pH. Residues such as lysine and its relatives Dab or ornithine (2,5-diaminovaleric acid) are common cationic moieties found in natural antimicrobial lipopeptides such as the polymyxins, octapeptins and tridecaptins, which target anionic bacterial membranes, whereas daptomycin and its congeners feature anionic residues involved in their calcium-directed mechanisms (Kato et al. <xref ref-type="bibr" rid="CR172">1979</xref>; Baltz et al. <xref ref-type="bibr" rid="CR14">2005</xref>; Kanazawa et al. <xref ref-type="bibr" rid="CR168">2009</xref>; Velkov et al. <xref ref-type="bibr" rid="CR357">2017</xref>). Rarely will membrane-lytic lipopeptide antibiotics have neutral net charge at physiological pH such as in the case of iturin A, a potent antifungal agent and surfactant (Besson et al. <xref ref-type="bibr" rid="CR26">1984</xref>).</p><p id="Par90">The incorporation of negatively charged residues into the peptide sequence is important for acidic lipopeptides such as daptomycin, amphomycins, tsushimycin, laspartomycins and friulimicins (Tanaka et al. <xref ref-type="bibr" rid="CR347">1977</xref>; Bunkoczi et al. <xref ref-type="bibr" rid="CR46">2005</xref>; Steenbergen et al. <xref ref-type="bibr" rid="CR338">2005</xref>; Borders et al. <xref ref-type="bibr" rid="CR38">2007</xref>; Schneider et al. <xref ref-type="bibr" rid="CR315">2009</xref>). These anionic lipopeptides often undergo conformational changes by interacting with calcium ions, effecting a stronger amphipathic structure and enhanced activity, whereas cationic lipopeptides, such as the polymyxins, have weaker antibiotic activity in vitro at higher concentrations of divalent cations such as Mg<sup>2+</sup> (Daugelavicius et al. <xref ref-type="bibr" rid="CR75">2000</xref>; Ho et al. <xref ref-type="bibr" rid="CR151">2008</xref>).</p></sec><sec id="Sec41"><title>Lipopeptide motifs for self-assembly into different colloidal morphologies</title><p id="Par91">Self-assembly into various types of colloids can be programmed by conjugating a peptide sequence to an acyl chain. The resulting morphologies range from nanofibers and nanoribbons to micelles and vesicles (Cui et al. <xref ref-type="bibr" rid="CR69">2010</xref>; Webber et al. <xref ref-type="bibr" rid="CR376">2011</xref>; Hendricks et al. <xref ref-type="bibr" rid="CR146">2017</xref>). The influence of both the peptide sequence and acyl chain on the resulting colloidal morphology has been thoroughly investigated by Stupp&#x02019;s group (Hendricks et al. <xref ref-type="bibr" rid="CR146">2017</xref>). For instance, a minimum of 10 carbon long acyl chain was found necessary to induce the hydrophobic effect needed to direct one-dimensional self-assembly into elongated morphologies. However, variation in the peptide residues closer to the acyl chain can still induce spherical micelles through altering hydrogen bonding capacity, while assembly into flat structures is favoured by alternating hydrophobic and hydrophilic residues in the peptide sequence (Hendricks et al. <xref ref-type="bibr" rid="CR146">2017</xref>). The conjugation of various bioactive peptide sequences to acyl chains has been reported to achieve the combination of nanostructure formation and biological/therapeutic activity in a single molecule (Silva et al. <xref ref-type="bibr" rid="CR326">2004</xref>; Webber et al. <xref ref-type="bibr" rid="CR376">2011</xref>; Hendricks et al. <xref ref-type="bibr" rid="CR146">2017</xref>).</p><p id="Par92">Table <xref rid="Tab7" ref-type="table">7</xref> compiles the main peptide motifs reported to enhance antimicrobial activity and other properties important in the molecular engineering of such peptide drug molecules.<table-wrap id="Tab7"><label>Table 7</label><caption><p>Summary of the main peptide motifs identified for molecular engineering AMPs (references in manuscript text, &#x0201c;Molecular engineering approaches for antimicrobial peptide motif design&#x0201d;)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Generic motifs</th><th>Main mechanisms for activity</th><th>Other properties</th></tr></thead><tbody><tr><td>&#x000a0;&#x000a0;Cationic residues: peptide net charge between +&#x02009;2 to +&#x02009;9</td><td><p>Electrostatic interaction with microbial phospholipids</p><p>Electrostatic interaction with LPS</p></td><td>Electrostatic interaction with DNA, RNA, LPS: immunomodulation via Toll-like receptors, anti-toxin activity</td></tr><tr><td>&#x000a0;&#x000a0;Amphipathic primary sequence (50% hydrophobic residues)</td><td>Membrane insertion</td><td>Self-assembly into nanostructures and/or hydrogels.</td></tr><tr><td>&#x000a0;&#x000a0;Aromatic side chains</td><td>Membrane insertion</td><td>Self-assembly into nanostructures and/or hydrogels</td></tr><tr><td>&#x000a0;&#x000a0;Unnatural amino acids</td><td>Proteolytic stability</td><td>Stabilisation of amphipathic secondary structures</td></tr><tr><td>Specific motifs</td><td>Added specificity to activity</td><td>Other properties</td></tr><tr><td>&#x000a0;&#x000a0;High arginine content</td><td>Electrostatic interactions with membrane components</td><td><p>Risk of haemolytic toxicity</p><p>Electrostatic interaction with DNA, RNA, LPS: immunomodulation via Toll-like receptors, anti-toxin activity</p></td></tr><tr><td>&#x000a0;&#x000a0;High lysine content</td><td>Electrostatic interactions with membrane components</td><td><p>Lower risk of haemolytic toxicity when compared to Arginine</p><p>Electrostatic interaction with DNA, RNA, LPS: immunomodulation via Toll-like receptors, anti-toxin activity</p></td></tr><tr><td>&#x000a0;&#x000a0;High proline content</td><td>Membrane insertion through stabilisation of amphipathic helical secondary structures</td><td>/</td></tr><tr><td>&#x000a0;&#x000a0;High tryptophan content</td><td>Membrane insertion through amphiphilic nature</td><td>Cation-pi interactions with cationic residues that promote membrane insertion</td></tr><tr><td>&#x000a0;&#x000a0;Termini amidation/acetylation</td><td><p>Amidation: proteolytic stability, increased net charge for membrane interactions</p><p>Acetylation: proteolytic stability</p></td><td><p>Stability of helical secondary structure</p><p>Improved pharmacokinetics, especially non-parenteral bioavailability</p></td></tr><tr><td>&#x000a0;&#x000a0;Fluorination</td><td>Membrane interaction through improved secondary structure stability</td><td>Proteolytic stability</td></tr><tr><td>&#x000a0;&#x000a0;Lipidation</td><td>Lipid membrane insertion</td><td><p>Proteolytic stability</p><p>Self-assembly into nanostructures and/or hydrogels</p></td></tr></tbody></table></table-wrap></p></sec></sec></sec><sec id="Sec42"><title>Translation opportunities of antimicrobial peptide&#x02013;based formulations and biomaterials</title><p id="Par93">Antimicrobial peptide drug discovery nowadays focuses on short synthetic peptides to overcome drawbacks inherent to naturally isolated AMPs, such as high production costs of long sequences and off-target cytotoxicity (Ong et al. <xref ref-type="bibr" rid="CR267">2014</xref>). A recent SWOT analysis identified critical weaknesses associated with the development of peptides as therapeutics: (1) chemically and physically instable, (2) prone to hydrolysis and oxidation, (3) tendency for aggregation, (4) short half-life and fast elimination, (5) not orally available and (6) low membrane permeability (Fosgerau and Hoffmann <xref ref-type="bibr" rid="CR111">2015</xref>). Besides the discovery and design of thousands of AMPs to date, very few AMP drugs have advanced to clinical development to date (Magana et al. <xref ref-type="bibr" rid="CR215">2020</xref>). In addition to molecular engineering principles developed in the previous sections, a number of formulation approaches are currently being investigated to overcome the challenge to reach clinical stage. An overview of peptide formulations is here provided with a focus on the latest advances in peptide and lipid nanotechnology, which are identified as the most promising formulations for translation (Magana et al. <xref ref-type="bibr" rid="CR215">2020</xref>).</p><sec id="Sec43"><title>Biomedical applications of antimicrobial peptide self-assembled nanostructures</title><p id="Par94">Peptide hydrogels result from the self-assembly of amphipathic and/or aromatic rich sequences into elongated nanostructures, including nanofibers and nanotubes, which reticulate the aqueous media into a gel. In recent years, peptide hydrogels have gained attention for broad biomedical applications, from therapeutic formulations to tissue engineering (Mondal et al. <xref ref-type="bibr" rid="CR243">2020</xref>). The intrinsic self-assembly of antimicrobial peptide sequences into elongated nanostructures was reported for various sequences, opening the door to hydrogel applications for self-assembling AMPs (Shi et al. <xref ref-type="bibr" rid="CR323">2021</xref>). A remarkable example is the molecular engineering of short AMP sequences into self-assembling peptides that form hydrogels. For instance, the antibacterial sequence (KIGAKI)<sub>3</sub>-NH<sub>2</sub> was incorporated into an engineered beta-hairpin sequence, resulting in hydrogels active against <italic>E. coli</italic> (Liu et al. <xref ref-type="bibr" rid="CR208">2013</xref>). Peptide sequences designed to self-assemble into nanostructured hydrogels also showed intrinsic antimicrobial properties. For instance, the synthetic sequence of MAX1 peptide was designed as an amphiphilic beta-hairpin of alternating lysine and valine residues, in order to induce self-assembly. This strategy resulted in the formation of rigid nanostructured hydrogels (Schneider et al. <xref ref-type="bibr" rid="CR314">2002</xref>). This elegantly designed hydrogel was shown to be active against both Gram negative and Gram positive bacteria when directly in contact with colonies, with a proposed mechanism of action involving disruption of the bacterial lipid membrane (Salick et al. <xref ref-type="bibr" rid="CR306">2007</xref>). Within the broad landscape of applications being currently explored for AMP hydrogels, one of the most promising ones appears to be their use as topical treatments, to cure skin infections or promote wound healing (Pfalzgraff et al. <xref ref-type="bibr" rid="CR282">2018</xref>).</p><p id="Par95">In the current context of a viral pandemic, self-assembling AMPs could be of use as vaccine adjuvants or nanocarriers. Subunit vaccines, which are composed of synthetic antigen peptides or proteins, require adjuvants to stimulate an appropriate immune response. Amongst the several immunological adjuvants that have been developed so far (such as nanoparticles, liposomes, and polymers), an interesting category could be self-assembling AMP nanostructures (Hudalla et al. <xref ref-type="bibr" rid="CR153">2014</xref>; Wang et al. <xref ref-type="bibr" rid="CR375">2016b</xref>). Self-assembling AMPs could be used as delivery carriers for antigenic proteins and/or to boost immunogenicity, especially considering the immunomodulatory properties of some AMP sequences.</p><p id="Par96">The deposition of arrays of solid-state peptide nanostructures was shown to provide antibacterial properties to the surface. The vertically aligned arrays of diphenylalanine nanotubes showed activity against <italic>E. coli</italic>, through their topological capacity to disrupt bacterial membranes (Schnaider et al. <xref ref-type="bibr" rid="CR313">2017</xref>). This original bionanomaterial deposition augurs well for a future use of self-assembling AMPs as medical coatings.</p></sec><sec id="Sec44"><title>Formulations of antimicrobial peptides with lipid nanomaterials</title><p id="Par97">The encapsulation of antimicrobial peptides in lipid nanoparticles (LNPs) confers&#x000a0;two main advantages: Firstly, LNPs provide encapsulated peptides protection from enzymatic and chemical degradation. Such protection is otherwise difficult to achieve via modifications to the peptides chemical structure, due to the inherently fragile constituent peptide bonds. Secondly, increases in efficacy and bioavailability are possible via further functionalization of lipid nanoparticles, enabling the formulation of targeted delivery vehicles through techniques such as surface conjugation of antibodies, or the design of environment-responsive or triggered release particles. A wide range of lipid-based nanoparticle species have been investigated as delivery vehicles for antimicrobial peptides, ranging from liposomes to liquid crystalline cubic nanoparticles (Table <xref rid="Tab8" ref-type="table">8</xref>).<table-wrap id="Tab8"><label>Table 8</label><caption><p>Summary of various studies in which antimicrobial peptides are encapsulated within LNPs</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Peptide</th><th>LNP type</th><th>Reference</th></tr></thead><tbody><tr><td>Gramicidin A, alamethicin, melittin, indolicidin, pexiganan, cecropin A</td><td>Liquid crystal nanoparticles</td><td>(Meikle et al. <xref ref-type="bibr" rid="CR232">2016</xref>; Meikle et al. <xref ref-type="bibr" rid="CR233">2017</xref>; Meikle et al. <xref ref-type="bibr" rid="CR235">2021</xref>)</td></tr><tr><td>LL-37, AP114, DP-060</td><td>Liquid crystal nanoparticles</td><td>(Boge et al. <xref ref-type="bibr" rid="CR33">2016</xref>; Gontsarik et al. <xref ref-type="bibr" rid="CR130">2016</xref>; Boge et al. <xref ref-type="bibr" rid="CR34">2017</xref>; Boge et al. <xref ref-type="bibr" rid="CR35">2019a</xref>; Boge et al. <xref ref-type="bibr" rid="CR36">2019b</xref>; Zabara et al. <xref ref-type="bibr" rid="CR394">2019</xref>)</td></tr><tr><td>Cyclosporin A</td><td>Liquid crystal nanoparticles</td><td>(Lai et al. <xref ref-type="bibr" rid="CR182">2010</xref>)</td></tr><tr><td>KSL-W</td><td>Liquid crystal nanoparticles</td><td>(Bernegossi et al. <xref ref-type="bibr" rid="CR25">2016</xref>)</td></tr><tr><td>Nisin</td><td>Liposome</td><td>(Benech et al. <xref ref-type="bibr" rid="CR21">2002</xref>; Benech et al. <xref ref-type="bibr" rid="CR22">2003</xref>; Laridi et al. <xref ref-type="bibr" rid="CR186">2003</xref>)</td></tr><tr><td>Vancomycin</td><td>Liposome</td><td>(Nicolosi et al. <xref ref-type="bibr" rid="CR257">2010</xref>)</td></tr><tr><td>Polymyxin B</td><td>Liposome</td><td>(Alipour et al. <xref ref-type="bibr" rid="CR3">2009</xref>)</td></tr><tr><td>Gramicidin</td><td>Liposome</td><td>(Ragioto et al. <xref ref-type="bibr" rid="CR296">2014</xref>)</td></tr><tr><td>Melittin</td><td>Liposome</td><td>(Zetterberg et al. <xref ref-type="bibr" rid="CR399">2011</xref>)</td></tr><tr><td>DP7-C</td><td>Liposome</td><td>(Liu et al. <xref ref-type="bibr" rid="CR209">2016</xref>)</td></tr><tr><td>Whey peptides</td><td>Liposome</td><td>(Mohan et al. <xref ref-type="bibr" rid="CR240">2018</xref>)</td></tr><tr><td>Indolicidin</td><td>Liposome</td><td>(Ahmad et al. <xref ref-type="bibr" rid="CR1">1995</xref>; Ron-Doitch et al. <xref ref-type="bibr" rid="CR301">2016</xref>)</td></tr><tr><td>LL-37</td><td>Liposome</td><td>(Ron-Doitch et al. <xref ref-type="bibr" rid="CR301">2016</xref>)</td></tr><tr><td>Alyteserin-1c</td><td>Liposome</td><td>(Cantor et al. <xref ref-type="bibr" rid="CR49">2019</xref>)</td></tr><tr><td>Microcin J25</td><td>Liposome</td><td>(Gomaa et al. <xref ref-type="bibr" rid="CR129">2017</xref>)</td></tr><tr><td>P34</td><td>Liposome</td><td>(da Silva Malheiros et al. <xref ref-type="bibr" rid="CR71">2011</xref>)</td></tr><tr><td>Pediocin AcH</td><td>Liposome</td><td>(Degnan and Luchansky <xref ref-type="bibr" rid="CR83">1992</xref>; Degnan et al. <xref ref-type="bibr" rid="CR84">1993</xref>)</td></tr><tr><td>Temporin</td><td>Liposome</td><td>(Mizukami et al. <xref ref-type="bibr" rid="CR239">2010</xref>)</td></tr><tr><td>CM3</td><td>Liposome</td><td>(Lange et al. <xref ref-type="bibr" rid="CR185">2001</xref>)</td></tr><tr><td>Polymyxin B</td><td>Lipid micelles</td><td>(Brandenburg et al. <xref ref-type="bibr" rid="CR41">2012</xref>)</td></tr><tr><td>Cyclosporin A</td><td>Solid lipid nanoparticles</td><td>(Zhang et al. <xref ref-type="bibr" rid="CR401">2000</xref>; M&#x000fc;ller et al. <xref ref-type="bibr" rid="CR249">2006</xref>; Kim et al. <xref ref-type="bibr" rid="CR174">2009</xref>)</td></tr><tr><td>Nisin</td><td>Solid lipid nanoparticles</td><td>(Prombutara et al. <xref ref-type="bibr" rid="CR288">2012</xref>)</td></tr><tr><td>Polymyxin B</td><td>Solid lipid nanoparticles</td><td>(Severino et al. <xref ref-type="bibr" rid="CR319">2017</xref>)</td></tr><tr><td>LL-37/serapinA1</td><td>Solid lipid nanoparticles</td><td>(Fumakia and Ho <xref ref-type="bibr" rid="CR116">2016</xref>)</td></tr></tbody></table></table-wrap></p><p id="Par98">Given the lipid bilayer structure inherent in these materials, it is unsurprising that membrane disruptive peptides have the potential to influence phase behaviour and structural parameters. Thus, careful characterization is necessary to determine any changes in material properties that come as a result of peptide loading and resulting peptide-membrane interactions. For example, the encapsulation of gramicidin A in cubic phase lipid materials has repeatedly revealed a shift towards structures with high negative curvature, such as hexosomes, with increasing peptide concentration (Liu and Caffrey <xref ref-type="bibr" rid="CR207">2005</xref>; Meikle et al. <xref ref-type="bibr" rid="CR232">2016</xref>; Meikle et al. <xref ref-type="bibr" rid="CR233">2017</xref>). The cationic charge of many AMPs must also be considered; electrostatic repulsion between membrane associated peptides appears to influence lipid phase behaviour as well as encapsulation efficiency (Boge et al. <xref ref-type="bibr" rid="CR34">2017</xref>; Meikle et al. <xref ref-type="bibr" rid="CR233">2017</xref>; Meikle et al. <xref ref-type="bibr" rid="CR235">2021</xref>). Manipulation of these interactions via the addition of anionic lipids to the cubosome formulation, or the inclusion of a charge screening buffer condition, can lead to favourable structural properties and increased peptide loading (Boge et al. <xref ref-type="bibr" rid="CR34">2017</xref>). Antimicrobial activity of cubosome encapsulated AMPs is seen to increase in some cases, decreasing in others. Work is currently underway exploring the fusion and uptake mechanisms involved in cubosome-bacteria interactions (Dyett et al. <xref ref-type="bibr" rid="CR96">2019</xref>; Meikle et al. <xref ref-type="bibr" rid="CR234">2020</xref>; Meikle et al. <xref ref-type="bibr" rid="CR235">2021</xref>).</p><p id="Par99">Liposomes have long been utilized as nanocarriers for various drugs, as their structure allows for both hydrophobic and amphiphilic drug encapsulation within the membrane, while hydrophilic drugs can be contained within the liposome interior. They are also highly biocompatible and non-toxic; the first FDA approved nanodrug was Doxil, a liposomal doxorubicin formulation (Barenholz <xref ref-type="bibr" rid="CR16">2012</xref>). Design considerations include maximising both stability and peptide loading efficiency, achieved via careful selection of lipid formulations. Accordingly, lipids for which AMPs display selectivity or increased activity, such as those containing anionic head groups, are often avoided due to complete disruption of the liposomal bilayer.</p><p id="Par100">A wide range of antimicrobial peptides have since been formulated with liposomes. In a recent study, DSPC/DSPE-PEG liposomes were used to encapsulate the AMP LL-37 (Ron-Doitch et al. <xref ref-type="bibr" rid="CR301">2016</xref>). Characterisation and activity experiments showed that the liposomal formulation possessed increased antiviral activity against HSV-1, with reduced toxicity over the free peptide. Cantor et al. have also demonstrated increased antimicrobial activity following encapsulation of the peptide alyteserin-1c in polymer-coated liposomes (Cantor et al. <xref ref-type="bibr" rid="CR49">2019</xref>).</p><p id="Par101">Other lipid-based nanoparticle formulations are under investigation for AMP delivery, including phospholipid micelles, recently investigated for the encapsulation of polymyxin B (Brandenburg et al. <xref ref-type="bibr" rid="CR41">2012</xref>). In this study, encapsulation of the peptide in DSPE-PEG(2000) micelles was high; however, the in vitro activity against <italic>P. aeruginosa</italic> was significantly reduced compared to free peptide, presumably due to reduced electrostatic interactions between the encapsulated peptide and the bacterial membrane as a result of the PEG (200) coating.</p><p id="Par102">Solid lipid nanoparticle solutions are colloidal dispersions of solid-state lipids, often stabilized with surfactants. They are formulated using lipids with increased melting points, such as mono- and tri-glycerides, steroids and fatty acids. Various production methods have been proposed, and parameters such as drug structure and solubility, final particle size and production conditions such as increased temperature must be considered. They have been used for the encapsulation of polymyxin B (Brandenburg et al. <xref ref-type="bibr" rid="CR41">2012</xref>), cyclosporin A (Zhang et al. <xref ref-type="bibr" rid="CR401">2000</xref>; M&#x000fc;ller et al. <xref ref-type="bibr" rid="CR249">2006</xref>; Kim et al. <xref ref-type="bibr" rid="CR174">2009</xref>) and nisin (Prombutara et al. <xref ref-type="bibr" rid="CR288">2012</xref>). To increase wound healing, Fumika et al. fabricated solid lipid nanoparticles comprised of glyceryl monostearate and phosphatidylcholine co-encapsulated with two AMPs, LL-37 and serpin A1 (Fumakia and Ho <xref ref-type="bibr" rid="CR116">2016</xref>). The nanoparticles were found to accelerate wound healing and closure via BJ fibroblasts and keratinocytes, and the two peptides were found to possess synergistic antimicrobial activity against <italic>S. aureus</italic> and <italic>E. coli</italic>.</p></sec></sec><sec id="Sec45"><title>Conclusion</title><p id="Par103">Worldwide health institutions generally project multidrug-resistant infections to cause several million deaths annually by 2050. In the search for new antimicrobial compounds and biomaterials to counter the alarming progression of such infections, antimicrobial peptides (AMPs) are considered as promising candidates by the research community. The increasing interest in these compounds is indicated by the exponential number of scientific articles published on AMPs, which led this review to cite close to 400 references to provide a global overview of this accelerating research area.</p><p id="Par104">AMPs present the advantage of typically targeting microbial lipid membranes, a site of action less prone to resistance. AMPs often concomitantly act on other microbial sites, either intracellular and/or extracellular targets. Such multi-target mechanisms of action further limit the occurrence of resistance.</p><p id="Par105">The recent years have seen the emergence of molecular engineering principles for the creation of optimised synthetic AMPs. Thanks to intense fundamental research in peptide design, it is now possible to engineer and optimise short peptide sequences that exhibit selective antimicrobial activity while limiting toxicity. Peptide molecular engineering is also now capable to optimise sequences towards biomaterial applications via controlling peptide self-assembling properties, including into nanostructured peptide hydrogels.</p><p id="Par106">Challenges still remain to translate this global research effort to marketed products, especially improving pharmacokinetic properties of peptide-based therapeutics and continuing to decrease the costs of synthesis. However, recent advances in peptide synthesis and bio-nanotechnology augur well for overcoming these issues and providing AMP-based formulations and biomaterials with optimised pharmacokinetic properties at a reasonable cost.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>I</given-names></name><name><surname>Perkins</surname><given-names>WR</given-names></name><name><surname>Lupan</surname><given-names>DM</given-names></name><name><surname>Selsted</surname><given-names>ME</given-names></name><name><surname>Janoff</surname><given-names>AS</given-names></name></person-group><article-title>Liposomal entrapment of the neutrophil-derived peptide indolicidin endows it with in vivo antifungal activity</article-title><source>Biochim Biophys Acta</source><year>1995</year><volume>1237</volume><fpage>109</fpage><lpage>114</lpage><?supplied-pmid 7632702?><pub-id pub-id-type="pmid">7632702</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000c5;kesson</surname><given-names>P</given-names></name><name><surname>Sj&#x000f6;holm</surname><given-names>AG</given-names></name><name><surname>Bj&#x000f6;rck</surname><given-names>L</given-names></name></person-group><article-title>Protein SIC, a novel extracellular protein of <italic>Streptococcus pyogenes</italic> interfering with complement function</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>1081</fpage><lpage>1088</lpage><?supplied-pmid 8557634?><pub-id pub-id-type="pmid">8557634</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alipour</surname><given-names>M</given-names></name><name><surname>Suntres</surname><given-names>ZE</given-names></name><name><surname>Halwani</surname><given-names>M</given-names></name><name><surname>Azghani</surname><given-names>AO</given-names></name><name><surname>Omri</surname><given-names>A</given-names></name></person-group><article-title>Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis</article-title><source>PLoS One</source><year>2009</year><volume>4</volume><fpage>e5724</fpage><?supplied-pmid 19479000?><pub-id pub-id-type="pmid">19479000</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>CA</given-names></name><name><surname>Adams</surname><given-names>LG</given-names></name><name><surname>Ficht</surname><given-names>TA</given-names></name></person-group><article-title>Transposon-derived <italic>Brucella abortus</italic> rough mutants are attenuated and exhibit reduced intracellular survival</article-title><source>Infect Immun</source><year>1998</year><volume>66</volume><fpage>1008</fpage><lpage>1016</lpage><?supplied-pmid 9488389?><pub-id pub-id-type="pmid">9488389</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amann</surname><given-names>R</given-names></name><name><surname>Ludwig</surname><given-names>W</given-names></name><name><surname>Schleifer</surname><given-names>K</given-names></name></person-group><article-title>Phylogenetic identification and in situ detection of individual microbial cells without cultivation</article-title><source>Microbiol Rev</source><year>1995</year><volume>59</volume><fpage>43</fpage><lpage>69</lpage></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrose</surname><given-names>KD</given-names></name><name><surname>Nisbet</surname><given-names>R</given-names></name><name><surname>Stephens</surname><given-names>DS</given-names></name></person-group><article-title>Macrolide efflux in <italic>Streptococcus pneumoniae</italic> is mediated by a dual efflux pump and is erythromycin inducible</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><fpage>4203</fpage><lpage>4209</lpage><?supplied-pmid 16189099?><pub-id pub-id-type="pmid">16189099</pub-id></element-citation></ref><ref id="CR7"><mixed-citation publication-type="other">Andreasen M et al. (2019) Physical determinants of amyloid assembly in biofilm formation. mBio 10:e02279&#x02013;02218</mixed-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrei</surname><given-names>S</given-names></name><name><surname>Droc</surname><given-names>G</given-names></name><name><surname>Stefan</surname><given-names>G</given-names></name></person-group><article-title>FDA approved antibacterial drugs: 2018-2019</article-title><source>Discoveries (Craiova)</source><year>2019</year><volume>7</volume><fpage>e102</fpage><pub-id pub-id-type="pmid">32309620</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aslam</surname><given-names>B</given-names></name><etal/></person-group><article-title>Antibiotic resistance: a rundown of a global crisis</article-title><source>Infect Drug Resist</source><year>2018</year><volume>11</volume><fpage>1645</fpage><lpage>1658</lpage><?supplied-pmid 30349322?><pub-id pub-id-type="pmid">30349322</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avrahami</surname><given-names>D</given-names></name><name><surname>Shai</surname><given-names>Y</given-names></name></person-group><article-title>Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity</article-title><source>Biochemistry</source><year>2002</year><volume>41</volume><fpage>2254</fpage><lpage>2263</lpage><?supplied-pmid 11841217?><pub-id pub-id-type="pmid">11841217</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bader</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Recognition of antimicrobial peptides by a bacterial sensor kinase</article-title><source>Cell</source><year>2005</year><volume>122</volume><fpage>461</fpage><lpage>472</lpage><?supplied-pmid 16096064?><pub-id pub-id-type="pmid">16096064</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baelo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections</article-title><source>J Control Release</source><year>2015</year><volume>209</volume><fpage>150</fpage><lpage>158</lpage><?supplied-pmid 25913364?><pub-id pub-id-type="pmid">25913364</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballantine</surname><given-names>RD</given-names></name><name><surname>McCallion</surname><given-names>CE</given-names></name><name><surname>Nassour</surname><given-names>E</given-names></name><name><surname>Tokajian</surname><given-names>S</given-names></name><name><surname>Cochrane</surname><given-names>SA</given-names></name></person-group><article-title>Tridecaptin-inspired antimicrobial peptides with activity against multidrug-resistant Gram-negative bacteria</article-title><source>MedChemComm</source><year>2019</year><volume>10</volume><fpage>484</fpage><lpage>487</lpage><?supplied-pmid 31015912?><pub-id pub-id-type="pmid">31015912</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baltz</surname><given-names>RH</given-names></name><name><surname>Miao</surname><given-names>V</given-names></name><name><surname>Wrigley</surname><given-names>SK</given-names></name></person-group><article-title>Natural products to drugs: daptomycin and related lipopeptide antibiotics</article-title><source>Natural Product Reports</source><year>2005</year><volume>22</volume><fpage>717</fpage><lpage>741</lpage><?supplied-pmid 16311632?><pub-id pub-id-type="pmid">16311632</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bara&#x00144;ska-Rybak</surname><given-names>W</given-names></name><name><surname>Sonesson</surname><given-names>A</given-names></name><name><surname>Nowicki</surname><given-names>R</given-names></name><name><surname>Schmidtchen</surname><given-names>A</given-names></name></person-group><article-title>Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids</article-title><source>J Antimicrob Chemother</source><year>2005</year><volume>57</volume><fpage>260</fpage><lpage>265</lpage><?supplied-pmid 16387752?><pub-id pub-id-type="pmid">16387752</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barenholz</surname><given-names>Y</given-names></name></person-group><article-title>Doxil - the first FDA-approved nano-drug: lessons learned</article-title><source>J Control Release</source><year>2012</year><volume>160</volume><fpage>117</fpage><lpage>134</lpage><?supplied-pmid 22484195?><pub-id pub-id-type="pmid">22484195</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bechinger</surname><given-names>B</given-names></name><name><surname>Gorr</surname><given-names>SU</given-names></name></person-group><article-title>Antimicrobial peptides: mechanisms of action and resistance</article-title><source>J Dent Res</source><year>2017</year><volume>96</volume><fpage>254</fpage><lpage>260</lpage><?supplied-pmid 27872334?><pub-id pub-id-type="pmid">27872334</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Boger</surname><given-names>P</given-names></name><name><surname>Oehlmann</surname><given-names>R</given-names></name><name><surname>Ernst</surname><given-names>A</given-names></name></person-group><article-title>PCR Bias in ecological analysis: a case study for quantitative Taq nuclease assays in analyses of microbial communities</article-title><source>Appl Environ Microbiol</source><year>2000</year><volume>66</volume><fpage>4945</fpage><lpage>4953</lpage><?supplied-pmid 11055948?><pub-id pub-id-type="pmid">11055948</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bednarska</surname><given-names>NG</given-names></name><etal/></person-group><article-title>Protein aggregation as an antibiotic design strategy</article-title><source>Mol Microbiol</source><year>2016</year><volume>99</volume><fpage>849</fpage><lpage>865</lpage><?supplied-pmid 26559925?><pub-id pub-id-type="pmid">26559925</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belas</surname><given-names>R</given-names></name><name><surname>Manos</surname><given-names>J</given-names></name><name><surname>Suvanasuthi</surname><given-names>R</given-names></name></person-group><article-title><italic>Proteus mirabilis</italic> ZapA metalloprotease degrades a broad spectrum of substrates, including antimicrobial peptides</article-title><source>Infect Immun</source><year>2004</year><volume>72</volume><fpage>5159</fpage><lpage>5167</lpage><?supplied-pmid 15322010?><pub-id pub-id-type="pmid">15322010</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benech</surname><given-names>RO</given-names></name><name><surname>Kheadr</surname><given-names>EE</given-names></name><name><surname>Laridi</surname><given-names>R</given-names></name><name><surname>Lacroix</surname><given-names>C</given-names></name><name><surname>Fliss</surname><given-names>I</given-names></name></person-group><article-title>Inhibition of Listeria innocua in cheddar cheese by addition of nisin Z in liposomes or by in situ production in mixed culture</article-title><source>Appl Environ Microbiol</source><year>2002</year><volume>68</volume><fpage>3683</fpage><lpage>3690</lpage><?supplied-pmid 12147460?><pub-id pub-id-type="pmid">12147460</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benech</surname><given-names>RO</given-names></name><name><surname>Kheadr</surname><given-names>EE</given-names></name><name><surname>Lacroix</surname><given-names>C</given-names></name><name><surname>Fliss</surname><given-names>I</given-names></name></person-group><article-title>Impact of nisin producing culture and liposome-encapsulated nisin on ripening of Lactobacillus added-cheddar cheese</article-title><source>J Dairy Sci</source><year>2003</year><volume>86</volume><fpage>1895</fpage><lpage>1909</lpage><?supplied-pmid 12836923?><pub-id pub-id-type="pmid">12836923</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengoechea</surname><given-names>JA</given-names></name><name><surname>Skurnik</surname><given-names>M</given-names></name></person-group><article-title>Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia</article-title><source>Mol Microbiol</source><year>2000</year><volume>37</volume><fpage>67</fpage><lpage>80</lpage><?supplied-pmid 10931306?><pub-id pub-id-type="pmid">10931306</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bera</surname><given-names>A</given-names></name><name><surname>Biswas</surname><given-names>R</given-names></name><name><surname>Herbert</surname><given-names>S</given-names></name><name><surname>Kulauzovic</surname><given-names>E</given-names></name><name><surname>Weidenmaier</surname><given-names>C</given-names></name><name><surname>Peschel</surname><given-names>A</given-names></name><name><surname>G&#x000f6;tz</surname><given-names>F</given-names></name></person-group><article-title>Influence of wall teichoic acid on lysozyme resistance in <italic>Staphylococcus aureus</italic></article-title><source>J Bacteriol</source><year>2007</year><volume>189</volume><fpage>280</fpage><lpage>283</lpage><?supplied-pmid 17085565?><pub-id pub-id-type="pmid">17085565</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernegossi</surname><given-names>J</given-names></name><name><surname>Calixto</surname><given-names>GMF</given-names></name><name><surname>Sanches</surname><given-names>PRS</given-names></name><name><surname>Fontana</surname><given-names>CR</given-names></name><name><surname>Cilli</surname><given-names>EM</given-names></name><name><surname>Garrido</surname><given-names>SS</given-names></name><name><surname>Chorilli</surname><given-names>M</given-names></name></person-group><article-title>Peptide KSL-W-loaded mucoadhesive liquid crystalline vehicle as an alternative treatment for multispecies oral biofilm</article-title><source>Molecules</source><year>2016</year><volume>21</volume><fpage>37</fpage></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besson</surname><given-names>F</given-names></name><name><surname>Peypoux</surname><given-names>F</given-names></name><name><surname>Quentin</surname><given-names>MJ</given-names></name><name><surname>Michel</surname><given-names>G</given-names></name></person-group><article-title>Action of antifungal peptidolipids from <italic>Bacillus subtilis</italic> on the cell membrane of <italic>Saccharomyces cerevisiae</italic></article-title><source>J Antibiot (Tokyo)</source><year>1984</year><volume>37</volume><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">6423598</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bianco</surname><given-names>A</given-names></name><name><surname>Venanzi</surname><given-names>M</given-names></name><name><surname>Aleman</surname><given-names>C</given-names></name></person-group><source>Peptide materials: from nanostructures to applications</source><year>2013</year><publisher-loc>Technology &#x00026; Engineering</publisher-loc><publisher-name>John Wiley &#x00026; Sons</publisher-name></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bierbaum</surname><given-names>G</given-names></name><name><surname>Sahl</surname><given-names>HG</given-names></name></person-group><article-title>Lantibiotics: mode of action, biosynthesis and bioengineering</article-title><source>Curr Pharm Biotech</source><year>2009</year><volume>10</volume><fpage>2</fpage><lpage>18</lpage></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bina</surname><given-names>XR</given-names></name><name><surname>Provenzano</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>N</given-names></name><name><surname>Bina</surname><given-names>JE</given-names></name></person-group><article-title>Vibrio cholerae RND family efflux systems are required for antimicrobial resistance, optimal virulence factor production, and colonization of the infant mouse small intestine</article-title><source>Infect Immun</source><year>2008</year><volume>76</volume><fpage>3595</fpage><lpage>3605</lpage><?supplied-pmid 18490456?><pub-id pub-id-type="pmid">18490456</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biron</surname><given-names>E</given-names></name><etal/></person-group><article-title>Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues</article-title><source>Angew Chem Int Ed Engl</source><year>2008</year><volume>47</volume><fpage>2595</fpage><lpage>2599</lpage><?supplied-pmid 18297660?><pub-id pub-id-type="pmid">18297660</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaskovich</surname><given-names>MA</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><article-title>Polishing the tarnished silver bullet: the quest for new antibiotics</article-title><source>Essays Biochem</source><year>2017</year><volume>61</volume><fpage>103</fpage><lpage>114</lpage><?supplied-pmid 28258234?><pub-id pub-id-type="pmid">28258234</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blin</surname><given-names>K</given-names></name><etal/></person-group><article-title>antiSMASH 4.0-improvements in chemistry prediction and gene cluster boundary identification</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><fpage>W36</fpage><lpage>W41</lpage><?supplied-pmid 28460038?><pub-id pub-id-type="pmid">28460038</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boge</surname><given-names>L</given-names></name><etal/></person-group><article-title>Lipid-based liquid crystals as carriers for antimicrobial peptides: phase behavior and antimicrobial effect</article-title><source>Langmuir</source><year>2016</year><volume>32</volume><fpage>4217</fpage><lpage>4228</lpage><?supplied-pmid 27033359?><pub-id pub-id-type="pmid">27033359</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boge</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cubosomes post-loaded with antimicrobial peptides: characterization, bactericidal effect and proteolytic stability</article-title><source>Int J Pharmaceutics</source><year>2017</year><volume>526</volume><fpage>400</fpage><lpage>412</lpage></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boge</surname><given-names>L</given-names></name><etal/></person-group><article-title>Peptide-loaded cubosomes functioning as an antimicrobial unit against <italic>Escherichia coli</italic></article-title><source>ACS Appl Mater Interf</source><year>2019</year><volume>11</volume><fpage>21314</fpage><lpage>21322</lpage></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boge</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cubosomes for topical delivery of the antimicrobial peptide LL-37</article-title><source>Eur J Pharm Biopharm</source><year>2019</year><volume>134</volume><fpage>60</fpage><lpage>67</lpage><?supplied-pmid 30445164?><pub-id pub-id-type="pmid">30445164</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokarewa</surname><given-names>M</given-names></name><name><surname>Tarkowski</surname><given-names>A</given-names></name></person-group><article-title>Human &#x003b1;-defensins neutralize fibrinolytic activity exerted by staphylokinase</article-title><source>Thrombosis and Haemostasis</source><year>2004</year><volume>91</volume><fpage>991</fpage><lpage>999</lpage><?supplied-pmid 15116261?><pub-id pub-id-type="pmid">15116261</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borders</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Laspartomycin, an acidic lipopeptide antibiotic with a unique peptide core</article-title><source>J Nat Prod</source><year>2007</year><volume>70</volume><fpage>443</fpage><lpage>446</lpage><?supplied-pmid 17315928?><pub-id pub-id-type="pmid">17315928</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourgade</surname><given-names>K</given-names></name><name><surname>Dupuis</surname><given-names>G</given-names></name><name><surname>Frost</surname><given-names>EH</given-names></name><name><surname>F&#x000fc;l&#x000f6;p</surname><given-names>T</given-names></name></person-group><article-title>Anti-viral properties of amyloid-&#x003b2; peptides</article-title><source>J Alzheimers Dis</source><year>2016</year><volume>54</volume><fpage>859</fpage><lpage>878</lpage><?supplied-pmid 27392871?><pub-id pub-id-type="pmid">27392871</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracci</surname><given-names>L</given-names></name><etal/></person-group><article-title>Synthetic peptides in the form of dendrimers become resistant to protease activity</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>46590</fpage><lpage>46595</lpage><?supplied-pmid 12972419?><pub-id pub-id-type="pmid">12972419</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandenburg</surname><given-names>KS</given-names></name><name><surname>Rubinstein</surname><given-names>I</given-names></name><name><surname>Sadikot</surname><given-names>RT</given-names></name><name><surname>&#x000d6;ny&#x000fc;ksel</surname><given-names>H</given-names></name></person-group><article-title>Polymyxin B self-associated with phospholipid nanomicelles</article-title><source>Pharm Dev Tech</source><year>2012</year><volume>17</volume><fpage>654</fpage><lpage>660</lpage></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Br&#x000f6;tz</surname><given-names>H</given-names></name><name><surname>Josten</surname><given-names>M</given-names></name><name><surname>Wiedemann</surname><given-names>I</given-names></name><name><surname>Schneider</surname><given-names>U</given-names></name><name><surname>G&#x000f6;tz</surname><given-names>F</given-names></name><name><surname>Bierbaum</surname><given-names>G</given-names></name><name><surname>Sahl</surname><given-names>H-G</given-names></name></person-group><article-title>Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics</article-title><source>Mol Microbiol</source><year>1998</year><volume>30</volume><fpage>317</fpage><lpage>327</lpage><?supplied-pmid 9791177?><pub-id pub-id-type="pmid">9791177</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>KL</given-names></name><name><surname>Hancock</surname><given-names>REW</given-names></name></person-group><article-title>Cationic host defense (antimicrobial) peptides</article-title><source>Curr Op Immun</source><year>2006</year><volume>18</volume><fpage>24</fpage><lpage>30</lpage></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>HL</given-names></name><name><surname>Hanman</surname><given-names>K</given-names></name><name><surname>Reuter</surname><given-names>M</given-names></name><name><surname>Betts</surname><given-names>RP</given-names></name><name><surname>van Vliet</surname><given-names>AH</given-names></name></person-group><article-title>Campylobacter jejuni biofilms contain extracellular DNA and are sensitive to DNase I treatment</article-title><source>Front Microbiol</source><year>2015</year><volume>6</volume><fpage>699</fpage><?supplied-pmid 26217328?><pub-id pub-id-type="pmid">26217328</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugg</surname><given-names>TDH</given-names></name><name><surname>Wright</surname><given-names>GD</given-names></name><name><surname>Dutka-Malen</surname><given-names>S</given-names></name><name><surname>Arthur</surname><given-names>M</given-names></name><name><surname>Courvalin</surname><given-names>P</given-names></name><name><surname>Walsh</surname><given-names>CT</given-names></name></person-group><article-title>Molecular basis for vancomycin resistance in <italic>Enterococcus faecium</italic> BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA</article-title><source>Biochemistry</source><year>1991</year><volume>30</volume><fpage>10408</fpage><lpage>10415</lpage><?supplied-pmid 1931965?><pub-id pub-id-type="pmid">1931965</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunkoczi</surname><given-names>G</given-names></name><name><surname>Vertesy</surname><given-names>L</given-names></name><name><surname>Sheldrick</surname><given-names>GM</given-names></name></person-group><article-title>Structure of the lipopeptide antibiotic tsushimycin</article-title><source>Acta Cryst D</source><year>2005</year><volume>61</volume><fpage>1160</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">16041082</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrd</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Genetic and biochemical analyses of the <italic>Pseudomonas aeruginosa</italic> Psl exopolysaccharide reveal overlapping roles for polysaccharide synthesis enzymes in Psl and LPS production</article-title><source>Mol Microbiol</source><year>2009</year><volume>73</volume><fpage>622</fpage><lpage>638</lpage><?supplied-pmid 19659934?><pub-id pub-id-type="pmid">19659934</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname><given-names>MA</given-names></name><name><surname>Vargas</surname><given-names>MA</given-names></name><name><surname>Regueiro</surname><given-names>V</given-names></name><name><surname>Llompart</surname><given-names>CM</given-names></name><name><surname>Albert&#x000ed;</surname><given-names>S</given-names></name><name><surname>Bengoechea</surname><given-names>JA</given-names></name></person-group><article-title>Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides</article-title><source>Infect Immun</source><year>2004</year><volume>72</volume><fpage>7107</fpage><lpage>7114</lpage><?supplied-pmid 15557634?><pub-id pub-id-type="pmid">15557634</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantor</surname><given-names>S</given-names></name><name><surname>Vargas</surname><given-names>L</given-names></name><name><surname>Rojas</surname><given-names>AOE</given-names></name><name><surname>Yarce</surname><given-names>CJ</given-names></name><name><surname>Salamanca</surname><given-names>CH</given-names></name><name><surname>O&#x000f1;ate-Garz&#x000f3;n</surname><given-names>J</given-names></name></person-group><article-title>Evaluation of the antimicrobial activity of cationic peptides loaded in surface-modified nanoliposomes against foodborne bacteria</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><fpage>680</fpage></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlisle</surname><given-names>MD</given-names></name><name><surname>Srikantha</surname><given-names>R</given-names></name><name><surname>Brogden</surname><given-names>K</given-names></name></person-group><article-title>Degradation of human &#x003b1;-and &#x003b2;-defensins by culture supernatants of <italic>Porphyromonas gingivalis</italic> strain 381</article-title><source>J Innate Immun</source><year>2009</year><volume>1</volume><fpage>118</fpage><lpage>122</lpage><?supplied-pmid 20375570?><pub-id pub-id-type="pmid">20375570</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>F</given-names></name><etal/></person-group><article-title>L-Rhamnosylation of <italic>Listeria monocytogenes</italic> wall teichoic acids promotes resistance to antimicrobial peptides by delaying interaction with the membrane</article-title><source>PLOS Pathogens</source><year>2015</year><volume>11</volume><fpage>e1004919</fpage><?supplied-pmid 26001194?><pub-id pub-id-type="pmid">26001194</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chairatana</surname><given-names>P</given-names></name><name><surname>Nolan</surname><given-names>EM</given-names></name></person-group><article-title>Human &#x003b1;-defensin 6: a small peptide that self-assembles and protects the host by entangling microbes</article-title><source>Acc Chem Res</source><year>2017</year><volume>50</volume><fpage>960</fpage><lpage>967</lpage><?supplied-pmid 28296382?><pub-id pub-id-type="pmid">28296382</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chairatana</surname><given-names>P</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Castillo</surname><given-names>PA</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Bevins</surname><given-names>CL</given-names></name><name><surname>Nolan</surname><given-names>EM</given-names></name></person-group><article-title>Proteolysis Triggers Self-Assembly and Unmasks Innate Immune Function of a Human &#x003b1;-Defensin Peptide</article-title><source>Chem Sci</source><year>2016</year><volume>7</volume><fpage>1738</fpage><lpage>1752</lpage><?supplied-pmid 27076903?><pub-id pub-id-type="pmid">27076903</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Burrows</surname><given-names>LL</given-names></name><name><surname>Deber</surname><given-names>CM</given-names></name></person-group><article-title>Helix induction in antimicrobial peptides by alginate in biofilms</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>38749</fpage><lpage>38754</lpage><?supplied-pmid 15247257?><pub-id pub-id-type="pmid">15247257</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>C</given-names></name><name><surname>Burrows</surname><given-names>LL</given-names></name><name><surname>Deber</surname><given-names>CM</given-names></name></person-group><article-title>Alginate as an auxiliary bacterial membrane: binding of membrane-active peptides by polysaccharides</article-title><source>J Pep Res</source><year>2005</year><volume>65</volume><fpage>343</fpage><lpage>351</lpage></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>DI</given-names></name><name><surname>Prenner</surname><given-names>EJ</given-names></name><name><surname>Vogel</surname><given-names>HJ</given-names></name></person-group><article-title>Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action</article-title><source>Biochim Biophys Acta</source><year>2006</year><volume>1758</volume><fpage>1184</fpage><lpage>1202</lpage><?supplied-pmid 16756942?><pub-id pub-id-type="pmid">16756942</pub-id></element-citation></ref><ref id="CR57"><mixed-citation publication-type="other">Chen C et al (2010) Antibacterial activities of short designer peptides: a link between propensity for nanostructuring and capacity for membrane destabilization. Biomacromolecules:402&#x02013;411</mixed-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><etal/></person-group><article-title>Self-assembled peptide nanofibers display natural antimicrobial peptides to selectively kill bacteria without compromising cytocompatibility</article-title><source>ACS Appl Mater Interf</source><year>2019</year><volume>11</volume><fpage>28681</fpage><lpage>28689</lpage></element-citation></ref><ref id="CR59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Sohn</surname><given-names>HY</given-names></name><name><surname>Lee</surname><given-names>DG</given-names></name></person-group><article-title>The antifungal activity and membrane-disruptive action of dioscin extracted from <italic>Dioscorea nipponica</italic></article-title><source>Biochim Biophys Acta</source><year>2013</year><volume>1828</volume><fpage>1153</fpage><lpage>1158</lpage><?supplied-pmid 23262192?><pub-id pub-id-type="pmid">23262192</pub-id></element-citation></ref><ref id="CR60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chooi</surname><given-names>YH</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name></person-group><article-title>Adding the lipo to lipopeptides: do more with less</article-title><source>Chem Biol</source><year>2010</year><volume>17</volume><fpage>791</fpage><lpage>793</lpage><?supplied-pmid 20797606?><pub-id pub-id-type="pmid">20797606</pub-id></element-citation></ref><ref id="CR61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chorev</surname><given-names>M</given-names></name><name><surname>Goodman</surname><given-names>M</given-names></name></person-group><article-title>Recent developments in retro peptides and proteins--an ongoing topochemical exploration</article-title><source>Trends Biotechnol</source><year>1995</year><volume>13</volume><fpage>438</fpage><lpage>445</lpage><?supplied-pmid 7546569?><pub-id pub-id-type="pmid">7546569</pub-id></element-citation></ref><ref id="CR62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>B</given-names></name><name><surname>Fink</surname><given-names>J</given-names></name><name><surname>Merrifield</surname><given-names>R</given-names></name><name><surname>Mauzerall</surname><given-names>D</given-names></name></person-group><article-title>Channel-forming properties of cecropins and related model compounds incorporated into planar lipid membranes</article-title><source>Proc Natl Acad Sci USA</source><year>1988</year><volume>85</volume><fpage>5072</fpage><lpage>5076</lpage><?supplied-pmid 2455891?><pub-id pub-id-type="pmid">2455891</pub-id></element-citation></ref><ref id="CR63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>PY</given-names></name><name><surname>Khanum</surname><given-names>R</given-names></name></person-group><article-title>Antimicrobial peptides as potential anti-biofilm agents against multidrug-resistant bacteria</article-title><source>J Microbiol Immun Infect</source><year>2017</year><volume>50</volume><fpage>405</fpage><lpage>410</lpage></element-citation></ref><ref id="CR64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cochrane</surname><given-names>SA</given-names></name><name><surname>Findlay</surname><given-names>B</given-names></name><name><surname>Vederas</surname><given-names>JC</given-names></name><name><surname>Ratemi</surname><given-names>ES</given-names></name></person-group><article-title>Key Residues in octyl-tridecaptin A1 analogues linked to stable secondary structures in the membrane</article-title><source>ChemBioChem</source><year>2014</year><volume>15</volume><fpage>1295</fpage><lpage>1299</lpage><?supplied-pmid 24816483?><pub-id pub-id-type="pmid">24816483</pub-id></element-citation></ref><ref id="CR65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>JN</given-names></name><name><surname>Pence</surname><given-names>MA</given-names></name><name><surname>von K&#x000f6;ckritz-Blickwede</surname><given-names>M</given-names></name><name><surname>Hollands</surname><given-names>A</given-names></name><name><surname>Gallo</surname><given-names>RL</given-names></name><name><surname>Walker</surname><given-names>MJ</given-names></name><name><surname>Nizet</surname><given-names>V</given-names></name></person-group><article-title>M Protein and hyaluronic acid capsule are essential for in vivo selection of covRS mutations characteristic of invasive serotype M1T1 group A streptococcus</article-title><source>mBio</source><year>2010</year><volume>1</volume><fpage>e00191&#x02013;00110</fpage><pub-id pub-id-type="pmid">20827373</pub-id></element-citation></ref><ref id="CR66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>B</given-names></name><name><surname>Curtis</surname><given-names>N</given-names></name><name><surname>Cotter</surname><given-names>PD</given-names></name><name><surname>Hill</surname><given-names>C</given-names></name><name><surname>Ross</surname><given-names>RP</given-names></name></person-group><article-title>The ABC transporter AnrAB contributes to the innate resistance of <italic>Listeria monocytogenes</italic> to nisin, bacitracin, and various &#x003b2;-lactam antibiotics</article-title><source>Antimicrob Agents Chemother</source><year>2010</year><volume>54</volume><fpage>4416</fpage><lpage>4423</lpage><?supplied-pmid 20643901?><pub-id pub-id-type="pmid">20643901</pub-id></element-citation></ref><ref id="CR67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colvin</surname><given-names>KM</given-names></name><etal/></person-group><article-title>The Pel and Psl polysaccharides provide <italic>Pseudomonas aeruginosa</italic> structural redundancy within the biofilm matrix</article-title><source>Environ Microbiol</source><year>2012</year><volume>14</volume><fpage>1913</fpage><lpage>1928</lpage><?supplied-pmid 22176658?><pub-id pub-id-type="pmid">22176658</pub-id></element-citation></ref><ref id="CR68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crofts</surname><given-names>TS</given-names></name><name><surname>Gasparrini</surname><given-names>AJ</given-names></name><name><surname>Dantas</surname><given-names>G</given-names></name></person-group><article-title>Next-generation approaches to understand and combat the antibiotic resistome</article-title><source>Nat Rev Microbiol</source><year>2017</year><volume>15</volume><fpage>422</fpage><lpage>434</lpage><?supplied-pmid 28392565?><pub-id pub-id-type="pmid">28392565</pub-id></element-citation></ref><ref id="CR69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Webber</surname><given-names>MJ</given-names></name><name><surname>Stupp</surname><given-names>SI</given-names></name></person-group><article-title>Self-assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials</article-title><source>Biopolymers</source><year>2010</year><volume>94</volume><fpage>1</fpage><lpage>18</lpage><?supplied-pmid 20091874?><pub-id pub-id-type="pmid">20091874</pub-id></element-citation></ref><ref id="CR70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Costa</surname><given-names>JP</given-names></name><name><surname>Cova</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>R</given-names></name><name><surname>Vitorino</surname><given-names>R</given-names></name></person-group><article-title>Antimicrobial peptides: an alternative for innovative medicines?</article-title><source>Appl Microbiol Biotechnol</source><year>2015</year><volume>99</volume><fpage>2023</fpage><lpage>2040</lpage><?supplied-pmid 25586583?><pub-id pub-id-type="pmid">25586583</pub-id></element-citation></ref><ref id="CR71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva Malheiros</surname><given-names>P</given-names></name><name><surname>Sant&#x02019;Anna</surname><given-names>V</given-names></name><name><surname>Micheletto</surname><given-names>YMS</given-names></name><name><surname>da Silveira</surname><given-names>NP</given-names></name><name><surname>Brandelli</surname><given-names>A</given-names></name></person-group><article-title>Nanovesicle encapsulation of antimicrobial peptide P34: physicochemical characterization and mode of action on <italic>Listeria monocytogenes</italic></article-title><source>J Nanoparticle Res</source><year>2011</year><volume>13</volume><fpage>3545</fpage><lpage>3552</lpage></element-citation></ref><ref id="CR72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daina</surname><given-names>A</given-names></name><name><surname>Michielin</surname><given-names>O</given-names></name><name><surname>Zoete</surname><given-names>V</given-names></name></person-group><article-title>SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>42717</fpage><?supplied-pmid 28256516?><pub-id pub-id-type="pmid">28256516</pub-id></element-citation></ref><ref id="CR73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danesi</surname><given-names>R</given-names></name><name><surname>Senesi</surname><given-names>S</given-names></name><name><surname>Wout</surname><given-names>JWVT</given-names></name><name><surname>JTv</surname><given-names>D</given-names></name><name><surname>Lupetti</surname><given-names>A</given-names></name><name><surname>Nibbering</surname><given-names>PH</given-names></name></person-group><article-title>Antimicrobial peptides: therapeutic potential for the treatment of Candida infections</article-title><source>Exp Opi Invest Drugs</source><year>2002</year><volume>11</volume><fpage>309</fpage><lpage>318</lpage></element-citation></ref><ref id="CR74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dathe</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hydrophobicity, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphipathic helical peptides</article-title><source>FEBS Lett</source><year>1997</year><volume>403</volume><fpage>208</fpage><lpage>212</lpage><?supplied-pmid 9042968?><pub-id pub-id-type="pmid">9042968</pub-id></element-citation></ref><ref id="CR75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daugelavicius</surname><given-names>R</given-names></name><name><surname>Bakiene</surname><given-names>E</given-names></name><name><surname>Bamford</surname><given-names>DH</given-names></name></person-group><article-title>Stages of polymyxin B interaction with the <italic>Escherichia coli</italic> cell envelope</article-title><source>Antimicrob Agents Chemother</source><year>2000</year><volume>44</volume><fpage>2969</fpage><lpage>2978</lpage><?supplied-pmid 11036008?><pub-id pub-id-type="pmid">11036008</pub-id></element-citation></ref><ref id="CR76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>J</given-names></name><name><surname>Davies</surname><given-names>D</given-names></name></person-group><article-title>Origins and evolution of antibiotic resistance</article-title><source>Microbiol Mol Biol Rev</source><year>2010</year><volume>74</volume><fpage>417</fpage><lpage>433</lpage><?supplied-pmid 2937522?><pub-id pub-id-type="pmid">20805405</pub-id></element-citation></ref><ref id="CR77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Fuente-Nunez</surname><given-names>C</given-names></name><name><surname>Reffuveille</surname><given-names>F</given-names></name><name><surname>Haney</surname><given-names>EF</given-names></name><name><surname>Straus</surname><given-names>SK</given-names></name><name><surname>Hancock</surname><given-names>RE</given-names></name></person-group><article-title>Broad-spectrum anti-biofilm peptide that targets a cellular stress response</article-title><source>PLoS Pathogens</source><year>2014</year><volume>10</volume><fpage>e1004152</fpage><?supplied-pmid 24852171?><pub-id pub-id-type="pmid">24852171</pub-id></element-citation></ref><ref id="CR78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Fuente-Nunez</surname><given-names>C</given-names></name><etal/></person-group><article-title>D-enantiomeric peptides that eradicate wild-type and multidrug-resistant biofilms and protect against lethal <italic>Pseudomonas aeruginosa</italic> infections</article-title><source>Chem Biol</source><year>2015</year><volume>22</volume><fpage>196</fpage><lpage>205</lpage><?supplied-pmid 25699603?><pub-id pub-id-type="pmid">25699603</pub-id></element-citation></ref><ref id="CR79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Leeuw</surname><given-names>E</given-names></name><etal/></person-group><article-title>Functional interaction of human neutrophil peptide-1 with the cell wall precursor lipid II</article-title><source>FEBS Lett</source><year>2010</year><volume>584</volume><fpage>1543</fpage><lpage>1548</lpage><?supplied-pmid 20214904?><pub-id pub-id-type="pmid">20214904</pub-id></element-citation></ref><ref id="CR80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Oliveira</surname><given-names>DMP</given-names></name><etal/></person-group><article-title>Antimicrobial resistance in ESKAPE Pathogens</article-title><source>Clin Microbiol Rev</source><year>2020</year><volume>33</volume><fpage>e00181</fpage><lpage>e00119</lpage><?supplied-pmid 32404435?><pub-id pub-id-type="pmid">32404435</pub-id></element-citation></ref><ref id="CR81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Zoysa</surname><given-names>GH</given-names></name><name><surname>Sarojini</surname><given-names>V</given-names></name></person-group><article-title>Feasibility study exploring the potential of novel battacin lipopeptides as antimicrobial coatings</article-title><source>ACS Appl Mater Interfaces</source><year>2017</year><volume>9</volume><fpage>1373</fpage><lpage>1383</lpage><?supplied-pmid 27992168?><pub-id pub-id-type="pmid">27992168</pub-id></element-citation></ref><ref id="CR82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Zoysa</surname><given-names>GH</given-names></name><name><surname>Cameron</surname><given-names>AJ</given-names></name><name><surname>Hegde</surname><given-names>VV</given-names></name><name><surname>Raghothama</surname><given-names>S</given-names></name><name><surname>Sarojini</surname><given-names>V</given-names></name></person-group><article-title>Antimicrobial peptides with potential for biofilm eradication: synthesis and structure activity relationship studies of battacin peptides</article-title><source>J Med Chem</source><year>2015</year><volume>58</volume><fpage>625</fpage><lpage>639</lpage><?supplied-pmid 25495219?><pub-id pub-id-type="pmid">25495219</pub-id></element-citation></ref><ref id="CR83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degnan</surname><given-names>AJ</given-names></name><name><surname>Luchansky</surname><given-names>JB</given-names></name></person-group><article-title>Influence of beef tallow and muscle on the antilisterial activity of pediocin AcH and liposome-encapsulated pediocin AcH</article-title><source>J Food Protect</source><year>1992</year><volume>55</volume><fpage>552</fpage><lpage>554</lpage></element-citation></ref><ref id="CR84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degnan</surname><given-names>AJ</given-names></name><name><surname>Buyong</surname><given-names>N</given-names></name><name><surname>Luchansky</surname><given-names>JB</given-names></name></person-group><article-title>Antilisterial activity of pediocin AcH in model food systems in the presence of an emulsifier or encapsulated within liposomes</article-title><source>Int J Food Microbiol</source><year>1993</year><volume>18</volume><fpage>127</fpage><lpage>138</lpage><?supplied-pmid 8494679?><pub-id pub-id-type="pmid">8494679</pub-id></element-citation></ref><ref id="CR85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delmar</surname><given-names>JA</given-names></name><name><surname>Su</surname><given-names>C-C</given-names></name><name><surname>Yu</surname><given-names>EW</given-names></name></person-group><article-title>Bacterial multidrug efflux transporters</article-title><source>Ann Rev Biophys</source><year>2014</year><volume>43</volume><fpage>93</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">24702006</pub-id></element-citation></ref><ref id="CR86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deslouches</surname><given-names>B</given-names></name><name><surname>Steckbeck</surname><given-names>JD</given-names></name><name><surname>Craigo</surname><given-names>JK</given-names></name><name><surname>Doi</surname><given-names>Y</given-names></name><name><surname>Mietzner</surname><given-names>TA</given-names></name><name><surname>Montelaro</surname><given-names>RC</given-names></name></person-group><article-title>Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens</article-title><source>Antimicrob Agents Chemother</source><year>2013</year><volume>57</volume><fpage>2511</fpage><lpage>2521</lpage><?supplied-pmid 23507278?><pub-id pub-id-type="pmid">23507278</pub-id></element-citation></ref><ref id="CR87"><mixed-citation publication-type="other">Dhand A, Snydman DR (2009) Mechanism of resistance in metronidazole. In: Mayers DL (ed) Antimicrobial drug resistance. Infectious Disease Humana Press, pp 223&#x02013;227</mixed-citation></ref><ref id="CR88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dharmadana</surname><given-names>D</given-names></name><name><surname>Reynolds</surname><given-names>NP</given-names></name><name><surname>Conn</surname><given-names>CE</given-names></name><name><surname>Val&#x000e9;ry</surname><given-names>C</given-names></name></person-group><article-title>Molecular interactions of amyloid nanofibrils with biological aggregation modifiers: implications for cytotoxicity mechanisms and biomaterial design</article-title><source>Interface Focus</source><year>2017</year><volume>7</volume><fpage>20160160</fpage><?supplied-pmid 28630679?><pub-id pub-id-type="pmid">28630679</pub-id></element-citation></ref><ref id="CR89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Weiss</surname><given-names>TM</given-names></name><name><surname>Waring</surname><given-names>AJ</given-names></name><name><surname>Lehrer</surname><given-names>RI</given-names></name><name><surname>Huang</surname><given-names>HW</given-names></name></person-group><article-title>Interaction of antimicrobial peptides with lipopolysaccharides</article-title><source>Biochemistry</source><year>2003</year><volume>42</volume><fpage>12251</fpage><lpage>12259</lpage><?supplied-pmid 14567687?><pub-id pub-id-type="pmid">14567687</pub-id></element-citation></ref><ref id="CR90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>RA</given-names></name><name><surname>Chopra</surname><given-names>I</given-names></name></person-group><article-title>Polymyxin B and polymyxin B nonapeptide alter cytoplasmic membrane permeability in <italic>Escherichia coli</italic></article-title><source>J Antimicrob Chemother</source><year>1986</year><volume>18</volume><fpage>557</fpage><lpage>563</lpage><?supplied-pmid 3027012?><pub-id pub-id-type="pmid">3027012</pub-id></element-citation></ref><ref id="CR91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donlan</surname><given-names>RM</given-names></name><name><surname>Costerton</surname><given-names>JW</given-names></name></person-group><article-title>Biofilms: survival mechanisms of clinically relevant microorganisms</article-title><source>Clin Microbiol Rev</source><year>2002</year><volume>15</volume><fpage>167</fpage><lpage>193</lpage><?supplied-pmid 11932229?><pub-id pub-id-type="pmid">11932229</pub-id></element-citation></ref><ref id="CR92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dostert</surname><given-names>M</given-names></name><name><surname>Belanger</surname><given-names>CR</given-names></name><name><surname>Hancock</surname><given-names>REW</given-names></name></person-group><article-title>Design and assessment of anti-biofilm peptides: steps toward clinical application</article-title><source>J Innate Immun</source><year>2019</year><volume>11</volume><fpage>193</fpage><lpage>204</lpage><?supplied-pmid 30134244?><pub-id pub-id-type="pmid">30134244</pub-id></element-citation></ref><ref id="CR93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunne</surname><given-names>WM</given-names><suffix>Jr</suffix></name></person-group><article-title>Bacterial adhesion: seen any good biofilms lately?</article-title><source>Clin Microbiol Rev</source><year>2002</year><volume>15</volume><fpage>155</fpage><lpage>166</lpage><?supplied-pmid 11932228?><pub-id pub-id-type="pmid">11932228</pub-id></element-citation></ref><ref id="CR94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x000fc;rr</surname><given-names>UHN</given-names></name><name><surname>Sudheendra</surname><given-names>US</given-names></name><name><surname>Ramamoorthy</surname><given-names>A</given-names></name></person-group><article-title>LL-37, the only human member of the cathelicidin family of antimicrobial peptides</article-title><source>Biochim Biophys Acta</source><year>2006</year><volume>1758</volume><fpage>1408</fpage><lpage>1425</lpage><?supplied-pmid 16716248?><pub-id pub-id-type="pmid">16716248</pub-id></element-citation></ref><ref id="CR95"><mixed-citation publication-type="other">Duval RE, Grare M, Demore B (2019) Fight against antimicrobial resistance: we always need new antibacterials but for right bacteria. Molecules:24</mixed-citation></ref><ref id="CR96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyett</surname><given-names>BP</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Strachan</surname><given-names>J</given-names></name><name><surname>Drummond</surname><given-names>CJ</given-names></name><name><surname>Conn</surname><given-names>CE</given-names></name></person-group><article-title>Fusion dynamics of cubosome nanocarriers with model cell membranes</article-title><source>Nat Comm</source><year>2019</year><volume>10</volume><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="CR97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbourne</surname><given-names>A</given-names></name><name><surname>Crawford</surname><given-names>RJ</given-names></name><name><surname>Ivanova</surname><given-names>EP</given-names></name></person-group><article-title>Nano-structured antimicrobial surfaces: from nature to synthetic analogues</article-title><source>J Colloid Interface Sci</source><year>2017</year><volume>508</volume><fpage>603</fpage><lpage>616</lpage><?supplied-pmid 28728752?><pub-id pub-id-type="pmid">28728752</pub-id></element-citation></ref><ref id="CR98"><mixed-citation publication-type="other">EMA (2020) Medicines. <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines">https://www.ema.europa.eu/en/medicines</ext-link>. Accessed 2020</mixed-citation></ref><ref id="CR99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>CM</given-names></name><etal/></person-group><article-title>The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion</article-title><source>PLoS Pathogens</source><year>2009</year><volume>5</volume><fpage>e1000660</fpage><?supplied-pmid 19915718?><pub-id pub-id-type="pmid">19915718</pub-id></element-citation></ref><ref id="CR100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fairman</surname><given-names>R</given-names></name><name><surname>Shoemaker</surname><given-names>KR</given-names></name><name><surname>York</surname><given-names>EJ</given-names></name><name><surname>Stewart</surname><given-names>JM</given-names></name><name><surname>Baldwin</surname><given-names>RL</given-names></name></person-group><article-title>Further studies of the helix dipole model: effects of a free alpha-NH3+ or alpha-COO- group on helix stability</article-title><source>Proteins</source><year>1989</year><volume>5</volume><fpage>1</fpage><lpage>7</lpage><?supplied-pmid 2748569?><pub-id pub-id-type="pmid">2748569</pub-id></element-citation></ref><ref id="CR101"><mixed-citation publication-type="other">Falanga A, Nigro E, De Biasi MG, Daniele A, Morelli G, Galdiero S, Scudiero O (2017) Cyclic peptides as novel therapeutic microbicides: engineering of human defensin mimetics. Molecules 22</mixed-citation></ref><ref id="CR102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falord</surname><given-names>M</given-names></name><name><surname>Karimova</surname><given-names>G</given-names></name><name><surname>Hiron</surname><given-names>A</given-names></name><name><surname>Msadek</surname><given-names>T</given-names></name></person-group><article-title>GraXSR proteins interact with the VraFG ABC transporter to form a five-component system required for cationic antimicrobial peptide sensing and resistance in <italic>Staphylococcus aureus</italic></article-title><source>Antimicrob Agents Chemother</source><year>2012</year><volume>56</volume><fpage>1047</fpage><lpage>1058</lpage><?supplied-pmid 22123691?><pub-id pub-id-type="pmid">22123691</pub-id></element-citation></ref><ref id="CR103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrell</surname><given-names>LJ</given-names></name><name><surname>Lo</surname><given-names>R</given-names></name><name><surname>Wanford</surname><given-names>JJ</given-names></name><name><surname>Jenkins</surname><given-names>A</given-names></name><name><surname>Maxwell</surname><given-names>A</given-names></name><name><surname>Piddock</surname><given-names>LJV</given-names></name></person-group><article-title>Revitalizing the drug pipeline: antibioticDB, an open access database to aid antibacterial research and development</article-title><source>J Antimicrob Chemother</source><year>2018</year><volume>73</volume><fpage>2284</fpage><lpage>2297</lpage><?supplied-pmid 29897476?><pub-id pub-id-type="pmid">29897476</pub-id></element-citation></ref><ref id="CR104"><mixed-citation publication-type="other">FDA (2020) Drugs@FDA: FDA-approved drugs. Food and Drug Administration. <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/">https://www.accessdata.fda.gov/</ext-link>. Accessed 2020</mixed-citation></ref><ref id="CR105"><mixed-citation publication-type="other">Fernandez-Lopez S et al. (2001) Antibacterial agents based on the cyclic d,l-&#x003b1;-peptide architecture. Nature 412:452&#x02013;455</mixed-citation></ref><ref id="CR106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>D</given-names></name><name><surname>Rumbaugh</surname><given-names>KP</given-names></name></person-group><article-title>Approaches to dispersing medical biofilms</article-title><source>Microorganisms</source><year>2017</year><volume>5</volume><fpage>15</fpage></element-citation></ref><ref id="CR107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flemming</surname><given-names>HC</given-names></name></person-group><article-title>Biofilms and environmental protection</article-title><source>Water Sci Tech</source><year>1993</year><volume>27</volume><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="CR108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flemming</surname><given-names>HC</given-names></name><name><surname>Wingender</surname><given-names>J</given-names></name></person-group><article-title>The biofilm matrix</article-title><source>Nat Rev Microbiol</source><year>2010</year><volume>8</volume><fpage>623</fpage><lpage>633</lpage><?supplied-pmid 20676145?><pub-id pub-id-type="pmid">20676145</pub-id></element-citation></ref><ref id="CR109"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>IW</given-names></name><name><surname>Shlaes</surname><given-names>DM</given-names></name><name><surname>Drlica</surname><given-names>K</given-names></name></person-group><source>Antimicrobial resistance in the 21st century</source><year>2018</year><edition>Second edn.</edition><publisher-loc>Cham, Switzerland</publisher-loc><publisher-name>Springer</publisher-name></element-citation></ref><ref id="CR110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foschiatti</surname><given-names>M</given-names></name><name><surname>Cescutti</surname><given-names>P</given-names></name><name><surname>Tossi</surname><given-names>A</given-names></name><name><surname>Rizzo</surname><given-names>R</given-names></name></person-group><article-title>Inhibition of cathelicidin activity by bacterial exopolysaccharides</article-title><source>Mol Microbiol</source><year>2009</year><volume>72</volume><fpage>1137</fpage><lpage>1146</lpage><?supplied-pmid 19400793?><pub-id pub-id-type="pmid">19400793</pub-id></element-citation></ref><ref id="CR111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fosgerau</surname><given-names>K</given-names></name><name><surname>Hoffmann</surname><given-names>T</given-names></name></person-group><article-title>Peptide therapeutics: current status and future directions</article-title><source>Drug Discov Today</source><year>2015</year><volume>20</volume><fpage>122</fpage><lpage>128</lpage><?supplied-pmid 25450771?><pub-id pub-id-type="pmid">25450771</pub-id></element-citation></ref><ref id="CR112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frecer</surname><given-names>V</given-names></name><name><surname>Ho</surname><given-names>B</given-names></name><name><surname>Ding</surname><given-names>JL</given-names></name></person-group><article-title>De novo design of potent antimicrobial peptides</article-title><source>Antimicrob Agents Chemother</source><year>2004</year><volume>48</volume><fpage>3349</fpage><lpage>3357</lpage><?supplied-pmid 15328096?><pub-id pub-id-type="pmid">15328096</pub-id></element-citation></ref><ref id="CR113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frick</surname><given-names>I-M</given-names></name><name><surname>&#x000c5;kesson</surname><given-names>P</given-names></name><name><surname>Rasmussen</surname><given-names>M</given-names></name><name><surname>Schmidtchen</surname><given-names>A</given-names></name><name><surname>Bj&#x000f6;rck</surname><given-names>L</given-names></name></person-group><article-title>SIC, a secreted protein of <italic>Streptococcus pyogenes</italic> that inactivates antibacterial peptides</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>16561</fpage><lpage>16566</lpage><?supplied-pmid 12621031?><pub-id pub-id-type="pmid">12621031</pub-id></element-citation></ref><ref id="CR114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frick</surname><given-names>I-M</given-names></name><name><surname>Nordin</surname><given-names>SL</given-names></name><name><surname>Baumgarten</surname><given-names>M</given-names></name><name><surname>M&#x000f6;rgelin</surname><given-names>M</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>OE</given-names></name><name><surname>Olin</surname><given-names>AI</given-names></name><name><surname>Egesten</surname><given-names>A</given-names></name></person-group><article-title>Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal finegoldia magna and the pathogen <italic>Streptococcus pyogenes</italic></article-title><source>J Immunol</source><year>2011</year><volume>187</volume><fpage>4300</fpage><lpage>4309</lpage><?supplied-pmid 21918193?><pub-id pub-id-type="pmid">21918193</pub-id></element-citation></ref><ref id="CR115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedrich</surname><given-names>CL</given-names></name><name><surname>Moyles</surname><given-names>D</given-names></name><name><surname>Beveridge</surname><given-names>TJ</given-names></name><name><surname>Hancock</surname><given-names>REW</given-names></name></person-group><article-title>Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria</article-title><source>Antimicrob Agents Chemother</source><year>2000</year><volume>44</volume><fpage>2086</fpage><lpage>2092</lpage><?supplied-pmid 10898680?><pub-id pub-id-type="pmid">10898680</pub-id></element-citation></ref><ref id="CR116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fumakia</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>EA</given-names></name></person-group><article-title>Nanoparticles encapsulated with LL37 and serpin A1 promotes wound healing and synergistically enhances antibacterial activity</article-title><source>Mol Pharmaceutics</source><year>2016</year><volume>13</volume><fpage>2318</fpage><lpage>2331</lpage></element-citation></ref><ref id="CR117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galdiero</surname><given-names>S</given-names></name><name><surname>Falanga</surname><given-names>A</given-names></name><name><surname>Cantisani</surname><given-names>M</given-names></name><name><surname>Vitiello</surname><given-names>M</given-names></name><name><surname>Morelli</surname><given-names>G</given-names></name><name><surname>Galdiero</surname><given-names>M</given-names></name></person-group><article-title>Peptide-lipid interactions: experiments and applications</article-title><source>Int J Mol Sci</source><year>2013</year><volume>14</volume><fpage>18758</fpage><lpage>18789</lpage><?supplied-pmid 24036440?><pub-id pub-id-type="pmid">24036440</pub-id></element-citation></ref><ref id="CR118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galv&#x000e1;n</surname><given-names>EM</given-names></name><name><surname>Lasaro</surname><given-names>MAS</given-names></name><name><surname>Schifferli</surname><given-names>DM</given-names></name></person-group><article-title>Capsular antigen fraction 1 and Pla modulate the susceptibility of <italic>Yersinia pestis</italic> to pulmonary antimicrobial peptides such as cathelicidin</article-title><source>Infect Immun</source><year>2008</year><volume>76</volume><fpage>1456</fpage><lpage>1464</lpage><?supplied-pmid 18227173?><pub-id pub-id-type="pmid">18227173</pub-id></element-citation></ref><ref id="CR119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganz</surname><given-names>T</given-names></name></person-group><article-title>Defensins: antimicrobial peptides of innate immunity</article-title><source>Nat Rev Immunol</source><year>2003</year><volume>3</volume><fpage>710</fpage><lpage>720</lpage><?supplied-pmid 12949495?><pub-id pub-id-type="pmid">12949495</pub-id></element-citation></ref><ref id="CR120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>G</given-names></name><etal/></person-group><article-title>The biocompatibility and biofilm resistance of implant coatings based on hydrophilic polymer brushes conjugated with antimicrobial peptides</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>3899</fpage><lpage>3909</lpage><?supplied-pmid 21377727?><pub-id pub-id-type="pmid">21377727</pub-id></element-citation></ref><ref id="CR121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrett</surname><given-names>TR</given-names></name><name><surname>Bhakoo</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>Bacterial adhesion and biofilms on surfaces</article-title><source>Prog Nat Sci</source><year>2008</year><volume>18</volume><fpage>1049</fpage><lpage>1056</lpage></element-citation></ref><ref id="CR122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gebhard</surname><given-names>S</given-names></name></person-group><article-title>ABC transporters of antimicrobial peptides in <italic>Firmicutes bacteria</italic> &#x02013; phylogeny, function and regulation</article-title><source>Mol Microbiol</source><year>2012</year><volume>86</volume><fpage>1295</fpage><lpage>1317</lpage><?supplied-pmid 23106164?><pub-id pub-id-type="pmid">23106164</pub-id></element-citation></ref><ref id="CR123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Getahun</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Trivedi</surname><given-names>K</given-names></name><name><surname>Paulin</surname><given-names>S</given-names></name><name><surname>Balkhy</surname><given-names>HH</given-names></name></person-group><article-title>Tackling antimicrobial resistance in the COVID-19 pandemic</article-title><source>Bulletin of the World Health Organization</source><year>2020</year><volume>98</volume><fpage>442</fpage><lpage>442A</lpage><?supplied-pmid 32742026?><pub-id pub-id-type="pmid">32742026</pub-id></element-citation></ref><ref id="CR124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Indolicidin targets duplex DNA: structural and mechanistic insight through a combination of spectroscopy and microscopy</article-title><source>ChemMedChem</source><year>2014</year><volume>9</volume><fpage>2052</fpage><lpage>2058</lpage><?supplied-pmid 25044630?><pub-id pub-id-type="pmid">25044630</pub-id></element-citation></ref><ref id="CR125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giuliani</surname><given-names>A</given-names></name><name><surname>Rinaldi</surname><given-names>AC</given-names></name></person-group><article-title>Beyond natural antimicrobial peptides: multimeric peptides and other peptidomimetic approaches</article-title><source>Cell Mol Life Sci</source><year>2011</year><volume>68</volume><fpage>2255</fpage><lpage>2266</lpage><?supplied-pmid 21598022?><pub-id pub-id-type="pmid">21598022</pub-id></element-citation></ref><ref id="CR126"><mixed-citation publication-type="other">Glossop HD, Pearl E, De Zoysa GH, Sarojini V (2018) Chapter eleven - linear analogues of the lipopeptide battacin with potent in vitro activity against <italic>S. aureus</italic>. In: Donev R (ed) Advances in protein chemistry and structural biology, vol 112. Academic Press, pp 385&#x02013;394</mixed-citation></ref><ref id="CR127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glossop</surname><given-names>HD</given-names></name><etal/></person-group><article-title>Battacin-inspired ultrashort peptides: nanostructure analysis and antimicrobial activity</article-title><source>Biomacromolecules</source><year>2019</year><volume>20</volume><fpage>2515</fpage><lpage>2529</lpage><?supplied-pmid 31145611?><pub-id pub-id-type="pmid">31145611</pub-id></element-citation></ref><ref id="CR128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldschmidt</surname><given-names>L</given-names></name><name><surname>Teng</surname><given-names>PK</given-names></name><name><surname>Riek</surname><given-names>R</given-names></name><name><surname>Eisenberg</surname><given-names>D</given-names></name></person-group><article-title>The amylome, all proteins capable of forming amyloid-like fibrils</article-title><source>Proc Natl Acad Sci USA</source><year>2010</year><volume>107</volume><fpage>3487</fpage><lpage>3492</lpage><?supplied-pmid 20133726?><pub-id pub-id-type="pmid">20133726</pub-id></element-citation></ref><ref id="CR129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomaa</surname><given-names>AI</given-names></name><name><surname>Martinent</surname><given-names>C</given-names></name><name><surname>Hammami</surname><given-names>R</given-names></name><name><surname>Fliss</surname><given-names>I</given-names></name><name><surname>Subirade</surname><given-names>M</given-names></name></person-group><article-title>Dual coating of liposomes as encapsulating matrix of antimicrobial peptides: development and characterization</article-title><source>Front Chem</source><year>2017</year><volume>5</volume><fpage>103</fpage><?supplied-pmid 29204423?><pub-id pub-id-type="pmid">29204423</pub-id></element-citation></ref><ref id="CR130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gontsarik</surname><given-names>M</given-names></name><name><surname>Buhmann</surname><given-names>MT</given-names></name><name><surname>Yaghmur</surname><given-names>A</given-names></name><name><surname>Ren</surname><given-names>Q</given-names></name><name><surname>Maniura-Weber</surname><given-names>K</given-names></name><name><surname>Salentinig</surname><given-names>S</given-names></name></person-group><article-title>Antimicrobial peptide-driven colloidal transformations in liquid-crystalline nanocarriers</article-title><source>J Phys Chem Lett</source><year>2016</year><volume>7</volume><fpage>3482</fpage><lpage>3486</lpage><?supplied-pmid 27541048?><pub-id pub-id-type="pmid">27541048</pub-id></element-citation></ref><ref id="CR131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodfellow</surname><given-names>M</given-names></name><name><surname>Fiedler</surname><given-names>HP</given-names></name></person-group><article-title>A guide to successful bioprospecting: informed by actinobacterial systematics</article-title><source>Antonie Van Leeuwenhoek</source><year>2010</year><volume>98</volume><fpage>119</fpage><lpage>142</lpage><?supplied-pmid 20582471?><pub-id pub-id-type="pmid">20582471</pub-id></element-citation></ref><ref id="CR132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>YJ</given-names></name><name><surname>Romanowski</surname><given-names>EG</given-names></name><name><surname>McDermott</surname><given-names>AM</given-names></name></person-group><article-title>A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs</article-title><source>Curr Eye Res</source><year>2005</year><volume>30</volume><fpage>505</fpage><lpage>515</lpage><?supplied-pmid 16020284?><pub-id pub-id-type="pmid">16020284</pub-id></element-citation></ref><ref id="CR133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottler</surname><given-names>LM</given-names></name><name><surname>Lee</surname><given-names>H-Y</given-names></name><name><surname>Shelburne</surname><given-names>CE</given-names></name><name><surname>Ramamoorthy</surname><given-names>A</given-names></name><name><surname>Marsh</surname><given-names>ENG</given-names></name></person-group><article-title>Using fluorous amino acids to modulate the biological activity of an antimicrobial peptide</article-title><source>ChemBioChem</source><year>2008</year><volume>9</volume><fpage>370</fpage><lpage>373</lpage><?supplied-pmid 18224631?><pub-id pub-id-type="pmid">18224631</pub-id></element-citation></ref><ref id="CR134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groisman</surname><given-names>EA</given-names></name><name><surname>Chiao</surname><given-names>E</given-names></name><name><surname>Lipps</surname><given-names>CJ</given-names></name><name><surname>Heffron</surname><given-names>F</given-names></name></person-group><article-title>Salmonella typhimurium phoP virulence gene is a transcriptional regulator</article-title><source>Proc Natl Acad Sci USA</source><year>1989</year><volume>86</volume><fpage>7077</fpage><lpage>7081</lpage><?supplied-pmid 2674945?><pub-id pub-id-type="pmid">2674945</pub-id></element-citation></ref><ref id="CR135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groisman</surname><given-names>EA</given-names></name><name><surname>Parra-Lopez</surname><given-names>C</given-names></name><name><surname>Salcedo</surname><given-names>M</given-names></name><name><surname>Lipps</surname><given-names>CJ</given-names></name><name><surname>Heffron</surname><given-names>F</given-names></name></person-group><article-title>Resistance to host antimicrobial peptides is necessary for Salmonella virulence</article-title><source>Proc Natl Acad Sci USA</source><year>1992</year><volume>89</volume><fpage>11939</fpage><lpage>11943</lpage><?supplied-pmid 1465423?><pub-id pub-id-type="pmid">1465423</pub-id></element-citation></ref><ref id="CR136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guilhelmelli</surname><given-names>F</given-names></name><name><surname>Vilela</surname><given-names>N</given-names></name><name><surname>Albuquerque</surname><given-names>P</given-names></name><name><surname>Derengowski</surname><given-names>L</given-names></name><name><surname>Silva-Pereira</surname><given-names>I</given-names></name><name><surname>Kyaw</surname><given-names>C</given-names></name></person-group><article-title>Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance</article-title><source>Front Microbiol</source><year>2013</year><volume>4</volume><fpage>353</fpage><?supplied-pmid 24367355?><pub-id pub-id-type="pmid">24367355</pub-id></element-citation></ref><ref id="CR137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guina</surname><given-names>T</given-names></name><name><surname>Yi</surname><given-names>EC</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Hackett</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>SI</given-names></name></person-group><article-title>A PhoP-regulated outer membrane protease of <italic>Salmonella enterica</italic> serovar typhimurium promotes resistance to alpha-helical antimicrobial peptides</article-title><source>J Bacteriol</source><year>2000</year><volume>182</volume><fpage>4077</fpage><lpage>4086</lpage><?supplied-pmid 10869088?><pub-id pub-id-type="pmid">10869088</pub-id></element-citation></ref><ref id="CR138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunn</surname><given-names>JS</given-names></name></person-group><article-title>Bacterial modification of LPS and resistance to antimicrobial peptides</article-title><source>J Endotoxin Res</source><year>2001</year><volume>7</volume><fpage>57</fpage><lpage>62</lpage><?supplied-pmid 11521084?><pub-id pub-id-type="pmid">11521084</pub-id></element-citation></ref><ref id="CR139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunn</surname><given-names>JS</given-names></name><name><surname>Lim</surname><given-names>KB</given-names></name><name><surname>Krueger</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Hackett</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>SI</given-names></name></person-group><article-title>PmrA&#x02013;PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance</article-title><source>Mol Microbiol</source><year>1998</year><volume>27</volume><fpage>1171</fpage><lpage>1182</lpage><?supplied-pmid 9570402?><pub-id pub-id-type="pmid">9570402</pub-id></element-citation></ref><ref id="CR140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammam</surname><given-names>R</given-names></name><name><surname>Fliss</surname><given-names>I</given-names></name></person-group><article-title>Current trends in antimicrobial agent research: chemo- and bioinformatics approaches</article-title><source>Drug Discov Today</source><year>2010</year><volume>15</volume><fpage>540</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">20546918</pub-id></element-citation></ref><ref id="CR141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammami</surname><given-names>R</given-names></name><name><surname>Hamida</surname><given-names>JB</given-names></name><name><surname>Vergoten</surname><given-names>G</given-names></name><name><surname>Fliss</surname><given-names>I</given-names></name></person-group><article-title>PhytAMP: a database dedicated to plant antimicrobial peptides</article-title><source>Nucleic Acids Res</source><year>2008</year><volume>37</volume><fpage>D963</fpage><lpage>D968</lpage><?supplied-pmid 18836196?><pub-id pub-id-type="pmid">18836196</pub-id></element-citation></ref><ref id="CR142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hancock</surname><given-names>RE</given-names></name><name><surname>Diamond</surname><given-names>G</given-names></name></person-group><article-title>The role of cationic antimicrobial peptides in innate host defences</article-title><source>Trends Microbiol</source><year>2000</year><volume>8</volume><fpage>402</fpage><lpage>410</lpage><?supplied-pmid 10989307?><pub-id pub-id-type="pmid">10989307</pub-id></element-citation></ref><ref id="CR143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hancock</surname><given-names>RE</given-names></name><name><surname>Sahl</surname><given-names>HG</given-names></name></person-group><article-title>Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies</article-title><source>Nat Biotechnol</source><year>2006</year><volume>24</volume><fpage>1551</fpage><lpage>1557</lpage><?supplied-pmid 17160061?><pub-id pub-id-type="pmid">17160061</pub-id></element-citation></ref><ref id="CR144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heilmann</surname><given-names>C</given-names></name><name><surname>Schweitzer</surname><given-names>O</given-names></name><name><surname>Gerke</surname><given-names>C</given-names></name><name><surname>Vanittanakom</surname><given-names>N</given-names></name><name><surname>Mack</surname><given-names>D</given-names></name><name><surname>G&#x000f6;tz</surname><given-names>F</given-names></name></person-group><article-title>Molecular basis of intercellular adhesion in the biofilm-forming <italic>Staphylococcus epidermidis</italic></article-title><source>Mol Microbiol</source><year>1996</year><volume>20</volume><fpage>1083</fpage><lpage>1091</lpage><?supplied-pmid 8809760?><pub-id pub-id-type="pmid">8809760</pub-id></element-citation></ref><ref id="CR145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinbockel</surname><given-names>L</given-names></name><etal/></person-group><article-title>Inhibition of Lipopolysaccharide- and Lipoprotein-induced inflammation by antitoxin peptide Pep19&#x02013;2.5</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>1704</fpage><lpage>1704</lpage><?supplied-pmid 30093904?><pub-id pub-id-type="pmid">30093904</pub-id></element-citation></ref><ref id="CR146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendricks</surname><given-names>MP</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Palmer</surname><given-names>LC</given-names></name><name><surname>Stupp</surname><given-names>SI</given-names></name></person-group><article-title>Supramolecular assembly of peptide amphiphiles</article-title><source>Acc Chem Res</source><year>2017</year><volume>50</volume><fpage>2440</fpage><lpage>2448</lpage><?supplied-pmid 28876055?><pub-id pub-id-type="pmid">28876055</pub-id></element-citation></ref><ref id="CR147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hentzer</surname><given-names>M</given-names></name><name><surname>Teitzel</surname><given-names>GM</given-names></name><name><surname>Balzer</surname><given-names>GJ</given-names></name><name><surname>Heydorn</surname><given-names>A</given-names></name><name><surname>Molin</surname><given-names>S</given-names></name><name><surname>Givskov</surname><given-names>M</given-names></name><name><surname>Parsek</surname><given-names>MR</given-names></name></person-group><article-title>Alginate overproduction affects <italic>Pseudomonas aeruginosa</italic> biofilm structure and function</article-title><source>J Bacteriol</source><year>2001</year><volume>183</volume><fpage>5395</fpage><lpage>5401</lpage><?supplied-pmid 11514525?><pub-id pub-id-type="pmid">11514525</pub-id></element-citation></ref><ref id="CR148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herasimenka</surname><given-names>Y</given-names></name><name><surname>Benincasa</surname><given-names>M</given-names></name><name><surname>Mattiuzzo</surname><given-names>M</given-names></name><name><surname>Cescutti</surname><given-names>P</given-names></name><name><surname>Gennaro</surname><given-names>R</given-names></name><name><surname>Rizzo</surname><given-names>R</given-names></name></person-group><article-title>Interaction of antimicrobial peptides with bacterial polysaccharides from lung pathogens</article-title><source>Peptides</source><year>2005</year><volume>26</volume><fpage>1127</fpage><lpage>1132</lpage><?supplied-pmid 15949630?><pub-id pub-id-type="pmid">15949630</pub-id></element-citation></ref><ref id="CR149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>CM</given-names></name><name><surname>Hankins</surname><given-names>JV</given-names></name><name><surname>Trent</surname><given-names>MS</given-names></name></person-group><article-title>Activation of PmrA inhibits LpxT-dependent phosphorylation of lipid A promoting resistance to antimicrobial peptides</article-title><source>Mol Microbiol</source><year>2010</year><volume>76</volume><fpage>1444</fpage><lpage>1460</lpage><?supplied-pmid 20384697?><pub-id pub-id-type="pmid">20384697</pub-id></element-citation></ref><ref id="CR150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilchie</surname><given-names>AL</given-names></name><name><surname>Wuerth</surname><given-names>K</given-names></name><name><surname>Hancock</surname><given-names>RE</given-names></name></person-group><article-title>Immune modulation by multifaceted cationic host defense (antimicrobial) peptides</article-title><source>Nat Chem Biol</source><year>2013</year><volume>9</volume><fpage>761</fpage><lpage>768</lpage><?supplied-pmid 24231617?><pub-id pub-id-type="pmid">24231617</pub-id></element-citation></ref><ref id="CR151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Effect of divalent cations on the structure of the antibiotic daptomycin</article-title><source>Eur Biophys J</source><year>2008</year><volume>37</volume><fpage>421</fpage><lpage>433</lpage><?supplied-pmid 17968536?><pub-id pub-id-type="pmid">17968536</pub-id></element-citation></ref><ref id="CR152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosaka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Antibacterial discovery in actinomycetes strains with mutations in RNA polymerase or ribosomal protein S12</article-title><source>Nat Biotechnol</source><year>2009</year><volume>27</volume><fpage>462</fpage><lpage>464</lpage><?supplied-pmid 19396160?><pub-id pub-id-type="pmid">19396160</pub-id></element-citation></ref><ref id="CR153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudalla</surname><given-names>GA</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Gasiorowski</surname><given-names>JZ</given-names></name><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>YF</given-names></name><name><surname>Chong</surname><given-names>AS</given-names></name><name><surname>Collier</surname><given-names>JH</given-names></name></person-group><article-title>Gradated assembly of multiple proteins into supramolecular nanomaterials</article-title><source>Nat Mater</source><year>2014</year><volume>13</volume><fpage>829</fpage><lpage>836</lpage><?supplied-pmid 24930032?><pub-id pub-id-type="pmid">24930032</pub-id></element-citation></ref><ref id="CR154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurdle</surname><given-names>JG</given-names></name><name><surname>O'Neill</surname><given-names>AJ</given-names></name><name><surname>Chopra</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>RE</given-names></name></person-group><article-title>Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections</article-title><source>Nat Rev Microbiol</source><year>2011</year><volume>9</volume><fpage>62</fpage><lpage>75</lpage><?supplied-pmid 21164535?><pub-id pub-id-type="pmid">21164535</pub-id></element-citation></ref><ref id="CR155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibanez de Aldecoa</surname><given-names>AL</given-names></name><name><surname>Zafra</surname><given-names>O</given-names></name><name><surname>Gonzalez-Pastor</surname><given-names>JE</given-names></name></person-group><article-title>Mechanisms and regulation of extracellular DNA release and its biological roles in microbial communities</article-title><source>Front Microbiol</source><year>2017</year><volume>8</volume><fpage>1390</fpage><?supplied-pmid 28798731?><pub-id pub-id-type="pmid">28798731</pub-id></element-citation></ref><ref id="CR156"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>N</given-names></name><name><surname>Czaplewski</surname><given-names>L</given-names></name><name><surname>Piddock</surname><given-names>LJV</given-names></name></person-group><article-title>Discovery and development of new antibacterial drugs: learning from experience?</article-title><source>J Antimicrob Chemother</source><year>2018</year><volume>73</volume><fpage>1452</fpage><lpage>1459</lpage><?supplied-pmid 29438542?><pub-id pub-id-type="pmid">29438542</pub-id></element-citation></ref><ref id="CR157"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>H</given-names></name><name><surname>Arce</surname><given-names>FT</given-names></name><name><surname>Mustata</surname><given-names>M</given-names></name><name><surname>Ramachandran</surname><given-names>S</given-names></name><name><surname>Capone</surname><given-names>R</given-names></name><name><surname>Nussinov</surname><given-names>R</given-names></name><name><surname>Lal</surname><given-names>R</given-names></name></person-group><article-title>Antimicrobial protegrin-1 forms amyloid-like fibrils with rapid kinetics suggesting a functional link</article-title><source>Biophys J</source><year>2011</year><volume>100</volume><fpage>1775</fpage><lpage>1783</lpage><?supplied-pmid 21463591?><pub-id pub-id-type="pmid">21463591</pub-id></element-citation></ref><ref id="CR158"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Sellati</surname><given-names>TJ</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name></person-group><article-title>Self-assembly of cationic multidomain peptide hydrogels: supramolecular nanostructure and rheological properties dictate antimicrobial activity</article-title><source>Nanoscale</source><year>2015</year><volume>7</volume><fpage>19160</fpage><lpage>19169</lpage><?supplied-pmid 26524425?><pub-id pub-id-type="pmid">26524425</pub-id></element-citation></ref><ref id="CR159"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>W</given-names></name><name><surname>Prenner</surname><given-names>EJ</given-names></name><name><surname>Vogel</surname><given-names>HJ</given-names></name><name><surname>Waring</surname><given-names>AJ</given-names></name><name><surname>Lehrer</surname><given-names>RI</given-names></name><name><surname>Lohner</surname><given-names>K</given-names></name></person-group><article-title>Headgroup structure and fatty acid chain length of the acidic phospholipids modulate the interaction of membrane mimetic vesicles with the antimicrobial peptide protegrin-1</article-title><source>J Pep Sci</source><year>2005</year><volume>11</volume><fpage>735</fpage><lpage>743</lpage></element-citation></ref><ref id="CR160"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>T</given-names></name><name><surname>Thomas</surname><given-names>T</given-names></name><name><surname>Abel</surname><given-names>B</given-names></name><name><surname>Wood</surname><given-names>BR</given-names></name><name><surname>Chalmers</surname><given-names>DK</given-names></name><name><surname>Martin</surname><given-names>LL</given-names></name></person-group><article-title>How kanamycin A interacts with bacterial and mammalian mimetic membranes</article-title><source>Biochim Biophys Acta</source><year>2017</year><volume>1859</volume><fpage>2242</fpage><lpage>2252</lpage></element-citation></ref><ref id="CR161"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>NC</given-names></name><name><surname>Baker</surname><given-names>JK</given-names></name><name><surname>Goldfine</surname><given-names>H</given-names></name></person-group><article-title>Phospholipids of <italic>Clostridium perfringens</italic>: a reexamination</article-title><source>FEMS Microbiol Lett</source><year>2004</year><volume>233</volume><fpage>65</fpage><lpage>68</lpage><?supplied-pmid 15043870?><pub-id pub-id-type="pmid">15043870</pub-id></element-citation></ref><ref id="CR162"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>DE</given-names></name><name><surname>Smith</surname><given-names>JD</given-names></name></person-group><article-title>Phospholipids of the differentiating bacterium <italic>Caulobacter crescentus</italic></article-title><source>Canadian J Biochem</source><year>1979</year><volume>57</volume><fpage>424</fpage><lpage>428</lpage></element-citation></ref><ref id="CR163"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>EA</given-names></name><name><surname>McGillivary</surname><given-names>G</given-names></name><name><surname>Bakaletz</surname><given-names>LO</given-names></name></person-group><article-title>Extracellular DNA within a nontypeable <italic>Haemophilus influenzae</italic>-induced biofilm binds human beta defensin-3 and reduces its antimicrobial activity</article-title><source>J Innate Immun</source><year>2013</year><volume>5</volume><fpage>24</fpage><lpage>38</lpage><?supplied-pmid 22922323?><pub-id pub-id-type="pmid">22922323</pub-id></element-citation></ref><ref id="CR164"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joo</surname><given-names>H-S</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name></person-group><article-title>Mechanisms of resistance to antimicrobial peptides in staphylococci</article-title><source>Biochim Biophys Acta</source><year>2015</year><volume>1848</volume><fpage>3055</fpage><lpage>3061</lpage><?supplied-pmid 25701233?><pub-id pub-id-type="pmid">25701233</pub-id></element-citation></ref><ref id="CR165"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joo</surname><given-names>H-S</given-names></name><name><surname>Fu</surname><given-names>C-I</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name></person-group><article-title>Bacterial strategies of resistance to antimicrobial peptides</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><year>2016</year><volume>371</volume><fpage>20150292</fpage><?supplied-pmid 27160595?><pub-id pub-id-type="pmid">27160595</pub-id></element-citation></ref><ref id="CR166"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagan</surname><given-names>BL</given-names></name><name><surname>Jang</surname><given-names>H</given-names></name><name><surname>Capone</surname><given-names>R</given-names></name><name><surname>Teran Arce</surname><given-names>F</given-names></name><name><surname>Ramachandran</surname><given-names>S</given-names></name><name><surname>Lal</surname><given-names>R</given-names></name><name><surname>Nussinov</surname><given-names>R</given-names></name></person-group><article-title>Antimicrobial properties of amyloid peptides</article-title><source>Mol Pharm</source><year>2012</year><volume>9</volume><fpage>708</fpage><lpage>717</lpage><?supplied-pmid 22081976?><pub-id pub-id-type="pmid">22081976</pub-id></element-citation></ref><ref id="CR167"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahne</surname><given-names>D</given-names></name><name><surname>Leimkuhler</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Walsh</surname><given-names>C</given-names></name></person-group><article-title>Glycopeptide and lipoglycopeptide antibiotics</article-title><source>Chem Rev</source><year>2005</year><volume>105</volume><fpage>425</fpage><lpage>448</lpage><?supplied-pmid 15700951?><pub-id pub-id-type="pmid">15700951</pub-id></element-citation></ref><ref id="CR168"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Ohki</surname><given-names>K</given-names></name><name><surname>Okimura</surname><given-names>K</given-names></name><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Shindo</surname><given-names>M</given-names></name><name><surname>Sakura</surname><given-names>N</given-names></name></person-group><article-title>Contribution of each amino acid residue in polymyxin B(3) to antimicrobial and lipopolysaccharide binding activity</article-title><source>Chem Pharm Bull (Tokyo)</source><year>2009</year><volume>57</volume><fpage>240</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">19252313</pub-id></element-citation></ref><ref id="CR169"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Mishig-Ochir</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>BJ</given-names></name></person-group><article-title>Antimicrobial peptides: therapeutic potentials</article-title><source>Expert Rev Anti Infect Ther</source><year>2014</year><volume>12</volume><fpage>1477</fpage><lpage>1486</lpage><?supplied-pmid 25371141?><pub-id pub-id-type="pmid">25371141</pub-id></element-citation></ref><ref id="CR170"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><etal/></person-group><article-title>DRAMP 2.0, an updated data repository of antimicrobial peptides</article-title><source>Scientific Data</source><year>2019</year><volume>6</volume><fpage>148</fpage><?supplied-pmid 31409791?><pub-id pub-id-type="pmid">31409791</pub-id></element-citation></ref><ref id="CR171"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>JB</given-names></name><name><surname>LoVetri</surname><given-names>K</given-names></name><name><surname>Cardona</surname><given-names>ST</given-names></name><name><surname>Madhyastha</surname><given-names>S</given-names></name><name><surname>Sadovskaya</surname><given-names>I</given-names></name><name><surname>Jabbouri</surname><given-names>S</given-names></name><name><surname>Izano</surname><given-names>EA</given-names></name></person-group><article-title>Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci</article-title><source>J Antibiot (Tokyo)</source><year>2012</year><volume>65</volume><fpage>73</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">22167157</pub-id></element-citation></ref><ref id="CR172"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Sakazaki</surname><given-names>R</given-names></name><name><surname>Hinoo</surname><given-names>H</given-names></name><name><surname>Shoji</surname><given-names>J</given-names></name></person-group><article-title>The structures of tridecaptins B and C (studies on antibiotics from the genus Bacillus. XXV)</article-title><source>J Antibiot (Tokyo)</source><year>1979</year><volume>32</volume><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">468717</pub-id></element-citation></ref><ref id="CR173"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>DA</given-names></name><name><surname>Read</surname><given-names>AF</given-names></name></person-group><article-title>Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><fpage>12878</fpage><lpage>12886</lpage><?supplied-pmid 30559199?><pub-id pub-id-type="pmid">30559199</pub-id></element-citation></ref><ref id="CR174"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Topical administration of cyclosporin A in a solid lipid nanoparticle formulation</article-title><source>Die Pharmazie</source><year>2009</year><volume>64</volume><fpage>510</fpage><lpage>514</lpage><?supplied-pmid 19746839?><pub-id pub-id-type="pmid">19746839</pub-id></element-citation></ref><ref id="CR175"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>S</given-names></name><etal/></person-group><article-title>Adaptation of <italic>Pseudomonas aeruginosa</italic> to various conditions includes tRNA-dependent formation of alanyl-phosphatidylglycerol</article-title><source>Mol Microbiol</source><year>2009</year><volume>71</volume><fpage>551</fpage><lpage>565</lpage><?supplied-pmid 19087229?><pub-id pub-id-type="pmid">19087229</pub-id></element-citation></ref><ref id="CR176"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klepeis</surname><given-names>JL</given-names></name><name><surname>Floudas</surname><given-names>CA</given-names></name><name><surname>Morikis</surname><given-names>D</given-names></name><name><surname>Tsokos</surname><given-names>CG</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name></person-group><article-title>Design of peptide analogs with improved activity using a novel de novo protein design approach</article-title><source>Ind Eng Chem Res</source><year>2004</year><volume>43</volume><fpage>3817</fpage><lpage>3826</lpage></element-citation></ref><ref id="CR177"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kocianova</surname><given-names>S</given-names></name><name><surname>Vuong</surname><given-names>C</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Voyich</surname><given-names>JM</given-names></name><name><surname>Fischer</surname><given-names>ER</given-names></name><name><surname>DeLeo</surname><given-names>FR</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name></person-group><article-title>Key role of poly-&#x003b3;-dl-glutamic acid in immune evasion and virulence of <italic>Staphylococcus epidermidis</italic></article-title><source>J Clin Invest</source><year>2005</year><volume>115</volume><fpage>688</fpage><lpage>694</lpage><?supplied-pmid 15696197?><pub-id pub-id-type="pmid">15696197</pub-id></element-citation></ref><ref id="CR178"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>N</given-names></name><name><surname>Araki</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>E</given-names></name></person-group><article-title>Structure of the linkage units between ribitol teichoic acids and peptidoglycan</article-title><source>J Bacteriol</source><year>1985</year><volume>161</volume><fpage>299</fpage><lpage>306</lpage><?supplied-pmid 3918002?><pub-id pub-id-type="pmid">3918002</pub-id></element-citation></ref><ref id="CR179"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kooi</surname><given-names>C</given-names></name><name><surname>Sokol</surname><given-names>PA</given-names></name></person-group><article-title>Burkholderia cenocepacia zinc metalloproteases influence resistance to antimicrobial peptides</article-title><source>Microbiol (Reading)</source><year>2009</year><volume>155</volume><fpage>2818</fpage><lpage>2825</lpage></element-citation></ref><ref id="CR180"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Eipper</surname><given-names>BA</given-names></name><name><surname>Mains</surname><given-names>RE</given-names></name></person-group><article-title>Amidation</article-title><source>Reference module in biomedical sciences</source><year>2014</year><publisher-loc>Amsterdam</publisher-loc><publisher-name>Elsevier</publisher-name></element-citation></ref><ref id="CR181"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumariya</surname><given-names>R</given-names></name><name><surname>Sood</surname><given-names>SK</given-names></name><name><surname>Rajput</surname><given-names>YS</given-names></name><name><surname>Saini</surname><given-names>N</given-names></name><name><surname>Garsa</surname><given-names>AK</given-names></name></person-group><article-title>Increased membrane surface positive charge and altered membrane fluidity leads to cationic antimicrobial peptide resistance in <italic>Enterococcus faecalis</italic></article-title><source>Biochim Biophys Acta</source><year>2015</year><volume>1848</volume><fpage>1367</fpage><lpage>1375</lpage><?supplied-pmid 25782727?><pub-id pub-id-type="pmid">25782727</pub-id></element-citation></ref><ref id="CR182"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name></person-group><article-title>Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles</article-title><source>Int J Nanomed</source><year>2010</year><volume>5</volume><fpage>13</fpage></element-citation></ref><ref id="CR183"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakshminarayanan</surname><given-names>R</given-names></name><etal/></person-group><article-title>Branched peptide, B2088, disrupts the supramolecular organization of lipopolysaccharides and sensitizes the Gram-negative bacteria</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>25905</fpage><?supplied-pmid 27174567?><pub-id pub-id-type="pmid">27174567</pub-id></element-citation></ref><ref id="CR184"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>R</given-names></name><name><surname>Lam</surname><given-names>K</given-names></name><name><surname>Costerton</surname><given-names>JW</given-names></name></person-group><article-title>Production of mucoid microcolonies by <italic>Pseudomonas aeruginosa</italic> within infected lungs in cystic fibrosis</article-title><source>Infect Immun</source><year>1980</year><volume>28</volume><fpage>546</fpage><lpage>556</lpage><?supplied-pmid 6772562?><pub-id pub-id-type="pmid">6772562</pub-id></element-citation></ref><ref id="CR185"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>CF</given-names></name><name><surname>Hancock</surname><given-names>RE</given-names></name><name><surname>Samuel</surname><given-names>J</given-names></name><name><surname>Finlay</surname><given-names>WH</given-names></name></person-group><article-title>In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide</article-title><source>J Pharm Sci</source><year>2001</year><volume>90</volume><fpage>1647</fpage><lpage>1657</lpage><?supplied-pmid 11745723?><pub-id pub-id-type="pmid">11745723</pub-id></element-citation></ref><ref id="CR186"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laridi</surname><given-names>R</given-names></name><name><surname>Kheadr</surname><given-names>E</given-names></name><name><surname>Benech</surname><given-names>R-O</given-names></name><name><surname>Vuillemard</surname><given-names>J</given-names></name><name><surname>Lacroix</surname><given-names>C</given-names></name><name><surname>Fliss</surname><given-names>I</given-names></name></person-group><article-title>Liposome encapsulated nisin Z: optimization, stability and release during milk fermentation</article-title><source>Int Dairy J</source><year>2003</year><volume>13</volume><fpage>325</fpage><lpage>336</lpage></element-citation></ref><ref id="CR187"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laureti</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Corre</surname><given-names>C</given-names></name><name><surname>Leblond</surname><given-names>P</given-names></name><name><surname>Challis</surname><given-names>GL</given-names></name><name><surname>Aigle</surname><given-names>B</given-names></name></person-group><article-title>Identification of a bioactive 51-membered macrolide complex by activation of a silent polyketide synthase in Streptomyces ambofaciens</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>6258</fpage><lpage>6263</lpage><?supplied-pmid 21444795?><pub-id pub-id-type="pmid">21444795</pub-id></element-citation></ref><ref id="CR188"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauth</surname><given-names>X</given-names></name><etal/></person-group><article-title>M1 Protein allows group A streptococcal survival in phagocyte extracellular traps through cathelicidin inhibition</article-title><source>J Innate Immun</source><year>2009</year><volume>1</volume><fpage>202</fpage><lpage>214</lpage><?supplied-pmid 20375578?><pub-id pub-id-type="pmid">20375578</pub-id></element-citation></ref><ref id="CR189"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>C-F</given-names></name><name><surname>Fang</surname><given-names>C-M</given-names></name><name><surname>Sekaran</surname><given-names>SD</given-names></name></person-group><article-title>Intracellular targeting mechanisms by antimicrobial peptides</article-title><source>Antimicrob Agents Chemother</source><year>2017</year><volume>61</volume><fpage>e02340</fpage><lpage>e02316</lpage><?supplied-pmid 28167546?><pub-id pub-id-type="pmid">28167546</pub-id></element-citation></ref><ref id="CR190"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Hsu</surname><given-names>F-F</given-names></name><name><surname>Turk</surname><given-names>J</given-names></name><name><surname>Groisman</surname><given-names>EA</given-names></name></person-group><article-title>The PmrA-regulated pmrC gene mediates phosphoethanolamine modification of lipid A and polymyxin resistance in <italic>Salmonella enterica</italic></article-title><source>J Bacteriol</source><year>2004</year><volume>186</volume><fpage>4124</fpage><lpage>4133</lpage><?supplied-pmid 15205413?><pub-id pub-id-type="pmid">15205413</pub-id></element-citation></ref><ref id="CR191"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Slutsky</surname><given-names>MM</given-names></name><name><surname>Anderson</surname><given-names>JT</given-names></name><name><surname>Marsh</surname><given-names>EN</given-names></name></person-group><article-title>Fluorous effect in proteins: de novo design and characterization of a four-alpha-helix bundle protein containing hexafluoroleucine</article-title><source>Biochemistry</source><year>2004</year><volume>43</volume><fpage>16277</fpage><lpage>16284</lpage><?supplied-pmid 15610021?><pub-id pub-id-type="pmid">15610021</pub-id></element-citation></ref><ref id="CR192"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Fulan</surname><given-names>BM</given-names></name><name><surname>Wong</surname><given-names>GC</given-names></name><name><surname>Ferguson</surname><given-names>AL</given-names></name></person-group><article-title>Mapping membrane activity in undiscovered peptide sequence space using machine learning</article-title><source>Proc Natl Acad Sci U S A</source><year>2016</year><volume>113</volume><fpage>13588</fpage><lpage>13593</lpage><?supplied-pmid 27849600?><pub-id pub-id-type="pmid">27849600</pub-id></element-citation></ref><ref id="CR193"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Lee</surname><given-names>MW</given-names></name><name><surname>Fulan</surname><given-names>BM</given-names></name><name><surname>Ferguson</surname><given-names>AL</given-names></name><name><surname>Wong</surname><given-names>GCL</given-names></name></person-group><article-title>What can machine learning do for antimicrobial peptides, and what can antimicrobial peptides do for machine learning?</article-title><source>Interface Focus</source><year>2017</year><volume>7</volume><fpage>20160153</fpage><?supplied-pmid 29147555?><pub-id pub-id-type="pmid">29147555</pub-id></element-citation></ref><ref id="CR194"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Curk</surname><given-names>T</given-names></name><name><surname>Dobnikar</surname><given-names>J</given-names></name><name><surname>Gallo</surname><given-names>RL</given-names></name><name><surname>Wong</surname><given-names>GCL</given-names></name></person-group><article-title>Crystallinity of double-stranded RNA-antimicrobial peptide complexes modulates toll-like receptor 3-mediated inflammation</article-title><source>ACS Nano</source><year>2017</year><volume>11</volume><fpage>12145</fpage><lpage>12155</lpage><?supplied-pmid 29016111?><pub-id pub-id-type="pmid">29016111</pub-id></element-citation></ref><ref id="CR195"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Wong</surname><given-names>GCL</given-names></name><name><surname>Ferguson</surname><given-names>AL</given-names></name></person-group><article-title>Machine learning-enabled discovery and design of membrane-active peptides</article-title><source>Bioorg Med Chem</source><year>2018</year><volume>26</volume><fpage>2708</fpage><lpage>2718</lpage><?supplied-pmid 28728899?><pub-id pub-id-type="pmid">28728899</pub-id></element-citation></ref><ref id="CR196"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MW</given-names></name><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Ferguson</surname><given-names>AL</given-names></name><name><surname>Wong</surname><given-names>GCL</given-names></name></person-group><article-title>Machine learning antimicrobial peptide sequences: some surprising variations on the theme of amphiphilic assembly</article-title><source>Curr Opin Colloid Interface Sci</source><year>2018</year><volume>38</volume><fpage>204</fpage><lpage>213</lpage><?supplied-pmid 31093008?><pub-id pub-id-type="pmid">31093008</pub-id></element-citation></ref><ref id="CR197"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Lee</surname><given-names>MW</given-names></name><name><surname>Wong</surname><given-names>GCL</given-names></name></person-group><article-title>Modulation of toll-like receptor signaling by antimicrobial peptides</article-title><source>Semin Cell Dev Biol</source><year>2019</year><volume>88</volume><fpage>173</fpage><lpage>184</lpage><?supplied-pmid 29432957?><pub-id pub-id-type="pmid">29432957</pub-id></element-citation></ref><ref id="CR198"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>EY</given-names></name><etal/></person-group><article-title>Helical antimicrobial peptides assemble into protofibril scaffolds that present ordered dsDNA to TLR9</article-title><source>Nat Comm</source><year>2019</year><volume>10</volume><fpage>1012</fpage></element-citation></ref><ref id="CR199"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewenza</surname><given-names>S</given-names></name></person-group><article-title>Extracellular DNA-induced antimicrobial peptide resistance mechanisms in <italic>Pseudomonas aeruginosa</italic></article-title><source>Front Microbiol</source><year>2013</year><volume>4</volume><fpage>21</fpage><?supplied-pmid 23419933?><pub-id pub-id-type="pmid">23419933</pub-id></element-citation></ref><ref id="CR200"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>LA</given-names></name><name><surname>Shafer</surname><given-names>WM</given-names></name><name><surname>Dutta Ray</surname><given-names>T</given-names></name><name><surname>Ram</surname><given-names>S</given-names></name><name><surname>Rice</surname><given-names>PA</given-names></name></person-group><article-title>Phosphoethanolamine residues on the lipid A moiety of <italic>Neisseria gonorrhoeae</italic> lipooligosaccharide modulate binding of complement inhibitors and resistance to complement killing</article-title><source>Infect Immun</source><year>2013</year><volume>81</volume><fpage>33</fpage><lpage>42</lpage><?supplied-pmid 23071134?><pub-id pub-id-type="pmid">23071134</pub-id></element-citation></ref><ref id="CR201"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name></person-group><article-title>Quorum sensing and bacterial social interactions in biofilms</article-title><source>Sensors (Basel)</source><year>2012</year><volume>12</volume><fpage>2519</fpage><lpage>2538</lpage><pub-id pub-id-type="pmid">22736963</pub-id></element-citation></ref><ref id="CR202"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Cha</surname><given-names>DJ</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Villaruz</surname><given-names>AE</given-names></name><name><surname>Sturdevant</surname><given-names>DE</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name></person-group><article-title>The antimicrobial peptide-sensing system aps of <italic>Staphylococcus aureus</italic></article-title><source>Mol Microbiol</source><year>2007</year><volume>66</volume><fpage>1136</fpage><lpage>1147</lpage><?supplied-pmid 17961141?><pub-id pub-id-type="pmid">17961141</pub-id></element-citation></ref><ref id="CR203"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Villaruz</surname><given-names>AE</given-names></name><name><surname>Cha</surname><given-names>DJ</given-names></name><name><surname>Sturdevant</surname><given-names>DE</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name></person-group><article-title>Gram-positive three-component antimicrobial peptide-sensing system</article-title><source>Proc Natl Acad Sci U S A</source><year>2007</year><volume>104</volume><fpage>9469</fpage><lpage>9474</lpage><?supplied-pmid 17517597?><pub-id pub-id-type="pmid">17517597</pub-id></element-citation></ref><ref id="CR204"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><etal/></person-group><article-title>Limitations of peptide retro-inverso isomerization in molecular mimicry</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>19572</fpage><lpage>19581</lpage><?supplied-pmid 20382735?><pub-id pub-id-type="pmid">20382735</pub-id></element-citation></ref><ref id="CR205"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name></person-group><article-title>Overview on the recent study of antimicrobial peptides: origins, functions, relative mechanisms and application</article-title><source>Peptides</source><year>2012</year><volume>37</volume><fpage>207</fpage><lpage>215</lpage><?supplied-pmid 22800692?><pub-id pub-id-type="pmid">22800692</pub-id></element-citation></ref><ref id="CR206"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name></person-group><article-title>Amexanthomycins A-J, pentangular polyphenols produced by <italic>Amycolatopsis mediterranei</italic> S699rifA</article-title><source>Appl Microbiol Biotechnol</source><year>2018</year><volume>102</volume><fpage>689</fpage><lpage>702</lpage><?supplied-pmid 29181568?><pub-id pub-id-type="pmid">29181568</pub-id></element-citation></ref><ref id="CR207"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Caffrey</surname><given-names>M</given-names></name></person-group><article-title>Gramicidin structure and disposition in highly curved membranes</article-title><source>J Struct Biol</source><year>2005</year><volume>150</volume><fpage>23</fpage><lpage>40</lpage><?supplied-pmid 15797727?><pub-id pub-id-type="pmid">15797727</pub-id></element-citation></ref><ref id="CR208"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name></person-group><article-title>Stimuli-responsive self-assembling peptides made from antibacterial peptides</article-title><source>Nanoscale</source><year>2013</year><volume>5</volume><fpage>6413</fpage><lpage>6421</lpage><?supplied-pmid 23739953?><pub-id pub-id-type="pmid">23739953</pub-id></element-citation></ref><ref id="CR209"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Novel antimicrobial peptide&#x02013;modified azithromycin-loaded liposomes against methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>International Journal of Nanomedicine</source><year>2016</year><volume>11</volume><fpage>6781</fpage><?supplied-pmid 28008253?><pub-id pub-id-type="pmid">28008253</pub-id></element-citation></ref><ref id="CR210"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llewellyn</surname><given-names>AC</given-names></name><etal/></person-group><article-title>NaxD is a deacetylase required for lipid A modification and Francisella pathogenesis</article-title><source>Mol Microbiol</source><year>2012</year><volume>86</volume><fpage>611</fpage><lpage>627</lpage><?supplied-pmid 22966934?><pub-id pub-id-type="pmid">22966934</pub-id></element-citation></ref><ref id="CR211"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llobet</surname><given-names>E</given-names></name><name><surname>Tom&#x000e1;s</surname><given-names>JM</given-names></name><name><surname>Bengoechea</surname><given-names>JA</given-names></name></person-group><article-title>Capsule polysaccharide is a bacterial decoy for antimicrobial peptides</article-title><source>Microbiology</source><year>2008</year><volume>154</volume><fpage>3877</fpage><lpage>3886</lpage><?supplied-pmid 19047754?><pub-id pub-id-type="pmid">19047754</pub-id></element-citation></ref><ref id="CR212"><mixed-citation publication-type="other">Lombardi L, Falanga A, Del Genio V, Galdiero S (2019) A new hope: self-assembling peptides with antimicrobial activity. Pharmaceutics 11</mixed-citation></ref><ref id="CR213"><mixed-citation publication-type="other">Loutet S, Valvano M (2011) Extreme antimicrobial peptide and polymyxin B resistance in the genus <italic>Burkholderia</italic>. Front Cell Infect Microbiol 2</mixed-citation></ref><ref id="CR214"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loutet</surname><given-names>SA</given-names></name><name><surname>Flannagan</surname><given-names>RS</given-names></name><name><surname>Kooi</surname><given-names>C</given-names></name><name><surname>Sokol</surname><given-names>PA</given-names></name><name><surname>Valvano</surname><given-names>MA</given-names></name></person-group><article-title>A complete lipopolysaccharide inner core oligosaccharide is required for resistance of <italic>Burkholderia cenocepacia</italic> to antimicrobial peptides and bacterial survival in vivo</article-title><source>J Bacteriol</source><year>2006</year><volume>188</volume><fpage>2073</fpage><lpage>2080</lpage><?supplied-pmid 16513737?><pub-id pub-id-type="pmid">16513737</pub-id></element-citation></ref><ref id="CR215"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magana</surname><given-names>M</given-names></name><etal/></person-group><article-title>The value of antimicrobial peptides in the age of resistance</article-title><source>The Lancet Infect Dis</source><year>2020</year><volume>20</volume><fpage>e216</fpage><lpage>e230</lpage><?supplied-pmid 32653070?><pub-id pub-id-type="pmid">32653070</pub-id></element-citation></ref><ref id="CR216"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mah</surname><given-names>T-FC</given-names></name><name><surname>O&#x02019;Toole</surname><given-names>GA</given-names></name></person-group><article-title>Mechanisms of biofilm resistance to antimicrobial agents</article-title><source>Trends Microbiol</source><year>2001</year><volume>9</volume><fpage>34</fpage><lpage>39</lpage><?supplied-pmid 11166241?><pub-id pub-id-type="pmid">11166241</pub-id></element-citation></ref><ref id="CR217"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maisey</surname><given-names>HC</given-names></name><name><surname>Quach</surname><given-names>D</given-names></name><name><surname>Hensler</surname><given-names>ME</given-names></name><name><surname>Liu</surname><given-names>GY</given-names></name><name><surname>Gallo</surname><given-names>RL</given-names></name><name><surname>Nizet</surname><given-names>V</given-names></name><name><surname>Doran</surname><given-names>KS</given-names></name></person-group><article-title>A group B streptococcal pilus protein promotes phagocyte resistance and systemic virulence</article-title><source>FASEB J</source><year>2008</year><volume>22</volume><fpage>1715</fpage><lpage>1724</lpage><?supplied-pmid 18198218?><pub-id pub-id-type="pmid">18198218</pub-id></element-citation></ref><ref id="CR218"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maity</surname><given-names>S</given-names></name><name><surname>Nir</surname><given-names>S</given-names></name><name><surname>Zada</surname><given-names>T</given-names></name><name><surname>Reches</surname><given-names>M</given-names></name></person-group><article-title>Self-assembly of a tripeptide into a functional coating that resists fouling</article-title><source>Chem Commun (Camb)</source><year>2014</year><volume>50</volume><fpage>11154</fpage><lpage>11157</lpage><pub-id pub-id-type="pmid">25110984</pub-id></element-citation></ref><ref id="CR219"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malekkhaiat H&#x000e4;ffner</surname><given-names>S</given-names></name><name><surname>Malmsten</surname><given-names>M</given-names></name></person-group><article-title>Influence of self-assembly on the performance of antimicrobial peptides</article-title><source>Curr Opin Colloid Interface Sci</source><year>2018</year><volume>38</volume><fpage>56</fpage><lpage>79</lpage></element-citation></ref><ref id="CR220"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malina</surname><given-names>A</given-names></name><name><surname>Shai</surname><given-names>Y</given-names></name></person-group><article-title>Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide</article-title><source>Biochem J</source><year>2005</year><volume>390</volume><fpage>695</fpage><lpage>702</lpage><?supplied-pmid 15907192?><pub-id pub-id-type="pmid">15907192</pub-id></element-citation></ref><ref id="CR221"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malmir</surname><given-names>S</given-names></name><name><surname>Bahreinian</surname><given-names>M</given-names></name><name><surname>Yeganeh</surname><given-names>SZ</given-names></name><name><surname>Mirnejad</surname><given-names>R</given-names></name><name><surname>Saberi</surname><given-names>MMMF</given-names></name></person-group><article-title>Molecular mechanisms of resistance to conventional antibiotics in bacteria</article-title><source>Int J Med Rev</source><year>2018</year><volume>5</volume><fpage>118</fpage><lpage>129</lpage></element-citation></ref><ref id="CR222"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>KM</given-names></name><name><surname>Munson</surname><given-names>RS</given-names></name><name><surname>Bakaletz</surname><given-names>LO</given-names></name></person-group><article-title>A Mutation in the sap Operon attenuates survival of nontypeable <italic>Haemophilus influenzae</italic> in a chinchilla model of otitis media</article-title><source>Infect Immun</source><year>2005</year><volume>73</volume><fpage>599</fpage><lpage>608</lpage><?supplied-pmid 15618200?><pub-id pub-id-type="pmid">15618200</pub-id></element-citation></ref><ref id="CR223"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>KM</given-names></name><name><surname>Bruggeman</surname><given-names>ME</given-names></name><name><surname>Munson</surname><given-names>RS</given-names></name><name><surname>Bakaletz</surname><given-names>LO</given-names></name></person-group><article-title>The non-typeable <italic>Haemophilus influenzae</italic> Sap transporter provides a mechanism of antimicrobial peptide resistance and SapD-dependent potassium acquisition</article-title><source>Mol Microbiol</source><year>2006</year><volume>62</volume><fpage>1357</fpage><lpage>1372</lpage><?supplied-pmid 17064364?><pub-id pub-id-type="pmid">17064364</pub-id></element-citation></ref><ref id="CR224"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>KM</given-names></name><name><surname>Raffel</surname><given-names>FK</given-names></name><name><surname>Ray</surname><given-names>WC</given-names></name><name><surname>Bakaletz</surname><given-names>LO</given-names></name></person-group><article-title>Heme utilization by nontypeable <italic>Haemophilus influenzae</italic> is essential and dependent on sap transporter function</article-title><source>J Bacteriol</source><year>2011</year><volume>193</volume><fpage>2527</fpage><lpage>2535</lpage><?supplied-pmid 21441512?><pub-id pub-id-type="pmid">21441512</pub-id></element-citation></ref><ref id="CR225"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzaki</surname><given-names>K</given-names></name></person-group><article-title>Control of cell selectivity of antimicrobial peptides</article-title><source>Biochim Biophys Acta</source><year>2009</year><volume>1788</volume><fpage>1687</fpage><lpage>1692</lpage><?supplied-pmid 18952049?><pub-id pub-id-type="pmid">18952049</pub-id></element-citation></ref><ref id="CR226"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzaki</surname><given-names>K</given-names></name><name><surname>Sugishita</surname><given-names>K-I</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name><name><surname>Fujii</surname><given-names>N</given-names></name><name><surname>Miyajima</surname><given-names>K</given-names></name></person-group><article-title>Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria</article-title><source>Biochim Biophys Acta</source><year>1997</year><volume>1327</volume><fpage>119</fpage><lpage>130</lpage><?supplied-pmid 9247173?><pub-id pub-id-type="pmid">9247173</pub-id></element-citation></ref><ref id="CR227"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattiuzzo</surname><given-names>M</given-names></name><name><surname>De Gobba</surname><given-names>C</given-names></name><name><surname>Runti</surname><given-names>G</given-names></name><name><surname>Mardirossian</surname><given-names>M</given-names></name><name><surname>Bandiera</surname><given-names>A</given-names></name><name><surname>Gennaro</surname><given-names>R</given-names></name><name><surname>Scocchi</surname><given-names>M</given-names></name></person-group><article-title>Proteolytic activity of <italic>Escherichia coli</italic> oligopeptidase B against proline-rich antimicrobial peptides</article-title><source>J Microbiol Biotechnol</source><year>2014</year><volume>24</volume><fpage>160</fpage><lpage>167</lpage><?supplied-pmid 24225368?><pub-id pub-id-type="pmid">24225368</pub-id></element-citation></ref><ref id="CR228"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayville</surname><given-names>P</given-names></name><name><surname>Ji</surname><given-names>G</given-names></name><name><surname>Beavis</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Goger</surname><given-names>M</given-names></name><name><surname>Novick</surname><given-names>RP</given-names></name><name><surname>Muir</surname><given-names>TW</given-names></name></person-group><article-title>Structure-activity analysis of synthetic autoinducing thiolactone peptides from <italic>Staphylococcus aureus</italic> responsible for virulence</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>1218</fpage><lpage>1223</lpage><?supplied-pmid 9990004?><pub-id pub-id-type="pmid">9990004</pub-id></element-citation></ref><ref id="CR229"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzotta</surname><given-names>AS</given-names></name><name><surname>Montville</surname><given-names>TJ</given-names></name></person-group><article-title>Nisin induces changes in membrane fatty acid composition of Listeria monocytogenes nisin-resistant strains at 10&#x000b0;C and 30&#x000b0;C</article-title><source>J Appl Microbiol</source><year>1997</year><volume>82</volume><fpage>32</fpage><lpage>38</lpage><?supplied-pmid 9113875?><pub-id pub-id-type="pmid">9113875</pub-id></element-citation></ref><ref id="CR230"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCloskey</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Self-assembling ultrashort NSAID-peptide nanosponges: multifunctional antimicrobial and anti-inflammatory materials</article-title><source>RSC Advances</source><year>2016</year><volume>6</volume><fpage>114738</fpage><lpage>114749</lpage></element-citation></ref><ref id="CR231"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medema</surname><given-names>MH</given-names></name><name><surname>Paalvast</surname><given-names>Y</given-names></name><name><surname>Nguyen</surname><given-names>DD</given-names></name><name><surname>Melnik</surname><given-names>A</given-names></name><name><surname>Dorrestein</surname><given-names>PC</given-names></name><name><surname>Takano</surname><given-names>E</given-names></name><name><surname>Breitling</surname><given-names>R</given-names></name></person-group><article-title>Pep2Path: automated mass spectrometry-guided genome mining of peptidic natural products</article-title><source>PLoS Comput Biol</source><year>2014</year><volume>10</volume><fpage>e1003822</fpage><?supplied-pmid 25188327?><pub-id pub-id-type="pmid">25188327</pub-id></element-citation></ref><ref id="CR232"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meikle</surname><given-names>TG</given-names></name><name><surname>Conn</surname><given-names>CE</given-names></name><name><surname>Separovic</surname><given-names>F</given-names></name><name><surname>Drummond</surname><given-names>CJ</given-names></name></person-group><article-title>Exploring the structural relationship between encapsulated antimicrobial peptides and the bilayer membrane mimetic lipidic cubic phase: studies with gramicidin A</article-title><source>RSC Advances</source><year>2016</year><volume>6</volume><fpage>68685</fpage><lpage>68694</lpage></element-citation></ref><ref id="CR233"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Meikle</surname><given-names>TG</given-names></name><name><surname>Zabara</surname><given-names>A</given-names></name><name><surname>Waddington</surname><given-names>L</given-names></name><name><surname>Separovic</surname><given-names>F</given-names></name><name><surname>Drummond</surname><given-names>C</given-names></name><name><surname>Conn</surname><given-names>CE</given-names></name></person-group><source>Incorporation of antimicrobial peptides in nanostructured lipid membrane mimetic bilayer cubosomes</source><year>2017</year><publisher-loc>Biointerf</publisher-loc><publisher-name>Colloids Surf B</publisher-name><fpage>143</fpage><lpage>151</lpage></element-citation></ref><ref id="CR234"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meikle</surname><given-names>TG</given-names></name><name><surname>Dyett</surname><given-names>BP</given-names></name><name><surname>Strachan</surname><given-names>JB</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Drummond</surname><given-names>CJ</given-names></name><name><surname>Conn</surname><given-names>CE</given-names></name></person-group><article-title>Preparation, characterization, and antimicrobial activity of cubosome encapsulated metal nanocrystals</article-title><source>ACS Appl Mater Interfaces</source><year>2020</year><volume>12</volume><fpage>6944</fpage><lpage>6954</lpage><?supplied-pmid 31917545?><pub-id pub-id-type="pmid">31917545</pub-id></element-citation></ref><ref id="CR235"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meikle</surname><given-names>TG</given-names></name><name><surname>Dharmadana</surname><given-names>D</given-names></name><name><surname>Hoffmann</surname><given-names>SV</given-names></name><name><surname>Jones</surname><given-names>NC</given-names></name><name><surname>Drummond</surname><given-names>CJ</given-names></name><name><surname>Conn</surname><given-names>CE</given-names></name></person-group><article-title>Analysis of the structure, loading and activity of six antimicrobial peptides encapsulated in cubic phase lipid nanoparticles</article-title><source>J Colloid Interface Sci</source><year>2021</year><volume>587</volume><fpage>90</fpage><lpage>100</lpage><?supplied-pmid 33360913?><pub-id pub-id-type="pmid">33360913</pub-id></element-citation></ref><ref id="CR236"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>H</given-names></name><name><surname>Kumar</surname><given-names>K</given-names></name></person-group><article-title>Antimicrobial activity and protease stability of peptides containing fluorinated amino acids</article-title><source>J Am Chem Soc</source><year>2007</year><volume>129</volume><fpage>15615</fpage><lpage>15622</lpage><?supplied-pmid 18041836?><pub-id pub-id-type="pmid">18041836</pub-id></element-citation></ref><ref id="CR237"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>SI</given-names></name><name><surname>Kukral</surname><given-names>AM</given-names></name><name><surname>Mekalanos</surname><given-names>JJ</given-names></name></person-group><article-title>A two-component regulatory system (phoP phoQ) controls <italic>Salmonella typhimurium</italic> virulence</article-title><source>Proc Natl Acad Sci U S A</source><year>1989</year><volume>86</volume><fpage>5054</fpage><lpage>5058</lpage><?supplied-pmid 2544889?><pub-id pub-id-type="pmid">2544889</pub-id></element-citation></ref><ref id="CR238"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>NN</given-names></name><name><surname>Liu</surname><given-names>GY</given-names></name><name><surname>Yeaman</surname><given-names>MR</given-names></name><name><surname>Nast</surname><given-names>CC</given-names></name><name><surname>Proctor</surname><given-names>RA</given-names></name><name><surname>McKinnell</surname><given-names>J</given-names></name><name><surname>Bayer</surname><given-names>AS</given-names></name></person-group><article-title>Carotenoid-related alteration of cell membrane fluidity impacts <italic>Staphylococcus aureus</italic> susceptibility to host defense peptides</article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><fpage>526</fpage><lpage>531</lpage><?supplied-pmid 21115796?><pub-id pub-id-type="pmid">21115796</pub-id></element-citation></ref><ref id="CR239"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizukami</surname><given-names>S</given-names></name><name><surname>Hosoda</surname><given-names>M</given-names></name><name><surname>Satake</surname><given-names>T</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><name><surname>Hori</surname><given-names>Y</given-names></name><name><surname>Furuta</surname><given-names>T</given-names></name><name><surname>Kikuchi</surname><given-names>K</given-names></name></person-group><article-title>Photocontrolled compound release system using caged antimicrobial peptide</article-title><source>J Am Chem Soc</source><year>2010</year><volume>132</volume><fpage>9524</fpage><lpage>9525</lpage><?supplied-pmid 20583831?><pub-id pub-id-type="pmid">20583831</pub-id></element-citation></ref><ref id="CR240"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohan</surname><given-names>A</given-names></name><name><surname>Rajendran</surname><given-names>SR</given-names></name><name><surname>Thibodeau</surname><given-names>J</given-names></name><name><surname>Bazinet</surname><given-names>L</given-names></name><name><surname>Udenigwe</surname><given-names>CC</given-names></name></person-group><article-title>Liposome encapsulation of anionic and cationic whey peptides: influence of peptide net charge on properties of the nanovesicles</article-title><source>LWT</source><year>2018</year><volume>87</volume><fpage>40</fpage><lpage>46</lpage></element-citation></ref><ref id="CR241"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohimani</surname><given-names>H</given-names></name><etal/></person-group><article-title>Automated genome mining of ribosomal peptide natural products</article-title><source>ACS Chem Biol</source><year>2014</year><volume>9</volume><fpage>1545</fpage><lpage>1551</lpage><?supplied-pmid 24802639?><pub-id pub-id-type="pmid">24802639</pub-id></element-citation></ref><ref id="CR242"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohimani</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>WT</given-names></name><name><surname>Kersten</surname><given-names>RD</given-names></name><name><surname>Moore</surname><given-names>BS</given-names></name><name><surname>Dorrestein</surname><given-names>PC</given-names></name><name><surname>Pevzner</surname><given-names>PA</given-names></name></person-group><article-title>NRPquest: coupling mass spectrometry and genome mining for nonribosomal peptide discovery</article-title><source>J Nat Prod</source><year>2014</year><volume>77</volume><fpage>1902</fpage><lpage>1909</lpage><?supplied-pmid 25116163?><pub-id pub-id-type="pmid">25116163</pub-id></element-citation></ref><ref id="CR243"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mondal</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Nandi</surname><given-names>AK</given-names></name></person-group><article-title>A review on recent advances in polymer and peptide hydrogels</article-title><source>Soft Matter</source><year>2020</year><volume>16</volume><fpage>1404</fpage><lpage>1454</lpage><?supplied-pmid 31984400?><pub-id pub-id-type="pmid">31984400</pub-id></element-citation></ref><ref id="CR244"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montanaro</surname><given-names>L</given-names></name><name><surname>Poggi</surname><given-names>A</given-names></name><name><surname>Visai</surname><given-names>L</given-names></name><name><surname>Ravaioli</surname><given-names>S</given-names></name><name><surname>Campoccia</surname><given-names>D</given-names></name><name><surname>Speziale</surname><given-names>P</given-names></name><name><surname>Arciola</surname><given-names>CR</given-names></name></person-group><article-title>Extracellular DNA in biofilms</article-title><source>Int J Artif Organs</source><year>2011</year><volume>34</volume><fpage>824</fpage><lpage>831</lpage><?supplied-pmid 22094562?><pub-id pub-id-type="pmid">22094562</pub-id></element-citation></ref><ref id="CR245"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mookherjee</surname><given-names>N</given-names></name><name><surname>Anderson</surname><given-names>MA</given-names></name><name><surname>Haagsman</surname><given-names>HP</given-names></name><name><surname>Davidson</surname><given-names>DJ</given-names></name></person-group><article-title>Antimicrobial host defence peptides: functions and clinical potential</article-title><source>Nat Rev Drug Discov</source><year>2020</year><volume>19</volume><fpage>311</fpage><lpage>332</lpage><?supplied-pmid 32107480?><pub-id pub-id-type="pmid">32107480</pub-id></element-citation></ref><ref id="CR246"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>JE</given-names></name><name><surname>Fisher</surname><given-names>PE</given-names></name><name><surname>Vick</surname><given-names>B</given-names></name><name><surname>Groisman</surname><given-names>EA</given-names></name><name><surname>Zychlinsky</surname><given-names>A</given-names></name></person-group><article-title>The regulatory protein PhoP controls susceptibility to the host inflammatory response in <italic>Shigella flexneri</italic></article-title><source>Cell Microbiol</source><year>2000</year><volume>2</volume><fpage>443</fpage><lpage>452</lpage><?supplied-pmid 11207599?><pub-id pub-id-type="pmid">11207599</pub-id></element-citation></ref><ref id="CR247"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulcahy</surname><given-names>H</given-names></name><name><surname>Charron-Mazenod</surname><given-names>L</given-names></name><name><surname>Lewenza</surname><given-names>S</given-names></name></person-group><article-title>Extracellular DNA chelates cations and induces antibiotic resistance in <italic>Pseudomonas aeruginosa</italic> biofilms</article-title><source>PLoS Pathogens</source><year>2008</year><volume>4</volume><fpage>e1000213</fpage><?supplied-pmid 19023416?><pub-id pub-id-type="pmid">19023416</pub-id></element-citation></ref><ref id="CR248"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulcahy</surname><given-names>H</given-names></name><name><surname>Charron-Mazenod</surname><given-names>L</given-names></name><name><surname>Lewenza</surname><given-names>S</given-names></name></person-group><article-title><italic>Pseudomonas aeruginosa</italic> produces an extracellular deoxyribonuclease that is required for utilization of DNA as a nutrient source</article-title><source>Environ Microbiol</source><year>2010</year><volume>12</volume><fpage>1621</fpage><lpage>1629</lpage><?supplied-pmid 20370819?><pub-id pub-id-type="pmid">20370819</pub-id></element-citation></ref><ref id="CR249"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>RH</given-names></name><name><surname>Runge</surname><given-names>S</given-names></name><name><surname>Ravelli</surname><given-names>V</given-names></name><name><surname>Mehnert</surname><given-names>W</given-names></name><name><surname>Th&#x000fc;nemann</surname><given-names>AF</given-names></name><name><surname>Souto</surname><given-names>EB</given-names></name></person-group><article-title>Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN&#x000ae;) versus drug nanocrystals</article-title><source>Int J Pharmaceutics</source><year>2006</year><volume>317</volume><fpage>82</fpage><lpage>89</lpage></element-citation></ref><ref id="CR250"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mura</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Pinna</surname><given-names>M</given-names></name><name><surname>Zvelindovsky</surname><given-names>AV</given-names></name><name><surname>Dennison</surname><given-names>SR</given-names></name><name><surname>Phoenix</surname><given-names>DA</given-names></name></person-group><article-title>The effect of amidation on the behaviour of antimicrobial peptides</article-title><source>Eur Biophys J</source><year>2016</year><volume>45</volume><fpage>195</fpage><lpage>207</lpage><?supplied-pmid 26745958?><pub-id pub-id-type="pmid">26745958</pub-id></element-citation></ref><ref id="CR251"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagarajan</surname><given-names>D</given-names></name><etal/></person-group><article-title>Computational antimicrobial peptide design and evaluation against multidrug-resistant clinical isolates of bacteria</article-title><source>J Biol Chem</source><year>2018</year><volume>293</volume><fpage>3492</fpage><lpage>3509</lpage><?supplied-pmid 29259134?><pub-id pub-id-type="pmid">29259134</pub-id></element-citation></ref><ref id="CR252"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naoki</surname><given-names>S</given-names></name><etal/></person-group><article-title>The contribution of the N-terminal structure of polymyxin B peptides to antimicrobial and lipopolysaccharide binding activity</article-title><source>Bull Chem Soc Japan</source><year>2004</year><volume>77</volume><fpage>1915</fpage><lpage>1924</lpage></element-citation></ref><ref id="CR253"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasompag</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of acyl chain length on therapeutic activity and mode of action of the CX-KYR-NH2 antimicrobial lipopeptide</article-title><source>Biochim Biophys Acta</source><year>2015</year><volume>1848</volume><fpage>2351</fpage><lpage>2364</lpage><?supplied-pmid 26170198?><pub-id pub-id-type="pmid">26170198</pub-id></element-citation></ref><ref id="CR254"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neut</surname><given-names>D</given-names></name><name><surname>Tijdens-Creusen</surname><given-names>EJ</given-names></name><name><surname>Bulstra</surname><given-names>SK</given-names></name><name><surname>van der Mei</surname><given-names>HC</given-names></name><name><surname>Busscher</surname><given-names>HJ</given-names></name></person-group><article-title>Biofilms in chronic diabetic foot ulcers--a study of 2 cases</article-title><source>Acta Orthop</source><year>2011</year><volume>82</volume><fpage>383</fpage><lpage>385</lpage><?supplied-pmid 21561305?><pub-id pub-id-type="pmid">21561305</pub-id></element-citation></ref><ref id="CR255"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>D</given-names></name><etal/></person-group><article-title>Use of ichip for high-throughput in situ cultivation of &#x0201c;uncultivable&#x0201d; microbial species</article-title><source>Appl Environ Microbiol</source><year>2010</year><volume>76</volume><fpage>2445</fpage><lpage>2450</lpage><?supplied-pmid 20173072?><pub-id pub-id-type="pmid">20173072</pub-id></element-citation></ref><ref id="CR256"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nickel</surname><given-names>JC</given-names></name><name><surname>Ruseska</surname><given-names>I</given-names></name><name><surname>Wright</surname><given-names>JB</given-names></name><name><surname>Costerton</surname><given-names>JW</given-names></name></person-group><article-title>Tobramycin resistance of <italic>Pseudomonas aeruginosa</italic> cells growing as a biofilm on urinary catheter material</article-title><source>Antimicrob Agents Chemother</source><year>1985</year><volume>27</volume><fpage>619</fpage><lpage>624</lpage><?supplied-pmid 3923925?><pub-id pub-id-type="pmid">3923925</pub-id></element-citation></ref><ref id="CR257"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolosi</surname><given-names>D</given-names></name><name><surname>Scalia</surname><given-names>M</given-names></name><name><surname>Nicolosi</surname><given-names>VM</given-names></name><name><surname>Pignatello</surname><given-names>R</given-names></name></person-group><article-title>Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria</article-title><source>Int J Antimicrob Agents</source><year>2010</year><volume>35</volume><fpage>553</fpage><lpage>558</lpage><?supplied-pmid 20219328?><pub-id pub-id-type="pmid">20219328</pub-id></element-citation></ref><ref id="CR258"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>JE</given-names></name><name><surname>Bjornestad</surname><given-names>VA</given-names></name><name><surname>Lund</surname><given-names>R</given-names></name></person-group><article-title>Resolving the structural interactions between antimicrobial peptides and lipid membranes using small-angle scattering methods: the case of indolicidin</article-title><source>Soft Matter</source><year>2018</year><volume>14</volume><fpage>8750</fpage><lpage>8763</lpage><?supplied-pmid 30358793?><pub-id pub-id-type="pmid">30358793</pub-id></element-citation></ref><ref id="CR259"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niemz</surname><given-names>A</given-names></name><name><surname>Tirrell</surname><given-names>DA</given-names></name></person-group><article-title>Self-association and membrane-binding behavior of melittins containing trifluoroleucine</article-title><source>J Am Chem Soc</source><year>2001</year><volume>123</volume><fpage>7407</fpage><lpage>7413</lpage><?supplied-pmid 11472172?><pub-id pub-id-type="pmid">11472172</pub-id></element-citation></ref><ref id="CR260"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nizet</surname><given-names>V</given-names></name></person-group><article-title>Antimicrobial peptide resistance mechanisms of human bacterial pathogens</article-title><source>Curr Issues Mol Biol</source><year>2006</year><volume>8</volume><fpage>11</fpage><?supplied-pmid 16450883?><pub-id pub-id-type="pmid">16450883</pub-id></element-citation></ref><ref id="CR261"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nyberg</surname><given-names>P</given-names></name><name><surname>Rasmussen</surname><given-names>M</given-names></name><name><surname>Bj&#x000f6;rck</surname><given-names>L</given-names></name></person-group><article-title>&#x003b1;2-Macroglobulin-Proteinase complexes protect <italic>Streptococcus pyogenes</italic> from killing by the antimicrobial peptide LL-37</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>52820</fpage><lpage>52823</lpage><?supplied-pmid 15520011?><pub-id pub-id-type="pmid">15520011</pub-id></element-citation></ref><ref id="CR262"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oddo</surname><given-names>A</given-names></name><name><surname>Hansen</surname><given-names>PR</given-names></name></person-group><article-title>Hemolytic activity of antimicrobial peptides</article-title><source>Methods Mol Biol</source><year>2017</year><volume>1548</volume><fpage>427</fpage><lpage>435</lpage><?supplied-pmid 28013523?><pub-id pub-id-type="pmid">28013523</pub-id></element-citation></ref><ref id="CR263"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogunleye</surname><given-names>A</given-names></name><name><surname>Bhat</surname><given-names>A</given-names></name><name><surname>Irorere</surname><given-names>VU</given-names></name><name><surname>Hill</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Radecka</surname><given-names>I</given-names></name></person-group><article-title>Poly-&#x003b3;-glutamic acid: production, properties and applications</article-title><source>Microbiology</source><year>2015</year><volume>161</volume><fpage>1</fpage><lpage>17</lpage><?supplied-pmid 25288645?><pub-id pub-id-type="pmid">25288645</pub-id></element-citation></ref><ref id="CR264"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohki</surname><given-names>R</given-names></name><name><surname>Giyanto</surname><given-names>TK</given-names></name><name><surname>Masuyama</surname><given-names>W</given-names></name><name><surname>Moriya</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Ogasawara</surname><given-names>N</given-names></name></person-group><article-title>The BceRS two-component regulatory system induces expression of the bacitracin transporter, BceAB, in Bacillus subtilis</article-title><source>Mol Microbiol</source><year>2003</year><volume>49</volume><fpage>1135</fpage><lpage>1144</lpage><?supplied-pmid 12890034?><pub-id pub-id-type="pmid">12890034</pub-id></element-citation></ref><ref id="CR265"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oie</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Kamiya</surname><given-names>A</given-names></name><name><surname>Konishi</surname><given-names>H</given-names></name><name><surname>Nakazawa</surname><given-names>T</given-names></name></person-group><article-title>Efficacy of disinfectants against biofilm cells of methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>Microbios</source><year>1996</year><volume>85</volume><fpage>223</fpage><lpage>230</lpage><?supplied-pmid 8699964?><pub-id pub-id-type="pmid">8699964</pub-id></element-citation></ref><ref id="CR266"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okshevsky</surname><given-names>M</given-names></name><name><surname>Meyer</surname><given-names>RL</given-names></name></person-group><article-title>The role of extracellular DNA in the establishment, maintenance and perpetuation of bacterial biofilms</article-title><source>Crit Rev Microbiol</source><year>2015</year><volume>41</volume><fpage>341</fpage><lpage>352</lpage><?supplied-pmid 24303798?><pub-id pub-id-type="pmid">24303798</pub-id></element-citation></ref><ref id="CR267"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>ZY</given-names></name><name><surname>Wiradharma</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>YY</given-names></name></person-group><article-title>Strategies employed in the design and optimization of synthetic antimicrobial peptide amphiphiles with enhanced therapeutic potentials</article-title><source>Adv Drug Deliv Rev</source><year>2014</year><volume>78</volume><fpage>28</fpage><lpage>45</lpage><?supplied-pmid 25453271?><pub-id pub-id-type="pmid">25453271</pub-id></element-citation></ref><ref id="CR268"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>M</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Romeo</surname><given-names>T</given-names></name></person-group><article-title>Staphylococcal biofilms</article-title><source>Bacterial biofilms</source><year>2008</year><publisher-loc>Heidelberg, Berlin</publisher-loc><publisher-name>Springer</publisher-name><fpage>207</fpage><lpage>228</lpage></element-citation></ref><ref id="CR269"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>M</given-names></name></person-group><article-title>Staphylococcus colonization of the skin and antimicrobial peptides</article-title><source>Exp Rev Derm</source><year>2010</year><volume>5</volume><fpage>183</fpage><lpage>195</lpage></element-citation></ref><ref id="CR270"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Peschel</surname><given-names>A</given-names></name><name><surname>G&#x000f6;tz</surname><given-names>F</given-names></name></person-group><article-title>Producer self-protection against the lantibiotic epidermin by the ABC transporter EpiFEG of <italic>Staphylococcus epidermidis</italic> T&#x000fc;3298</article-title><source>FEMS Microbiol Lett</source><year>1998</year><volume>166</volume><fpage>203</fpage><lpage>211</lpage><?supplied-pmid 9770275?><pub-id pub-id-type="pmid">9770275</pub-id></element-citation></ref><ref id="CR271"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyston</surname><given-names>PCF</given-names></name><name><surname>Dorrell</surname><given-names>N</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>S-R</given-names></name><name><surname>Green</surname><given-names>M</given-names></name><name><surname>Titball</surname><given-names>RW</given-names></name><name><surname>Wren</surname><given-names>BW</given-names></name></person-group><article-title>The response regulator PhoP is important for survival under conditions of macrophage-induced stress and virulence in <italic>Yersinia pestis</italic></article-title><source>Infect Immun</source><year>2000</year><volume>68</volume><fpage>3419</fpage><lpage>3425</lpage><?supplied-pmid 10816493?><pub-id pub-id-type="pmid">10816493</pub-id></element-citation></ref><ref id="CR272"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padilla</surname><given-names>E</given-names></name><name><surname>Llobet</surname><given-names>E</given-names></name><name><surname>Dom&#x000e9;nech-S&#x000e1;nchez</surname><given-names>A</given-names></name><name><surname>Mart&#x000ed;nez-Mart&#x000ed;nez</surname><given-names>L</given-names></name><name><surname>Bengoechea</surname><given-names>JA</given-names></name><name><surname>Albert&#x000ed;</surname><given-names>S</given-names></name></person-group><article-title><italic>Klebsiella pneumoniae</italic> AcrAB efflux pump contributes to antimicrobial resistance and virulence</article-title><source>Antimicrob Agents Chemother</source><year>2010</year><volume>54</volume><fpage>177</fpage><lpage>183</lpage><?supplied-pmid 19858254?><pub-id pub-id-type="pmid">19858254</pub-id></element-citation></ref><ref id="CR273"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papenfort</surname><given-names>K</given-names></name><name><surname>Bassler</surname><given-names>BL</given-names></name></person-group><article-title>Quorum sensing signal-response systems in Gram-negative bacteria</article-title><source>Nat Rev Microbiol</source><year>2016</year><volume>14</volume><fpage>576</fpage><lpage>588</lpage><?supplied-pmid 27510864?><pub-id pub-id-type="pmid">27510864</pub-id></element-citation></ref><ref id="CR274"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parish</surname><given-names>T</given-names></name></person-group><article-title>Steps to address anti-microbial drug resistance in today&#x02019;s drug discovery</article-title><source>Expert Opin Drug Discov</source><year>2019</year><volume>14</volume><fpage>91</fpage><lpage>94</lpage><?supplied-pmid 30466326?><pub-id pub-id-type="pmid">30466326</pub-id></element-citation></ref><ref id="CR275"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parthsarathy</surname><given-names>V</given-names></name><etal/></person-group><article-title>A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1&#x00394;E9 mouse model of Alzheimer&#x02019;s disease</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e54769</fpage><?supplied-pmid 23382963?><pub-id pub-id-type="pmid">23382963</pub-id></element-citation></ref><ref id="CR276"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parveen</surname><given-names>N</given-names></name><name><surname>Cornell</surname><given-names>KA</given-names></name></person-group><article-title>Methylthioadenosine/S-adenosylhomocysteine nucleosidase, a critical enzyme for bacterial metabolism</article-title><source>Mol Microbiol</source><year>2011</year><volume>79</volume><fpage>7</fpage><lpage>20</lpage><?supplied-pmid 21166890?><pub-id pub-id-type="pmid">21166890</pub-id></element-citation></ref><ref id="CR277"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of <italic>Acinetobacter baumannii</italic></article-title><source>Antimicrob Agents Chemother</source><year>2013</year><volume>57</volume><fpage>4831</fpage><lpage>4840</lpage><?supplied-pmid 23877686?><pub-id pub-id-type="pmid">23877686</pub-id></element-citation></ref><ref id="CR278"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peschel</surname><given-names>A</given-names></name><name><surname>Sahl</surname><given-names>H-G</given-names></name></person-group><article-title>The co-evolution of host cationic antimicrobial peptides and microbial resistance</article-title><source>Nat Rev Microbiol</source><year>2006</year><volume>4</volume><fpage>529</fpage><lpage>536</lpage><?supplied-pmid 16778838?><pub-id pub-id-type="pmid">16778838</pub-id></element-citation></ref><ref id="CR279"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peschel</surname><given-names>A</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Jack</surname><given-names>RW</given-names></name><name><surname>Kalbacher</surname><given-names>H</given-names></name><name><surname>Jung</surname><given-names>G</given-names></name><name><surname>G&#x000f6;tz</surname><given-names>F</given-names></name></person-group><article-title>Inactivation of the dlt Operon in <italic>Staphylococcus aureus</italic> confers sensitivity to defensins, protegrins, and other antimicrobial peptides</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>8405</fpage><lpage>8410</lpage><?supplied-pmid 10085071?><pub-id pub-id-type="pmid">10085071</pub-id></element-citation></ref><ref id="CR280"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peschel</surname><given-names>A</given-names></name><etal/></person-group><article-title><italic>Staphylococcus aureus</italic> resistance to human defensins and evasion of neutrophil killing via the novel virulence factor Mprf is based on modification of membrane lipids with l-lysine</article-title><source>J Exp Med</source><year>2001</year><volume>193</volume><fpage>1067</fpage><lpage>1076</lpage><?supplied-pmid 11342591?><pub-id pub-id-type="pmid">11342591</pub-id></element-citation></ref><ref id="CR281"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>E</given-names></name><name><surname>Kaur</surname><given-names>P</given-names></name></person-group><article-title>Antibiotic resistance mechanisms in bacteria: relationships between resistance determinants of antibiotic producers, environmental bacteria, and clinical pathogens</article-title><source>Front Microbiol</source><year>2018</year><volume>9</volume><fpage>2928</fpage><?supplied-pmid 30555448?><pub-id pub-id-type="pmid">30555448</pub-id></element-citation></ref><ref id="CR282"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfalzgraff</surname><given-names>A</given-names></name><name><surname>Brandenburg</surname><given-names>K</given-names></name><name><surname>Weindl</surname><given-names>G</given-names></name></person-group><article-title>Antimicrobial peptides and their therapeutic potential for bacterial skin infections and wounds</article-title><source>Front Pharmacol</source><year>2018</year><volume>9</volume><fpage>281</fpage><?supplied-pmid 29643807?><pub-id pub-id-type="pmid">29643807</pub-id></element-citation></ref><ref id="CR283"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piddock</surname><given-names>LJV</given-names></name></person-group><article-title>Multidrug-resistance efflux pumps ? Not just for resistance</article-title><source>Nat Rev Microbiol</source><year>2006</year><volume>4</volume><fpage>629</fpage><lpage>636</lpage><?supplied-pmid 16845433?><pub-id pub-id-type="pmid">16845433</pub-id></element-citation></ref><ref id="CR284"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pini</surname><given-names>A</given-names></name><etal/></person-group><article-title>A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo</article-title><source>The FASEB Journal</source><year>2010</year><volume>24</volume><fpage>1015</fpage><lpage>1022</lpage><?supplied-pmid 19917670?><pub-id pub-id-type="pmid">19917670</pub-id></element-citation></ref><ref id="CR285"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirtskhalava</surname><given-names>M</given-names></name><etal/></person-group><article-title>DBAASP v.2: an enhanced database of structure and antimicrobial/cytotoxic activity of natural and synthetic peptides</article-title><source>Nucl Acids Res</source><year>2016</year><volume>44</volume><fpage>1104</fpage><lpage>1112</lpage></element-citation></ref><ref id="CR286"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poole</surname><given-names>K</given-names></name></person-group><article-title>Efflux pumps as antimicrobial resistance mechanisms</article-title><source>Annals of Medicine</source><year>2007</year><volume>39</volume><fpage>162</fpage><lpage>176</lpage><?supplied-pmid 17457715?><pub-id pub-id-type="pmid">17457715</pub-id></element-citation></ref><ref id="CR287"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pristovsek</surname><given-names>P</given-names></name><name><surname>Kidric</surname><given-names>J</given-names></name></person-group><article-title>Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: an NMR and molecular modeling study</article-title><source>J Med Chem</source><year>1999</year><volume>42</volume><fpage>4604</fpage><lpage>4613</lpage><?supplied-pmid 10579822?><pub-id pub-id-type="pmid">10579822</pub-id></element-citation></ref><ref id="CR288"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prombutara</surname><given-names>P</given-names></name><name><surname>Kulwatthanasal</surname><given-names>Y</given-names></name><name><surname>Supaka</surname><given-names>N</given-names></name><name><surname>Sramala</surname><given-names>I</given-names></name><name><surname>Chareonpornwattana</surname><given-names>S</given-names></name></person-group><article-title>Production of nisin-loaded solid lipid nanoparticles for sustained antimicrobial activity</article-title><source>Food Control</source><year>2012</year><volume>24</volume><fpage>184</fpage><lpage>190</lpage></element-citation></ref><ref id="CR289"><mixed-citation publication-type="other">Pronk S et al (2013) GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics:845&#x02013;854</mixed-citation></ref><ref id="CR290"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pucci</surname><given-names>MJ</given-names></name></person-group><article-title>Use of genomics to select antibacterial targets</article-title><source>Biochem Pharmacol</source><year>2006</year><volume>71</volume><fpage>1066</fpage><lpage>1072</lpage><?supplied-pmid 16412986?><pub-id pub-id-type="pmid">16412986</pub-id></element-citation></ref><ref id="CR291"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>M</given-names></name><name><surname>Saris</surname><given-names>PEJ</given-names></name></person-group><article-title>Evidence for a role of NisT in transport of the lantibiotic nisin produced by <italic>Lactococcus lactis</italic> N8</article-title><source>FEMS Microbiol Lett</source><year>1996</year><volume>144</volume><fpage>89</fpage><lpage>93</lpage><?supplied-pmid 8870256?><pub-id pub-id-type="pmid">8870256</pub-id></element-citation></ref><ref id="CR292"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quirynen</surname><given-names>M</given-names></name><name><surname>Bollen</surname><given-names>CM</given-names></name></person-group><article-title>The influence of surface roughness and surface-free energy on supra- and subgingival plaque formation in man</article-title><source>A review of the literature. J Clin Periodontol</source><year>1995</year><volume>22</volume><fpage>1</fpage><lpage>14</lpage><?supplied-pmid 7706534?><pub-id pub-id-type="pmid">7706534</pub-id></element-citation></ref><ref id="CR293"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname><given-names>A</given-names></name><name><surname>Thakur</surname><given-names>N</given-names></name><name><surname>Himani</surname><given-names>T</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name></person-group><article-title>AVPdb: a database of experimentally validated antiviral peptides targeting medically important viruses</article-title><source>Nucl Acids Res</source><year>2014</year><volume>42</volume><fpage>1147</fpage><lpage>1153</lpage></element-citation></ref><ref id="CR294"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radzishevsky</surname><given-names>IS</given-names></name><name><surname>Rotem</surname><given-names>S</given-names></name><name><surname>Zaknoon</surname><given-names>F</given-names></name><name><surname>Gaidukov</surname><given-names>L</given-names></name><name><surname>Dagan</surname><given-names>A</given-names></name><name><surname>Mor</surname><given-names>A</given-names></name></person-group><article-title>Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><fpage>2412</fpage><lpage>2420</lpage><?supplied-pmid 15917541?><pub-id pub-id-type="pmid">15917541</pub-id></element-citation></ref><ref id="CR295"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raetz</surname><given-names>CRH</given-names></name><name><surname>Whitfield</surname><given-names>C</given-names></name></person-group><article-title>Lipopolysaccharide endotoxins</article-title><source>Annual Rev Biochem</source><year>2002</year><volume>71</volume><fpage>635</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">12045108</pub-id></element-citation></ref><ref id="CR296"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragioto</surname><given-names>DA</given-names></name><name><surname>Carrasco</surname><given-names>LD</given-names></name><name><surname>Carmona-Ribeiro</surname><given-names>AM</given-names></name></person-group><article-title>Novel gramicidin formulations in cationic lipid as broad-spectrum microbicidal agents</article-title><source>Int J Nanomedicine</source><year>2014</year><volume>9</volume><fpage>3183</fpage><?supplied-pmid 25061295?><pub-id pub-id-type="pmid">25061295</pub-id></element-citation></ref><ref id="CR297"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajeev</surname><given-names>L</given-names></name></person-group><article-title>Antibiotic discovery</article-title><source>Mater Methods</source><year>2018</year><volume>8</volume><fpage>2671</fpage></element-citation></ref><ref id="CR298"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebeil</surname><given-names>R</given-names></name><name><surname>Ernst</surname><given-names>RK</given-names></name><name><surname>Gowen</surname><given-names>BB</given-names></name><name><surname>Miller</surname><given-names>SI</given-names></name><name><surname>Hinnebusch</surname><given-names>BJ</given-names></name></person-group><article-title>Variation in lipid A structure in the pathogenic yersiniae</article-title><source>Mol Microbiol</source><year>2004</year><volume>52</volume><fpage>1363</fpage><lpage>1373</lpage><?supplied-pmid 15165239?><pub-id pub-id-type="pmid">15165239</pub-id></element-citation></ref><ref id="CR299"><mixed-citation publication-type="other">Renwick MJ, Simpkin V, Mossialos E (2016) Targeting innovation in antibiotic drug discovery and development. In. Health Policy Series, vol 45. European Observatory on Health Systems and Policies., Copenhagen (Denmark),</mixed-citation></ref><ref id="CR300"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro da Cunha</surname><given-names>B</given-names></name><name><surname>Fonseca</surname><given-names>LP</given-names></name><name><surname>Calado</surname><given-names>CRC</given-names></name></person-group><article-title>Antibiotic discovery: where have we come from, where do we go?</article-title><source>Antibiotics (Basel)</source><year>2019</year><volume>8</volume><fpage>45</fpage></element-citation></ref><ref id="CR301"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ron-Doitch</surname><given-names>S</given-names></name><etal/></person-group><article-title>Reduced cytotoxicity and enhanced bioactivity of cationic antimicrobial peptides liposomes in cell cultures and 3D epidermis model against HSV</article-title><source>J Control Release</source><year>2016</year><volume>229</volume><fpage>163</fpage><lpage>171</lpage><?supplied-pmid 27012977?><pub-id pub-id-type="pmid">27012977</pub-id></element-citation></ref><ref id="CR302"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rousseau</surname><given-names>F</given-names></name><name><surname>Schymkowitz</surname><given-names>J</given-names></name><name><surname>Serrano</surname><given-names>L</given-names></name></person-group><article-title>Protein aggregation and amyloidosis: confusion of the kinds?</article-title><source>Curr Opin Struct Biol</source><year>2006</year><volume>16</volume><fpage>118</fpage><lpage>126</lpage><?supplied-pmid 16434184?><pub-id pub-id-type="pmid">16434184</pub-id></element-citation></ref><ref id="CR303"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rupp</surname><given-names>ME</given-names></name><name><surname>Ulphani</surname><given-names>JS</given-names></name><name><surname>Fey</surname><given-names>PD</given-names></name><name><surname>Bartscht</surname><given-names>K</given-names></name><name><surname>Mack</surname><given-names>D</given-names></name></person-group><article-title>Characterization of the Importance of polysaccharide intercellular adhesin/hemagglutinin of <italic>Staphylococcus epidermidis</italic> in the pathogenesis of biomaterial-based infection in a mouse foreign body infection model</article-title><source>Infect Immun</source><year>1999</year><volume>67</volume><fpage>2627</fpage><lpage>2632</lpage><?supplied-pmid 10225932?><pub-id pub-id-type="pmid">10225932</pub-id></element-citation></ref><ref id="CR304"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saar-Dover</surname><given-names>R</given-names></name><etal/></person-group><article-title>D-Alanylation of lipoteichoic acids confers resistance to cationic peptides in group B streptococcus by increasing the cell wall density</article-title><source>PLoS Pathogens</source><year>2012</year><volume>8</volume><fpage>e1002891</fpage><?supplied-pmid 22969424?><pub-id pub-id-type="pmid">22969424</pub-id></element-citation></ref><ref id="CR305"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakala</surname><given-names>GP</given-names></name><name><surname>Reches</surname><given-names>M</given-names></name></person-group><article-title>Peptide-based approaches to fight biofouling</article-title><source>Advanced Materials Interfaces</source><year>2018</year><volume>5</volume><fpage>1800073</fpage></element-citation></ref><ref id="CR306"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salick</surname><given-names>DA</given-names></name><name><surname>Kretsinger</surname><given-names>JK</given-names></name><name><surname>Pochan</surname><given-names>DJ</given-names></name><name><surname>Schneider</surname><given-names>JP</given-names></name></person-group><article-title>Inherent antibacterial activity of a peptide-based beta-hairpin hydrogel</article-title><source>J Am Chem Soc</source><year>2007</year><volume>129</volume><fpage>14793</fpage><lpage>14799</lpage><?supplied-pmid 17985907?><pub-id pub-id-type="pmid">17985907</pub-id></element-citation></ref><ref id="CR307"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santajit</surname><given-names>S</given-names></name><name><surname>Indrawattana</surname><given-names>N</given-names></name></person-group><article-title>Mechanisms of antimicrobial resistance in ESKAPE pathogens</article-title><source>Biomed Res Int</source><year>2016</year><volume>2016</volume><fpage>2475067</fpage><?supplied-pmid 27274985?><pub-id pub-id-type="pmid">27274985</pub-id></element-citation></ref><ref id="CR308"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>NW</given-names></name><name><surname>Wong</surname><given-names>GC</given-names></name></person-group><article-title>Antimicrobial peptides and induced membrane curvature: geometry, coordination chemistry, and molecular engineering</article-title><source>Curr Opin Solid State Mater Sci</source><year>2013</year><volume>17</volume><fpage>151</fpage><lpage>163</lpage><?supplied-pmid 24778573?><pub-id pub-id-type="pmid">24778573</pub-id></element-citation></ref><ref id="CR309"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>NW</given-names></name><etal/></person-group><article-title>Criterion for amino acid composition of defensins and antimicrobial peptides based on geometry of membrane destabilization</article-title><source>J Am Chem Soc</source><year>2011</year><volume>133</volume><fpage>6720</fpage><lpage>6727</lpage><?supplied-pmid 21473577?><pub-id pub-id-type="pmid">21473577</pub-id></element-citation></ref><ref id="CR310"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>NW</given-names></name><etal/></person-group><article-title>Liquid-crystalline ordering of antimicrobial peptide&#x02013;DNA complexes controls TLR9 activation</article-title><source>Nat Mater</source><year>2015</year><volume>14</volume><fpage>696</fpage><lpage>700</lpage><?supplied-pmid 26053762?><pub-id pub-id-type="pmid">26053762</pub-id></element-citation></ref><ref id="CR311"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidtchen</surname><given-names>A</given-names></name><name><surname>Frick</surname><given-names>I-M</given-names></name><name><surname>Bj&#x000f6;rck</surname><given-names>L</given-names></name></person-group><article-title>Dermatan sulphate is released by proteinases of common pathogenic bacteria and inactivates antibacterial &#x003b1;-defensin</article-title><source>Mol Microbiol</source><year>2001</year><volume>39</volume><fpage>708</fpage><lpage>713</lpage><?supplied-pmid 11169110?><pub-id pub-id-type="pmid">11169110</pub-id></element-citation></ref><ref id="CR312"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidtchen</surname><given-names>A</given-names></name><name><surname>Frick</surname><given-names>I-M</given-names></name><name><surname>Andersson</surname><given-names>E</given-names></name><name><surname>Tapper</surname><given-names>H</given-names></name><name><surname>Bj&#x000f6;rck</surname><given-names>L</given-names></name></person-group><article-title>Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37</article-title><source>Mol Microbiol</source><year>2002</year><volume>46</volume><fpage>157</fpage><lpage>168</lpage><?supplied-pmid 12366839?><pub-id pub-id-type="pmid">12366839</pub-id></element-citation></ref><ref id="CR313"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnaider</surname><given-names>L</given-names></name><etal/></person-group><article-title>Self-assembling dipeptide antibacterial nanostructures with membrane disrupting activity</article-title><source>Nat Comm</source><year>2017</year><volume>8</volume><fpage>1365</fpage></element-citation></ref><ref id="CR314"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>JP</given-names></name><name><surname>Pochan</surname><given-names>DJ</given-names></name><name><surname>Ozbas</surname><given-names>B</given-names></name><name><surname>Rajagopal</surname><given-names>K</given-names></name><name><surname>Pakstis</surname><given-names>L</given-names></name><name><surname>Kretsinger</surname><given-names>J</given-names></name></person-group><article-title>Responsive hydrogels from the intramolecular folding and self-assembly of a designed peptide</article-title><source>J Am Chem Soc</source><year>2002</year><volume>124</volume><fpage>15030</fpage><lpage>15037</lpage><?supplied-pmid 12475347?><pub-id pub-id-type="pmid">12475347</pub-id></element-citation></ref><ref id="CR315"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Gries</surname><given-names>K</given-names></name><name><surname>Josten</surname><given-names>M</given-names></name><name><surname>Wiedemann</surname><given-names>I</given-names></name><name><surname>Pelzer</surname><given-names>S</given-names></name><name><surname>Labischinski</surname><given-names>H</given-names></name><name><surname>Sahl</surname><given-names>HG</given-names></name></person-group><article-title>The lipopeptide antibiotic Friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate</article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><fpage>1610</fpage><lpage>1618</lpage><?supplied-pmid 19164139?><pub-id pub-id-type="pmid">19164139</pub-id></element-citation></ref><ref id="CR316"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Kadlec</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Brenner Michael</surname><given-names>G</given-names></name><name><surname>Fessler</surname><given-names>AT</given-names></name><name><surname>Vester</surname><given-names>B</given-names></name></person-group><article-title>Lincosamides, streptogramins, phenicols, and pleuromutilins: mode of action and mechanisms of resistance</article-title><source>Cold Spring Harb Perspect Med</source><year>2016</year><volume>6</volume><fpage>a027037</fpage><?supplied-pmid 27549310?><pub-id pub-id-type="pmid">27549310</pub-id></element-citation></ref><ref id="CR317"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scudiero</surname><given-names>O</given-names></name><etal/></person-group><article-title>Design and activity of a cyclic mini-&#x003b2;-defensin analog: a novel antimicrobial tool</article-title><source>Int J Nanomedicine</source><year>2015</year><volume>10</volume><fpage>6523</fpage><lpage>6539</lpage><?supplied-pmid 26508857?><pub-id pub-id-type="pmid">26508857</pub-id></element-citation></ref><ref id="CR318"><mixed-citation publication-type="other">Sekyere JO (2018) Genomic insights into nitrofurantoin resistance mechanisms and epidemiology in clinical Enterobacteriaceae. Future Sci OA 4</mixed-citation></ref><ref id="CR319"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Severino</surname><given-names>P</given-names></name><etal/></person-group><article-title>Antimicrobial activity of polymyxin-loaded solid lipid nanoparticles (PLX-SLN): characterization of physicochemical properties and in vitro efficacy</article-title><source>Eur J Pharm Sci</source><year>2017</year><volume>106</volume><fpage>177</fpage><lpage>184</lpage><?supplied-pmid 28576561?><pub-id pub-id-type="pmid">28576561</pub-id></element-citation></ref><ref id="CR320"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sfor&#x000e7;a</surname><given-names>ML</given-names></name><etal/></person-group><article-title>How C-terminal carboxyamidation alters the biological activity of peptides from the venom of the eumenine solitary wasp</article-title><source>Biochemistry</source><year>2004</year><volume>43</volume><fpage>5608</fpage><lpage>5617</lpage><?supplied-pmid 15134435?><pub-id pub-id-type="pmid">15134435</pub-id></element-citation></ref><ref id="CR321"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>NR</given-names></name><name><surname>Hancock</surname><given-names>REW</given-names></name><name><surname>Fernandez</surname><given-names>RC</given-names></name></person-group><article-title>Lipid A glucosamine modification confers resistance to cationic antimicrobial peptides and increases resistance to outer membrane perturbation</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><fpage>4931</fpage><lpage>4934</lpage><?supplied-pmid 24867963?><pub-id pub-id-type="pmid">24867963</pub-id></element-citation></ref><ref id="CR322"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>CL</given-names></name><name><surname>Raffel</surname><given-names>FK</given-names></name><name><surname>Beatty</surname><given-names>WL</given-names></name><name><surname>Johnson</surname><given-names>SM</given-names></name><name><surname>Mason</surname><given-names>KM</given-names></name></person-group><article-title>Sap transporter mediated import and subsequent degradation of antimicrobial peptides in haemophilus</article-title><source>PLoS Pathogens</source><year>2011</year><volume>7</volume><fpage>e1002360</fpage><?supplied-pmid 22072973?><pub-id pub-id-type="pmid">22072973</pub-id></element-citation></ref><ref id="CR323"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Wareham</surname><given-names>DW</given-names></name><name><surname>Phee</surname><given-names>LM</given-names></name><name><surname>Azevedo</surname><given-names>HS</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Guler</surname><given-names>MO</given-names></name></person-group><article-title>Self-assembled peptide nanostructures for antibacterial applications</article-title><source>Peptide-based biomaterials</source><year>2021</year><publisher-loc>Cambridge, UK</publisher-loc><publisher-name>The Royal Society of Chemistry</publisher-name><fpage>395</fpage><lpage>428</lpage></element-citation></ref><ref id="CR324"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>S</given-names></name><name><surname>Grilley</surname><given-names>M</given-names></name><name><surname>Fosso</surname><given-names>MY</given-names></name><name><surname>Chang</surname><given-names>CW</given-names></name><name><surname>Takemoto</surname><given-names>JY</given-names></name></person-group><article-title>Membrane lipid-modulated mechanism of action and non-cytotoxicity of novel fungicide aminoglycoside FG08</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e73843</fpage><?supplied-pmid 24040088?><pub-id pub-id-type="pmid">24040088</pub-id></element-citation></ref><ref id="CR325"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierra</surname><given-names>JM</given-names></name><name><surname>Fuste</surname><given-names>E</given-names></name><name><surname>Rabanal</surname><given-names>F</given-names></name><name><surname>Vinuesa</surname><given-names>T</given-names></name><name><surname>Vinas</surname><given-names>M</given-names></name></person-group><article-title>An overview of antimicrobial peptides and the latest advances in their development</article-title><source>Expert Opin Biol Ther</source><year>2017</year><volume>17</volume><fpage>663</fpage><lpage>676</lpage><?supplied-pmid 28368216?><pub-id pub-id-type="pmid">28368216</pub-id></element-citation></ref><ref id="CR326"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>GA</given-names></name><name><surname>Czeisler</surname><given-names>C</given-names></name><name><surname>Niece</surname><given-names>KL</given-names></name><name><surname>Beniash</surname><given-names>E</given-names></name><name><surname>Harrington</surname><given-names>DA</given-names></name><name><surname>Kessler</surname><given-names>JA</given-names></name><name><surname>Stupp</surname><given-names>SI</given-names></name></person-group><article-title>Selective differentiation of neural progenitor cells by high-epitope density nanofibers</article-title><source>Science</source><year>2004</year><volume>303</volume><fpage>1352</fpage><lpage>1355</lpage><?supplied-pmid 14739465?><pub-id pub-id-type="pmid">14739465</pub-id></element-citation></ref><ref id="CR327"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvestro</surname><given-names>L</given-names></name><name><surname>Gupta</surname><given-names>K</given-names></name><name><surname>Weiser</surname><given-names>JN</given-names></name><name><surname>Axelsen</surname><given-names>PH</given-names></name></person-group><article-title>The concentration-dependent membrane activity of cecropin A</article-title><source>Biochemistry</source><year>1997</year><volume>36</volume><fpage>11452</fpage><lpage>11460</lpage><?supplied-pmid 9298965?><pub-id pub-id-type="pmid">9298965</pub-id></element-citation></ref><ref id="CR328"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>KJ</given-names></name><name><surname>Chopra</surname><given-names>I</given-names></name><name><surname>Fishwick</surname><given-names>CW</given-names></name></person-group><article-title>Structure-based discovery of antibacterial drugs</article-title><source>Nat Rev Microbiol</source><year>2010</year><volume>8</volume><fpage>501</fpage><lpage>510</lpage><?supplied-pmid 20551974?><pub-id pub-id-type="pmid">20551974</pub-id></element-citation></ref><ref id="CR329"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Chowdhury</surname><given-names>I</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name></person-group><article-title>Understanding the Mechanism of bacterial biofilms resistance to antimicrobial agents</article-title><source>Open Microbiol J</source><year>2017</year><volume>11</volume><fpage>53</fpage><lpage>62</lpage><?supplied-pmid 28553416?><pub-id pub-id-type="pmid">28553416</pub-id></element-citation></ref><ref id="CR330"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skinnider</surname><given-names>MA</given-names></name><name><surname>Merwin</surname><given-names>NJ</given-names></name><name><surname>Johnston</surname><given-names>CW</given-names></name><name><surname>Magarvey</surname><given-names>NA</given-names></name></person-group><article-title>PRISM 3: expanded prediction of natural product chemical structures from microbial genomes</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><fpage>W49</fpage><lpage>W54</lpage><?supplied-pmid 28460067?><pub-id pub-id-type="pmid">28460067</pub-id></element-citation></ref><ref id="CR331"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smadbeck</surname><given-names>J</given-names></name><etal/></person-group><article-title>De novo peptide design and experimental validation of histone methyltransferase inhibitors</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e90095</fpage><?supplied-pmid 24587223?><pub-id pub-id-type="pmid">24587223</pub-id></element-citation></ref><ref id="CR332"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohlenkamp</surname><given-names>C</given-names></name><etal/></person-group><article-title>The lipid lysyl-phosphatidylglycerol is present in membranes of <italic>Rhizobium tropici</italic> CIAT899 and confers increased resistance to polymyxin B under acidic growth conditions</article-title><source>Mol Plant Microbe Interact</source><year>2007</year><volume>20</volume><fpage>1421</fpage><lpage>1430</lpage><?supplied-pmid 17977153?><pub-id pub-id-type="pmid">17977153</pub-id></element-citation></ref><ref id="CR333"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Som</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wong</surname><given-names>GC</given-names></name><name><surname>Tew</surname><given-names>GN</given-names></name></person-group><article-title>Divalent metal ion triggered activity of a synthetic antimicrobial in cardiolipin membranes</article-title><source>J Am Chem Soc</source><year>2009</year><volume>131</volume><fpage>15102</fpage><lpage>15103</lpage><?supplied-pmid 19807082?><pub-id pub-id-type="pmid">19807082</pub-id></element-citation></ref><ref id="CR334"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Koo</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>D</given-names></name></person-group><article-title>Effects of material properties on bacterial adhesion and biofilm formation</article-title><source>J Dent Res</source><year>2015</year><volume>94</volume><fpage>1027</fpage><lpage>1034</lpage><?supplied-pmid 26001706?><pub-id pub-id-type="pmid">26001706</pub-id></element-citation></ref><ref id="CR335"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sood</surname><given-names>R</given-names></name><name><surname>Domanov</surname><given-names>Y</given-names></name><name><surname>Pieti&#x000e4;inen</surname><given-names>M</given-names></name><name><surname>Kontinen</surname><given-names>VP</given-names></name><name><surname>Kinnunen</surname><given-names>PK</given-names></name></person-group><article-title>Binding of LL-37 to model biomembranes: insight into target vs host cell recognition</article-title><source>Biochim Biophys Acta</source><year>2008</year><volume>1778</volume><fpage>983</fpage><lpage>996</lpage><?supplied-pmid 18166145?><pub-id pub-id-type="pmid">18166145</pub-id></element-citation></ref><ref id="CR336"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soscia</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e9505</fpage><?supplied-pmid 20209079?><pub-id pub-id-type="pmid">20209079</pub-id></element-citation></ref><ref id="CR337"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spoering</surname><given-names>AL</given-names></name><name><surname>Gilmore</surname><given-names>MS</given-names></name></person-group><article-title>Quorum sensing and DNA release in bacterial biofilms</article-title><source>Curr Opin Microbiol</source><year>2006</year><volume>9</volume><fpage>133</fpage><lpage>137</lpage><?supplied-pmid 16529982?><pub-id pub-id-type="pmid">16529982</pub-id></element-citation></ref><ref id="CR338"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steenbergen</surname><given-names>JN</given-names></name><name><surname>Alder</surname><given-names>J</given-names></name><name><surname>Thorne</surname><given-names>GM</given-names></name><name><surname>Tally</surname><given-names>FP</given-names></name></person-group><article-title>Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections</article-title><source>J Antimicrob Chemother</source><year>2005</year><volume>55</volume><fpage>283</fpage><lpage>288</lpage><?supplied-pmid 15705644?><pub-id pub-id-type="pmid">15705644</pub-id></element-citation></ref><ref id="CR339"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strom</surname><given-names>MB</given-names></name><name><surname>Rekdal</surname><given-names>O</given-names></name><name><surname>Svendsen</surname><given-names>JS</given-names></name></person-group><article-title>Antimicrobial activity of short arginine- and tryptophan-rich peptides</article-title><source>J Pept Sci</source><year>2002</year><volume>8</volume><fpage>431</fpage><lpage>437</lpage><?supplied-pmid 12212806?><pub-id pub-id-type="pmid">12212806</pub-id></element-citation></ref><ref id="CR340"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stromstedt</surname><given-names>AA</given-names></name><name><surname>Pasupuleti</surname><given-names>M</given-names></name><name><surname>Schmidtchen</surname><given-names>A</given-names></name><name><surname>Malmsten</surname><given-names>M</given-names></name></person-group><article-title>Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37</article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><fpage>593</fpage><lpage>602</lpage><?supplied-pmid 19029324?><pub-id pub-id-type="pmid">19029324</pub-id></element-citation></ref><ref id="CR341"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stumpe</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>R</given-names></name><name><surname>Stephens</surname><given-names>DL</given-names></name><name><surname>Georgiou</surname><given-names>G</given-names></name><name><surname>Bakker</surname><given-names>EP</given-names></name></person-group><article-title>Identification of OmpT as the protease that hydrolyzes the antimicrobial peptide protamine before it enters growing cells of <italic>Escherichia coli</italic></article-title><source>J Bacteriol</source><year>1998</year><volume>180</volume><fpage>4002</fpage><lpage>4006</lpage><?supplied-pmid 9683502?><pub-id pub-id-type="pmid">9683502</pub-id></element-citation></ref><ref id="CR342"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugano</surname><given-names>M</given-names></name><name><surname>Morisaki</surname><given-names>H</given-names></name><name><surname>Negishi</surname><given-names>Y</given-names></name><name><surname>Endo-Takahashi</surname><given-names>Y</given-names></name><name><surname>Kuwata</surname><given-names>H</given-names></name><name><surname>Miyazaki</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name></person-group><article-title>Potential effect of cationic liposomes on interactions with oral bacterial cells and biofilms</article-title><source>J Liposome Res</source><year>2016</year><volume>26</volume><fpage>156</fpage><lpage>162</lpage><?supplied-pmid 26152278?><pub-id pub-id-type="pmid">26152278</pub-id></element-citation></ref><ref id="CR343"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suntharalingam</surname><given-names>P</given-names></name><name><surname>Senadheera</surname><given-names>MD</given-names></name><name><surname>Mair</surname><given-names>RW</given-names></name><name><surname>L&#x000e9;vesque</surname><given-names>CM</given-names></name><name><surname>Cvitkovitch</surname><given-names>DG</given-names></name></person-group><article-title>The LiaFSR system regulates the cell envelope stress response in <italic>Streptococcus mutans</italic></article-title><source>J Bacteriol</source><year>2009</year><volume>191</volume><fpage>2973</fpage><lpage>2984</lpage><?supplied-pmid 19251860?><pub-id pub-id-type="pmid">19251860</pub-id></element-citation></ref><ref id="CR344"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sykes</surname><given-names>R</given-names></name></person-group><article-title>The 2009 Garrod lecture: the evolution of antimicrobial resistance: a Darwinian perspective</article-title><source>J Antimicrob Chemother</source><year>2010</year><volume>65</volume><fpage>1842</fpage><lpage>1852</lpage><?supplied-pmid 20573657?><pub-id pub-id-type="pmid">20573657</pub-id></element-citation></ref><ref id="CR345"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taha</surname><given-names>MN</given-names></name><name><surname>Saafan</surname><given-names>AE</given-names></name><name><surname>Ahmedy</surname><given-names>A</given-names></name><name><surname>El Gebaly</surname><given-names>E</given-names></name><name><surname>Khairalla</surname><given-names>AS</given-names></name></person-group><article-title>Two novel synthetic peptides inhibit quorum sensing-dependent biofilm formation and some virulence factors in <italic>Pseudomonas aeruginosa</italic> PAO1</article-title><source>J Microbiol</source><year>2019</year><volume>57</volume><fpage>618</fpage><lpage>625</lpage><?supplied-pmid 31054133?><pub-id pub-id-type="pmid">31054133</pub-id></element-citation></ref><ref id="CR346"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tam</surname><given-names>JP</given-names></name></person-group><article-title>Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system</article-title><source>Proc Natl Acad Sci U S A</source><year>1988</year><volume>85</volume><fpage>5409</fpage><lpage>5413</lpage><?supplied-pmid 3399498?><pub-id pub-id-type="pmid">3399498</pub-id></element-citation></ref><ref id="CR347"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Iwai</surname><given-names>Y</given-names></name><name><surname>Oiwa</surname><given-names>R</given-names></name><name><surname>Shinohara</surname><given-names>S</given-names></name><name><surname>Shimizu</surname><given-names>S</given-names></name><name><surname>Oka</surname><given-names>T</given-names></name><name><surname>Omura</surname><given-names>S</given-names></name></person-group><article-title>Studies on bacterial cell wall inhibitors. II. Inhibition of peptidoglycan synthesis in vivo and in vitro by amphomycin</article-title><source>Biochim Biophys Acta</source><year>1977</year><volume>497</volume><fpage>633</fpage><lpage>640</lpage><?supplied-pmid 407940?><pub-id pub-id-type="pmid">407940</pub-id></element-citation></ref><ref id="CR348"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taneja</surname><given-names>NK</given-names></name><name><surname>Ganguly</surname><given-names>T</given-names></name><name><surname>Bakaletz</surname><given-names>LO</given-names></name><name><surname>Nelson</surname><given-names>KJ</given-names></name><name><surname>Dubey</surname><given-names>P</given-names></name><name><surname>Poole</surname><given-names>LB</given-names></name><name><surname>Deora</surname><given-names>R</given-names></name></person-group><article-title>Alanine modification of a protease-susceptible outer membrane component by the <italic>Bordetella pertussis</italic> locus promotes resistance to antimicrobial peptides and polymorphonuclear leukocyte-mediated killing</article-title><source>J Bacteriol</source><year>2013</year><volume>195</volume><fpage>5102</fpage><lpage>5111</lpage><?supplied-pmid 24013634?><pub-id pub-id-type="pmid">24013634</pub-id></element-citation></ref><ref id="CR349"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tasiemski</surname><given-names>A</given-names></name><name><surname>Schikorski</surname><given-names>D</given-names></name><name><surname>Le Marrec-Croq</surname><given-names>F</given-names></name><name><surname>Pontoire-Van Camp</surname><given-names>C</given-names></name><name><surname>Boidin-Wichlacz</surname><given-names>C</given-names></name><name><surname>Sauti&#x000e8;re</surname><given-names>P-E</given-names></name></person-group><article-title>Hedistin: a novel antimicrobial peptide containing bromotryptophan constitutively expressed in the NK cells-like of the marine annelid, <italic>Nereis diversicolor</italic></article-title><source>Dev Comp Immun</source><year>2007</year><volume>31</volume><fpage>749</fpage><lpage>762</lpage></element-citation></ref><ref id="CR350"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tetz</surname><given-names>VV</given-names></name><name><surname>Tetz</surname><given-names>GV</given-names></name></person-group><article-title>Effect of extracellular DNA destruction by DNase I on characteristics of forming biofilms</article-title><source>DNA Cell Biol</source><year>2010</year><volume>29</volume><fpage>399</fpage><lpage>405</lpage><?supplied-pmid 20491577?><pub-id pub-id-type="pmid">20491577</pub-id></element-citation></ref><ref id="CR351"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thedieck</surname><given-names>K</given-names></name><etal/></person-group><article-title>The MprF protein is required for lysinylation of phospholipids in listerial membranes and confers resistance to cationic antimicrobial peptides (CAMPs) on <italic>Listeria monocytogenes</italic></article-title><source>Mol Microbiol</source><year>2006</year><volume>62</volume><fpage>1325</fpage><lpage>1339</lpage><?supplied-pmid 17042784?><pub-id pub-id-type="pmid">17042784</pub-id></element-citation></ref><ref id="CR352"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoendel</surname><given-names>M</given-names></name><name><surname>Kavanaugh</surname><given-names>JS</given-names></name><name><surname>Flack</surname><given-names>CE</given-names></name><name><surname>Horswill</surname><given-names>AR</given-names></name></person-group><article-title>Peptide signaling in the staphylococci</article-title><source>Chem Rev</source><year>2011</year><volume>111</volume><fpage>117</fpage><lpage>151</lpage><?supplied-pmid 21174435?><pub-id pub-id-type="pmid">21174435</pub-id></element-citation></ref><ref id="CR353"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>X-R</given-names></name><name><surname>Luo</surname><given-names>S-Z</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Role of peptide self-assembly in antimicrobial peptides</article-title><source>J Pep Sci</source><year>2015</year><volume>21</volume><fpage>530</fpage><lpage>539</lpage></element-citation></ref><ref id="CR354"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Travkova</surname><given-names>OG</given-names></name><name><surname>Moehwald</surname><given-names>H</given-names></name><name><surname>Brezesinski</surname><given-names>G</given-names></name></person-group><article-title>The interaction of antimicrobial peptides with membranes</article-title><source>Adv Colloid Interface Sci</source><year>2017</year><volume>247</volume><fpage>521</fpage><lpage>532</lpage><?supplied-pmid 28606715?><pub-id pub-id-type="pmid">28606715</pub-id></element-citation></ref><ref id="CR355"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzeng</surname><given-names>Y-L</given-names></name><name><surname>Ambrose</surname><given-names>KD</given-names></name><name><surname>Zughaier</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Miller</surname><given-names>YK</given-names></name><name><surname>Shafer</surname><given-names>WM</given-names></name><name><surname>Stephens</surname><given-names>DS</given-names></name></person-group><article-title>Cationic antimicrobial peptide resistance in <italic>Neisseria meningitidis</italic></article-title><source>J Bacteriol</source><year>2005</year><volume>187</volume><fpage>5387</fpage><lpage>5396</lpage><?supplied-pmid 16030233?><pub-id pub-id-type="pmid">16030233</pub-id></element-citation></ref><ref id="CR356"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uzzell</surname><given-names>T</given-names></name><name><surname>Stolzenberg</surname><given-names>ED</given-names></name><name><surname>Shinnar</surname><given-names>AE</given-names></name><name><surname>Zasloff</surname><given-names>M</given-names></name></person-group><article-title>Hagfish intestinal antimicrobial peptides are ancient cathelicidins</article-title><source>Peptides</source><year>2003</year><volume>24</volume><fpage>1655</fpage><lpage>1667</lpage><?supplied-pmid 15019197?><pub-id pub-id-type="pmid">15019197</pub-id></element-citation></ref><ref id="CR357"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velkov</surname><given-names>T</given-names></name><name><surname>Roberts</surname><given-names>KD</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Rediscovering the octapeptins</article-title><source>Natural Product Reports</source><year>2017</year><volume>34</volume><fpage>295</fpage><lpage>309</lpage><?supplied-pmid 28180225?><pub-id pub-id-type="pmid">28180225</pub-id></element-citation></ref><ref id="CR358"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventola</surname><given-names>CL</given-names></name></person-group><article-title>The antibiotic resistance crisis: part 1: causes and threats</article-title><source>Pharm Ther</source><year>2015</year><volume>40</volume><fpage>277</fpage><lpage>283</lpage></element-citation></ref><ref id="CR359"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventola</surname><given-names>CL</given-names></name></person-group><article-title>The antibiotic resistance crisis: part 2: management strategies and new agents</article-title><source>Pharm Ther</source><year>2015</year><volume>40</volume><fpage>344</fpage><lpage>352</lpage></element-citation></ref><ref id="CR360"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verkleij</surname><given-names>A</given-names></name><name><surname>Zwaal</surname><given-names>R</given-names></name><name><surname>Roelofsen</surname><given-names>B</given-names></name><name><surname>Comfurius</surname><given-names>P</given-names></name><name><surname>Kastelijn</surname><given-names>D</given-names></name><name><surname>Van Deenen</surname><given-names>L</given-names></name></person-group><article-title>The asymmetric distribution of phospholipids in the human red cell membrane. A combined study using phospholipases and freeze-etch electron microscopy</article-title><source>Biochim Biophys Acta</source><year>1973</year><volume>323</volume><fpage>178</fpage><lpage>193</lpage><?supplied-pmid 4356540?><pub-id pub-id-type="pmid">4356540</pub-id></element-citation></ref><ref id="CR361"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verly</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Effect of cholesterol on the interaction of the amphibian antimicrobial peptide DD K with liposomes</article-title><source>Peptides</source><year>2008</year><volume>29</volume><fpage>15</fpage><lpage>24</lpage><?supplied-pmid 18083275?><pub-id pub-id-type="pmid">18083275</pub-id></element-citation></ref><ref id="CR362"><mixed-citation publication-type="other">Vestby LK, Gronseth T, Simm R, Nesse LL (2020) Bacterial biofilm and its role in the pathogenesis of disease. Antibiotics (Basel) 9</mixed-citation></ref><ref id="CR363"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vizioli</surname><given-names>J</given-names></name><name><surname>Salzet</surname><given-names>M</given-names></name></person-group><article-title>Antimicrobial peptides from animals: focus on invertebrates</article-title><source>Trends in Pharmacological Sciences</source><year>2002</year><volume>23</volume><fpage>494</fpage><lpage>496</lpage><?supplied-pmid 12413797?><pub-id pub-id-type="pmid">12413797</pub-id></element-citation></ref><ref id="CR364"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vorkapic</surname><given-names>D</given-names></name><name><surname>Pressler</surname><given-names>K</given-names></name><name><surname>Schild</surname><given-names>S</given-names></name></person-group><article-title>Multifaceted roles of extracellular DNA in bacterial physiology</article-title><source>Curr Genet</source><year>2016</year><volume>62</volume><fpage>71</fpage><lpage>79</lpage><?supplied-pmid 26328805?><pub-id pub-id-type="pmid">26328805</pub-id></element-citation></ref><ref id="CR365"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuong</surname><given-names>C</given-names></name><name><surname>Kocianova</surname><given-names>S</given-names></name><name><surname>Voyich</surname><given-names>JM</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Fischer</surname><given-names>ER</given-names></name><name><surname>DeLeo</surname><given-names>FR</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name></person-group><article-title>a crucial role for exopolysaccharide modification in bacterial biofilm formation, immune evasion, and virulence</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>54881</fpage><lpage>54886</lpage><?supplied-pmid 15501828?><pub-id pub-id-type="pmid">15501828</pub-id></element-citation></ref><ref id="CR366"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuong</surname><given-names>C</given-names></name><name><surname>Voyich</surname><given-names>JM</given-names></name><name><surname>Fischer</surname><given-names>ER</given-names></name><name><surname>Braughton</surname><given-names>KR</given-names></name><name><surname>Whitney</surname><given-names>AR</given-names></name><name><surname>DeLeo</surname><given-names>FR</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name></person-group><article-title>Polysaccharide intercellular adhesin (PIA) protects <italic>Staphylococcus epidermidis</italic> against major components of the human innate immune system</article-title><source>Cell Microbiol</source><year>2004</year><volume>6</volume><fpage>269</fpage><lpage>275</lpage><?supplied-pmid 14764110?><pub-id pub-id-type="pmid">14764110</pub-id></element-citation></ref><ref id="CR367"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wachinger</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression</article-title><source>J Gen Virol</source><year>1998</year><volume>79</volume><fpage>731</fpage><lpage>740</lpage><?supplied-pmid 9568968?><pub-id pub-id-type="pmid">9568968</pub-id></element-citation></ref><ref id="CR368"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waghu</surname><given-names>FH</given-names></name><name><surname>Barai</surname><given-names>RS</given-names></name><name><surname>Gurung</surname><given-names>P</given-names></name><name><surname>Idicula-Thomas</surname><given-names>S</given-names></name></person-group><article-title>CAMPR3: a database on sequences, structures and signatures of antimicrobial peptides</article-title><source>Nucleic Acids Res</source><year>2016</year><volume>44</volume><fpage>D1094</fpage><lpage>D1097</lpage><?supplied-pmid 26467475?><pub-id pub-id-type="pmid">26467475</pub-id></element-citation></ref><ref id="CR369"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>MC</given-names><suffix>3rd</suffix></name><name><surname>Roe</surname><given-names>F</given-names></name><name><surname>Bugnicourt</surname><given-names>A</given-names></name><name><surname>Franklin</surname><given-names>MJ</given-names></name><name><surname>Stewart</surname><given-names>PS</given-names></name></person-group><article-title>Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of <italic>Pseudomonas aeruginosa</italic> biofilms to ciprofloxacin and tobramycin</article-title><source>Antimicrob Agents Chemother</source><year>2003</year><volume>47</volume><fpage>317</fpage><lpage>323</lpage><?supplied-pmid 12499208?><pub-id pub-id-type="pmid">12499208</pub-id></element-citation></ref><ref id="CR370"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name></person-group><article-title>APD: the antimicrobial peptide database</article-title><source>Nucleic Acids Res</source><year>2004</year><volume>32</volume><fpage>D590</fpage><lpage>D592</lpage><?supplied-pmid 14681488?><pub-id pub-id-type="pmid">14681488</pub-id></element-citation></ref><ref id="CR371"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Karbarz</surname><given-names>MJ</given-names></name><name><surname>McGrath</surname><given-names>SC</given-names></name><name><surname>Cotter</surname><given-names>RJ</given-names></name><name><surname>Raetz</surname><given-names>CRH</given-names></name></person-group><article-title>MsbA Transporter-dependent Lipid A 1-dephosphorylation on the periplasmic surface of the inner membrane: topography of francisella novicida LpxE expressed in <italic>Escherichia coli</italic></article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>49470</fpage><lpage>49478</lpage><?supplied-pmid 15339914?><pub-id pub-id-type="pmid">15339914</pub-id></element-citation></ref><ref id="CR372"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Preston</surname><given-names>JF</given-names></name><name><surname>Romeo</surname><given-names>T</given-names></name></person-group><article-title>The pgaABCD Locus of <italic>Escherichia coli</italic> promotes the synthesis of a polysaccharide adhesin required for biofilm formation</article-title><source>J Bacteriol</source><year>2004</year><volume>186</volume><fpage>2724</fpage><lpage>2734</lpage><?supplied-pmid 15090514?><pub-id pub-id-type="pmid">15090514</pub-id></element-citation></ref><ref id="CR373"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>McGrath</surname><given-names>SC</given-names></name><name><surname>Cotter</surname><given-names>RJ</given-names></name><name><surname>Raetz</surname><given-names>CRH</given-names></name></person-group><article-title>Expression, cloning and periplasmic orientation of the <italic>Francisella novicida</italic> lipid A 4&#x02032;-phosphatase LpxF</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>9321</fpage><lpage>9330</lpage><?supplied-pmid 16467300?><pub-id pub-id-type="pmid">16467300</pub-id></element-citation></ref><ref id="CR374"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>APD3: the antimicrobial peptide database as a tool for research and education</article-title><source>Nucleic Acids Res</source><year>2016</year><volume>44</volume><fpage>D1087</fpage><lpage>D1093</lpage><?supplied-pmid 26602694?><pub-id pub-id-type="pmid">26602694</pub-id></element-citation></ref><ref id="CR375"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Enzyme-catalyzed formation of supramolecular hydrogels as promising vaccine adjuvants</article-title><source>Adv Funct Mater</source><year>2016</year><volume>26</volume><fpage>1822</fpage><lpage>1829</lpage></element-citation></ref><ref id="CR376"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webber</surname><given-names>MJ</given-names></name><name><surname>Tongers</surname><given-names>J</given-names></name><name><surname>Newcomb</surname><given-names>CJ</given-names></name><name><surname>Marquardt</surname><given-names>KT</given-names></name><name><surname>Bauersachs</surname><given-names>J</given-names></name><name><surname>Losordo</surname><given-names>DW</given-names></name><name><surname>Stupp</surname><given-names>SI</given-names></name></person-group><article-title>Supramolecular nanostructures that mimic VEGF as a strategy for ischemic tissue repair</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>13438</fpage><lpage>13443</lpage><?supplied-pmid 21808036?><pub-id pub-id-type="pmid">21808036</pub-id></element-citation></ref><ref id="CR377"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstock</surname><given-names>MT</given-names></name><name><surname>Francis</surname><given-names>JN</given-names></name><name><surname>Redman</surname><given-names>JS</given-names></name><name><surname>Kay</surname><given-names>MS</given-names></name></person-group><article-title>Protease-resistant peptide design-empowering nature's fragile warriors against HIV</article-title><source>Biopolymers</source><year>2012</year><volume>98</volume><fpage>431</fpage><lpage>442</lpage><?supplied-pmid 23203688?><pub-id pub-id-type="pmid">23203688</pub-id></element-citation></ref><ref id="CR378"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitchurch</surname><given-names>CB</given-names></name><name><surname>Tolker-Nielsen</surname><given-names>T</given-names></name><name><surname>Ragas</surname><given-names>PC</given-names></name><name><surname>Mattick</surname><given-names>JS</given-names></name></person-group><article-title>Extracellular DNA required for bacterial biofilm formation</article-title><source>Science</source><year>2002</year><volume>295</volume><fpage>1487</fpage><?supplied-pmid 11859186?><pub-id pub-id-type="pmid">11859186</pub-id></element-citation></ref><ref id="CR379"><mixed-citation publication-type="other">WHO (2015) Global Antimicrobial Resistance Surveillance System (GLASS). <ext-link ext-link-type="uri" xlink:href="https://www.who.int/glass/en/">https://www.who.int/glass/en/</ext-link>. Accessed 2020</mixed-citation></ref><ref id="CR380"><mixed-citation publication-type="other">WHO (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. . <ext-link ext-link-type="uri" xlink:href="https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/">https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/</ext-link>. Accessed 2019</mixed-citation></ref><ref id="CR381"><mixed-citation publication-type="other">WHO (2019a) 2019 antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. ISBN 9789240000193. Geneva. <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/handle/10665/330420">https://apps.who.int/iris/handle/10665/330420</ext-link></mixed-citation></ref><ref id="CR382"><mixed-citation publication-type="other">WHO (2019b) Antibacterial agents in preclinical development: an open access database. WHO/EMP/IAU/2019.12. Geneva. <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/330290/WHO-EMP-IAU-2019.12-eng.pdf">https://apps.who.int/iris/bitstream/handle/10665/330290/WHO-EMP-IAU-2019.12-eng.pdf</ext-link></mixed-citation></ref><ref id="CR383"><mixed-citation publication-type="other">WHO (2020a) First meeting of the WHO Antifungal Expert Group on Identifying Priority Fungal Pathogens: meeting report. ISBN 978-92-4-000635-5. Geneva. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789240006355">https://www.who.int/publications/i/item/9789240006355</ext-link></mixed-citation></ref><ref id="CR384"><mixed-citation publication-type="other">WHO (2020b) Record number of countries contribute data revealing disturbing rates of antimicrobial resistance. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/detail/01-06-2020-record-number-of-countries-contribute-data-revealing-disturbing-rates-of-antimicrobial-resistance">https://www.who.int/news-room/detail/01-06-2020-record-number-of-countries-contribute-data-revealing-disturbing-rates-of-antimicrobial-resistance</ext-link>. Accessed 2020</mixed-citation></ref><ref id="CR385"><mixed-citation publication-type="other">WHO (2020c) Target product profiles for needed antibacterial agents: enteric fever, gonorrhea, neonatal sepsis, urinary tract infections and meeting report. ISBN 978&#x02013;92&#x02013;4-000389-7. Geneva. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789240003897">https://www.who.int/publications/i/item/9789240003897</ext-link></mixed-citation></ref><ref id="CR386"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilton</surname><given-names>M</given-names></name><name><surname>Charron-Mazenod</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>R</given-names></name><name><surname>Lewenza</surname><given-names>S</given-names></name></person-group><article-title>Extracellular DNA acidifies biofilms and induces aminoglycoside resistance in <italic>Pseudomonas aeruginosa</italic></article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><fpage>544</fpage><lpage>553</lpage><?supplied-pmid 26552982?><pub-id pub-id-type="pmid">26552982</pub-id></element-citation></ref><ref id="CR387"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohlleben</surname><given-names>W</given-names></name><name><surname>Mast</surname><given-names>Y</given-names></name><name><surname>Stegmann</surname><given-names>E</given-names></name><name><surname>Ziemert</surname><given-names>N</given-names></name></person-group><article-title>Antibiotic drug discovery</article-title><source>Microb Biotechnol</source><year>2016</year><volume>9</volume><fpage>541</fpage><lpage>548</lpage><?supplied-pmid 27470984?><pub-id pub-id-type="pmid">27470984</pub-id></element-citation></ref><ref id="CR388"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>GD</given-names></name></person-group><article-title>Q&#x00026;A Antibiotic resistance where does it come from and what can we do about it</article-title><source>BMC Biology</source><year>2010</year><volume>8</volume><fpage>123</fpage><?supplied-pmid 20887638?><pub-id pub-id-type="pmid">20887638</pub-id></element-citation></ref><ref id="CR389"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>D</given-names></name><etal/></person-group><article-title>&#x003b2;-Defensins: linking innate and adaptive immunity through dendritic and T Cell CCR6</article-title><source>Science</source><year>1999</year><volume>286</volume><fpage>525</fpage><lpage>528</lpage><?supplied-pmid 10521347?><pub-id pub-id-type="pmid">10521347</pub-id></element-citation></ref><ref id="CR390"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name></person-group><article-title>Intracellular hydrogelation of small molecules inhibits bacterial growth</article-title><source>Angew Chem Int Ed Engl</source><year>2007</year><volume>46</volume><fpage>8216</fpage><lpage>8219</lpage><?supplied-pmid 17705321?><pub-id pub-id-type="pmid">17705321</pub-id></element-citation></ref><ref id="CR391"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Mechanism of a prototypical synthetic membrane-active antimicrobial: efficient hole-punching via interaction with negative intrinsic curvature lipids</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><fpage>20595</fpage><lpage>20600</lpage><?supplied-pmid 19106303?><pub-id pub-id-type="pmid">19106303</pub-id></element-citation></ref><ref id="CR392"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeaman</surname><given-names>MR</given-names></name><name><surname>Yount</surname><given-names>NY</given-names></name></person-group><article-title>Mechanisms of antimicrobial peptide action and resistance</article-title><source>Pharmacol Rev</source><year>2003</year><volume>55</volume><fpage>27</fpage><lpage>55</lpage><?supplied-pmid 12615953?><pub-id pub-id-type="pmid">12615953</pub-id></element-citation></ref><ref id="CR393"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoder</surname><given-names>NC</given-names></name><name><surname>Kumar</surname><given-names>K</given-names></name></person-group><article-title>Fluorinated amino acids in protein design and engineering</article-title><source>Chem Soc Rev</source><year>2002</year><volume>31</volume><fpage>335</fpage><lpage>341</lpage><?supplied-pmid 12491748?><pub-id pub-id-type="pmid">12491748</pub-id></element-citation></ref><ref id="CR394"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zabara</surname><given-names>M</given-names></name><etal/></person-group><article-title>Multifunctional nano-biointerfaces: cytocompatible antimicrobial nanocarriers from stabilizer-free cubosomes</article-title><source>Adv Funct Mater</source><year>2019</year><volume>29</volume><fpage>1904007</fpage></element-citation></ref><ref id="CR395"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Z&#x000e4;hner</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Chancey</surname><given-names>ST</given-names></name><name><surname>Pohl</surname><given-names>J</given-names></name><name><surname>Shafer</surname><given-names>WM</given-names></name><name><surname>Stephens</surname><given-names>DS</given-names></name></person-group><article-title>Human antimicrobial peptide LL-37 induces MefE/Mel-mediated macrolide resistance in <italic>Streptococcus pneumoniae</italic></article-title><source>Antimicrob Agents Chemother</source><year>2010</year><volume>54</volume><fpage>3516</fpage><lpage>3519</lpage><?supplied-pmid 20498319?><pub-id pub-id-type="pmid">20498319</pub-id></element-citation></ref><ref id="CR396"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zasloff</surname><given-names>M</given-names></name></person-group><article-title>Antimicrobial peptides of multicellular organisms</article-title><source>Nature</source><year>2002</year><volume>415</volume><fpage>389</fpage><lpage>395</lpage><?supplied-pmid 11807545?><pub-id pub-id-type="pmid">11807545</pub-id></element-citation></ref><ref id="CR397"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zavascki</surname><given-names>AP</given-names></name><name><surname>Goldani</surname><given-names>LZ</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Nation</surname><given-names>RL</given-names></name></person-group><article-title>Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review</article-title><source>J Antimicrob Chemother</source><year>2007</year><volume>60</volume><fpage>1206</fpage><lpage>1215</lpage><?supplied-pmid 17878146?><pub-id pub-id-type="pmid">17878146</pub-id></element-citation></ref><ref id="CR398"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zelezetsky</surname><given-names>I</given-names></name><name><surname>Tossi</surname><given-names>A</given-names></name></person-group><article-title>Alpha-helical antimicrobial peptides-using a sequence template to guide structure-activity relationship studies</article-title><source>Biochim Biophys Acta</source><year>2006</year><volume>1758</volume><fpage>1436</fpage><lpage>1449</lpage><?supplied-pmid 16678118?><pub-id pub-id-type="pmid">16678118</pub-id></element-citation></ref><ref id="CR399"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zetterberg</surname><given-names>MM</given-names></name><name><surname>Reijmar</surname><given-names>K</given-names></name><name><surname>Pr&#x000e4;nting</surname><given-names>M</given-names></name><name><surname>Engstr&#x000f6;m</surname><given-names>&#x000c5;</given-names></name><name><surname>Andersson</surname><given-names>DI</given-names></name><name><surname>Edwards</surname><given-names>K</given-names></name></person-group><article-title>PEG-stabilized lipid disks as carriers for amphiphilic antimicrobial peptides</article-title><source>J Control Release</source><year>2011</year><volume>156</volume><fpage>323</fpage><lpage>328</lpage><?supplied-pmid 21903146?><pub-id pub-id-type="pmid">21903146</pub-id></element-citation></ref><ref id="CR400"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>LJ</given-names></name><name><surname>Gallo</surname><given-names>RL</given-names></name></person-group><article-title>Antimicrobial peptides</article-title><source>Curr Biol</source><year>2016</year><volume>26</volume><fpage>R14</fpage><lpage>R19</lpage><?supplied-pmid 26766224?><pub-id pub-id-type="pmid">26766224</pub-id></element-citation></ref><ref id="CR401"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Yie</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Nagai</surname><given-names>T</given-names></name></person-group><article-title>Studies on the cyclosporin A loaded stearic acid nanoparticles</article-title><source>Int J Pharmaceutics</source><year>2000</year><volume>200</volume><fpage>153</fpage><lpage>159</lpage></element-citation></ref><ref id="CR402"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name></person-group><source>LAMP: a database linking antimicrobial peptides PLoS One</source><year>2013</year><volume>8</volume><fpage>66557</fpage></element-citation></ref><ref id="CR403"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Lau</surname><given-names>GW</given-names></name></person-group><article-title>Inhibition of competence development, horizontal gene transfer and virulence in <italic>Streptococcus pneumoniae</italic> by a modified competence stimulating peptide</article-title><source>PLoS Pathogens</source><year>2011</year><volume>7</volume><fpage>e1002241</fpage><?supplied-pmid 21909280?><pub-id pub-id-type="pmid">21909280</pub-id></element-citation></ref><ref id="CR404"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Niu</surname><given-names>Z-W</given-names></name></person-group><article-title>A perspective on general direction and challenges facing antimicrobial peptides</article-title><source>Chinese Chemical Letters</source><year>2017</year><volume>28</volume><fpage>703</fpage><lpage>708</lpage></element-citation></ref><ref id="CR405"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>The application of ribosome engineering to natural product discovery and yield improvement in streptomyces</article-title><source>Antibiotics (Basel)</source><year>2019</year><volume>8</volume><fpage>133</fpage></element-citation></ref><ref id="CR406"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerberg</surname><given-names>J</given-names></name><name><surname>Kozlov</surname><given-names>MM</given-names></name></person-group><article-title>How proteins produce cellular membrane curvature</article-title><source>Nat Rev Mol Cell Biol</source><year>2006</year><volume>7</volume><fpage>9</fpage><lpage>19</lpage><?supplied-pmid 16365634?><pub-id pub-id-type="pmid">16365634</pub-id></element-citation></ref></ref-list></back></article>